Tricyclic compounds and their uses

Abstract

The present invention relates to tricyclic compounds and their uses. More particularly, the present invention relates to tricyclic compounds, pharmaceutical compositions containing them, methods for their preparation, and their use in therapy.

Description

[Technical field]

[0001] The present invention relates to tricyclic compounds, pharmaceutical compositions containing them, processes for their preparation, and their medical uses. [Background technology]

[0002] The RAS / RAF / MEK / ERK pathway is an evolutionarily conserved signaling cascade that regulates diverse processes, including cell adhesion, cell cycle progression, cell migration, cell survival, differentiation, metabolism, and proliferation. Aberrant activation of this pathway is widely known to be closely associated with various types of cancer. The ERK signaling pathway is overactivated in a high percentage of tumors, most frequently due to activating mutations in the KRAS, NRAS, and BRAF genes. It has been found that approximately 30% of all human cancers harbor RAS mutations, with 90% of pancreatic cancers, 50% of colon cancers, 50% of papillary thyroid cancers, 30% of non-small cell lung cancers (NSCLC), and 25% of melanomas harboring RAS mutations. BRAF mutations have been widely identified in tumors and are present in a significant proportion (7%) of all human cancers. This mutation is prevalent in hairy cell leukemia (100%), melanoma (50%-60%), papillary thyroid cancer (40%-60%), colorectal cancer (CRC, 5%-10%), pilocytic astrocytoma (10%-15%) and non-small cell lung cancer (NSCLC) (3%-5%). MEK mutations have been identified primarily in melanoma, but also in ovarian cancer cell lines and gliomas. In general, all upstream mutations can lead to hyperactivation of ERK protein, which is responsible for a series of substrate activations regulated by ERK signaling, and are consequently associated with a wide range of tumors.

[0003] Targeting the MAPK / ERK pathway has attracted significant interest in cancer therapy. The clinical benefits achieved by BRAF and MEK inhibitors indicate that targeting these downstream RAS effectors is a very promising approach for the treatment of cancers with BRAF mutations. However, current evidence indicates that inhibition of BRAF or MEK alone is not sufficient to obtain clinical benefit in RAS-mutated cancers. Both intrinsic and acquired resistance to BRAF and MEK inhibitors is highly associated with persistence of ERK signaling in the presence of the drugs, implying the need to target ERK. The major efficacy of ERK inhibitors has already been observed in clinical trials. In a phase I study of BVD-523, clinical responses were observed in patients with BRAF and NRAS mutations, even among those who had progressed on conventional BRAF and / or MEK inhibitors. Combination approaches with ERK inhibitors have been explored, and preclinical data support combo strategies with other targeted inhibitors such as CDK4 / 6 inhibitors, VEGFR2 inhibitors, PARP inhibitors, multi-ERBB inhibitors, and autophagy inhibitors in KRAS-mutated cancer cells, so ERK inhibitors may benefit a broader patient population in the clinic.

[0004] Thus, there is a need for novel compounds and methods for modulating ERK activity and treating related diseases, including cancer. The present invention addresses these needs. Summary of the Invention

[0005] The present invention relates to compounds of formula (I):

[0006] [ka]

[0007] or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

[0008] In the above formula, Z1 and Z2 are independently N or C, and

[0009] [ka]

[0010] is a 5-membered heteroaryl containing 1, 2, 3 or 4 ring heteroatoms selected from N, O or S; said 5-membered heteroaryl optionally includes deuterium, halo, hydroxy, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -CN, Mercapto, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-OH, and -(C 1-6 Alkyl)-O-(C 1-6 alkyl), wherein the C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Each haloalkyl may be optionally substituted with one or more deuterium atoms; L is absent or L is -NR c , O or S; R c is hydrogen or C 1-6 is alkyl; Ar is deuterium, halo, hydroxy, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -CN, Mercapto, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-OH, -(C 1-6Alkyl)-O-(C 1-6 Alkyl), C 3-8 Heteroaryl optionally substituted with one or more substituents independently selected from cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl, wherein 1-6 Alkyl, C 1-6 Alkoxyl, C 1-6 Haloalkyl, C 3-8 Each of cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl may be optionally substituted with one or more deuterium atoms; R1 is hydrogen; C optionally substituted with one or more deuterium atoms; 1-6 Alkyl;C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 alkyl), -(C 1-6 Alkyl)-(C 3-8 Cycloalkyl), -(C 1-6 alkyl)-(3-8 membered heterocyclyl), -(C 1-6 alkyl)-phenyl, -(C 1-6 Alkyl)-heteroaryl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl, 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Each of cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl is selected from the group consisting of deuterium, halo, -CN, hydroxy, mercapto, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), C 3-8 Cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, heteroaryl, C optionally substituted with one or more deuterium atoms 1-6 Alkyl, C 1-6Alkoxyl, and C 1-6 optionally substituted with one or more substituents independently selected from haloalkyl; R2 is hydrogen, deuterium, halo, hydroxy, amino, -NH(C 1-6 alkyl), -N(C 1-6 alkyl), -CN, mercapto, C optionally substituted with one or more deuterium 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 alkyl), -(C 1-6 Alkyl)-(C 3-8 Cycloalkyl), -(C 1-6 alkyl)-(3-8 membered heterocyclyl), -(C 1-6 alkyl)-phenyl, -(C 1-6 Alkyl)-heteroaryl, C 3-8 cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl, 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Each of cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl is selected from the group consisting of deuterium, halo, -CN, hydroxy, mercapto, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), C 1-6 Alkyl, C 1-6 Alkoxyl, C 1-6 optionally substituted with one or more substituents independently selected from haloalkyl, and oxo; R a and R b are independently hydrogen, deuterium, halo, hydroxy, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -(C1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), -CN, Mercapto, C 1-6 Alkyl, C 1-6 Alkoxyl, and C 1-6 haloalkyl; or R a and R b together with the carbon atom to which they are attached, 3-6 cycloalkyl or 4- to 6-membered heterocyclyl, 3-6 Each of the cycloalkyl and 4- to 6-membered heterocyclyl groups may be selected from the group consisting of deuterium, halo, -CN, hydroxy, mercapto, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), C 1-6 Alkyl, C 1-6 Alkoxyl, and C 1-6 optionally substituted with one or more substituents independently selected from haloalkyl;

[0011] [ka] is a double bond or a single bond, and

[0012] [ka]

[0013] is a double bond, then R3 and R5 are absent; R3, R4, R5, R6, R7 and R8 are hydrogen, deuterium, halo, hydroxy, -CN, mercapto, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), C 1-6 Alkyl, -(C1-6 Alkyl)-phenyl, C 1-6 Alkoxy and C 1-6 haloalkyl; or any two of R3, R4, R5, R6, R7 and R8, together with the carbon atom to which they are attached and the B ring, may form an 8-13 membered spiro, fused or bridged ring, optionally containing 1-3 ring heteroatoms independently selected from N, O or S; wherein said rings are selected from deuterium, halo, -CN, hydroxy, mercapto, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 haloalkyl; wherein said spiro, fused or bridged rings are optionally substituted with one or more substituents independently selected from deuterium, halo, -CN, hydroxy, mercapto, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 optionally substituted with one or more substituents independently selected from haloalkyl; or R3 and R4 taken together, R5 and R6 taken together, or R7 and R8 taken together represent oxo; n is 0, 1 or 2; m is 0, 1, 2, 3, 4 or 5.

[0014] The compounds described above, as well as active compounds disclosed in the context of the present invention and encompassed within the scope of the compounds described above, are collectively referred to as "compounds of the present invention."

[0015] Also provided are compounds of the invention for use in inhibiting ERK activity in vivo or in vitro.

[0016] There is also provided a compound of the invention for use as a medicine, particularly a compound of the invention for use in treating or preventing a disease which responds to the inhibition of ERK.

[0017] Pharmaceutical compositions comprising a compound of the invention, and optionally a pharma- ceutically acceptable carrier, are also provided.

[0018] Also provided is a method of inhibiting the activity of ERK in vivo or in vitro comprising contacting ERK with an effective amount of a compound of the invention.

[0019] Also provided is a method for treating or preventing a disease responsive to inhibition of ERK, comprising administering to a subject in need thereof an effective amount of a compound of the invention.

[0020] There is also provided the use of a compound of the invention for treating or preventing a disease that responds to the inhibition of ERK.

[0021] There is also provided the use of a compound of the invention in the manufacture of a medicament for treating or preventing a disease responsive to the inhibition of ERK. [Brief description of the drawings]

[0022] [Figure 1] FIG. 1 shows a synthetic route for preparing compounds of the invention, where X is halo; Z1, Z2, [ka] , L, R1, R2, R3, R4, R5, R6, R7, R8, R a , R b , m and n are defined as in the compounds of formula (I) and subformulas (I-1), (I-2) or (I-3); R is defined as in the compounds of formula (II) or (III). [Detailed Description of the Invention]

[0023] definition As used in this application, the following words, phrases and symbols have the meanings set forth below, unless the context clearly indicates otherwise.

[0024] A dash ("-") that is not between two letters or symbols is used to indicate the point of attachment of a substituent. For example, -O(C 1-6 Alkyl) is attached to the rest of the molecule through an oxygen.

[0025] A dotted line across a chemical bond is used to indicate the site of attachment of a group to the rest of the molecule. For example, Ar is

[0026] [ka]

[0027] where the two dotted lines on the left and right indicate the bond to R1-NH- and the bond to the A ring, respectively.

[0028] As used herein, the term "alkyl" refers to an alkyl group having 1 to 18 carbon atoms (C 1-18 ), preferably 1 to 10 carbon atoms (C 1-10 ), more preferably 1 to 6 carbon atoms (C 1-6 ) refers to a linear or branched saturated hydrocarbon group. For example, "C 1-6 "Alkyl" refers to an alkyl having 1 to 6 carbon atoms. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, and t-butyl.

[0029] As used herein, the term "alkenyl" refers to an alkyl group containing one or more, e.g., one, two or three, carbon-carbon double bonds (C=C) and having 2 to 10 carbon atoms (C 2-10 ), preferably 2 to 6 carbon atoms (C2-6 ), more preferably 2 to 4 carbon atoms (C 2-4 ) refers to a straight-chain or branched unsaturated hydrocarbon group. For example, "C 2-6 "Alkenyl" refers to an alkenyl having 2 to 6 carbon atoms, which preferably contains 1 or 2 carbon-carbon double bonds. 2-4 "Alkenyl" refers to an alkenyl having 2 to 4 carbon atoms, which preferably contains one carbon-carbon double bond. Examples of alkenyl include, but are not limited to, vinyl, 2-propenyl, and 2-butenyl. The point of attachment of the alkenyl may or may not be on the double bond.

[0030] The term "alkynyl" as used herein refers to an alkynyl group containing one or more, e.g., one, two or three, carbon-carbon triple bonds (C≡C) and having 2 to 10 carbon atoms (C 2-10 ), preferably 2 to 6 carbon atoms (C 2-6 ), more preferably 2 to 4 carbon atoms (C 2-4 ) refers to a linear or branched unsaturated hydrocarbon group. For example, "C 2-6 "Alkynyl" refers to an alkynyl having 2 to 6 carbon atoms, preferably containing 1 or 2 carbon-carbon triple bonds; 2-4 "Alkynyl" refers to an alkynyl having from 2 to 4 carbon atoms, preferably containing one carbon-carbon triple bond. Examples of alkynyl include, but are not limited to, ethynyl, 2-propynyl, and 2-butynyl. The point of attachment of an alkynyl may or may not be on the triple bond.

[0031] The term "halogen" or "halo" as used herein refers to fluoro, chloro, bromo and iodo, preferably fluoro, chloro and bromo, and more preferably fluoro and chloro.

[0032] The term "haloalkyl" as used herein refers to an alkyl as defined herein, in which one or more, e.g., 1, 2, 3, 4 or 5, hydrogen atoms are replaced by halogen atoms, and when multiple (two or more) hydrogen atoms are replaced by halogen atoms, the halogen atoms may be the same or different from each other. In one embodiment, the term "haloalkyl" as used herein refers to an alkyl as defined herein, in which two or more, e.g., 2, 3, 4 or 5, hydrogen atoms are replaced by halogen atoms, where the halogen atoms are the same as each other. In another embodiment, the term "haloalkyl" as used herein refers to an alkyl as defined herein, in which two or more, e.g., 2, 3, 4 or 5, hydrogen atoms are replaced by halogen atoms, where the halogen atoms are different from each other. Examples of haloalkyl include, but are not limited to, -CF3, -CHF2, -CH2F, -CH2CF3, -CF2CF3, -CF2CH3, and the like.

[0033] The term "alkoxyl" as used herein refers to the group -O-alkyl, where alkyl is as defined above. Examples of alkoxyl include, but are not limited to, C alkoxyl, such as methoxy. 1-6 Alkoxyl includes, for example, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, t-butoxy, pentoxy, and hexyloxy, including their isomers.

[0034] As used herein, the term "cycloalkyl" refers to a cycloalkyl group having 3 to 12 ring carbon atoms (C 3-12 ), 3 to 8 ring carbon atoms (C 3-8 ), 3 to 7 ring carbon atoms (C 3-7 ), or 3 to 6 ring carbon atoms (C 3-6"Cycloalkyl" refers to a saturated or partially unsaturated cyclic hydrocarbon group having a ring structure of 1 or 2 carbon atoms, which may have one or two rings. "Cycloalkyl" may include fused, bridged, or spiro rings. The ring of a cycloalkyl may be saturated or may have one or more, e.g., one or two, double bonds in the ring (i.e., is partially unsaturated), but is not fully conjugated and is not an aryl as defined herein. In one embodiment, the cycloalkyl is a monocyclic cycloalkyl, preferably a monocyclic C 3-8 Cycloalkyl, more preferably monocyclic C 3-6 In another embodiment, the cycloalkyl is a saturated monocyclic cycloalkyl, preferably a saturated monocyclic C 3-8 Cycloalkyl, more preferably saturated monocyclic C 3-6 Examples of monocyclic cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclopropenyl, cyclobutenyl, cyclopentenyl (e.g., 1-cyclopent-1-enyl, 1-cyclopent-2-enyl, 1-cyclopent-3-enyl), cyclohexenyl (e.g., 1-cyclohex-1-enyl, 1-cyclohex-2-enyl, 1-cyclohex-3-enyl), and cyclohexadienyl. In another embodiment, the cycloalkyl is a bicyclic cycloalkyl, preferably a bicyclic C 5-12 Cycloalkyl, more preferably bicyclic C 7-12 Examples of bicyclic cycloalkyl include, but are not limited to, bicyclo[4.1.0]heptyl, bicyclo[3.1.1]heptyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, bicyclo[3.2.2]nonyl, spiro[3.3]heptyl, spiro[2.2]pentyl, spiro[2.3]hexyl, spiro[2.4]heptyl, spiro[2.5]octyl, spiro[4.5]decyl, and bicyclo[3.1.1]hept-2-enyl. Most preferably, the cycloalkyl is a saturated monocyclic C 3-6Cycloalkyl, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

[0035] The term "heterocycle", "heterocyclyl" or "heterocyclic" as used herein refers to a saturated or partially unsaturated ring having 3-12 ring atoms (3-12 members), e.g., 3-8 ring atoms (3-8 members), 5-7 ring atoms (5-7 members), 3-6 ring atoms (3-6 members) or 4-6 ring atoms (4-6 members), in which 1, 2 or 3, preferably 1 or 2, of the ring atoms are heteroatoms independently selected from N, O and S, the remaining ring atoms are carbon, and having one or more, e.g., 1, 2 or 3, preferably 1 or 2, rings, in which the N or S heteroatoms may be optionally oxidized to various oxidation states. The point of attachment of the heterocyclyl can be on the N heteroatom or on the carbon atom. Heterocyclyl rings also include fused, bridged, or spiro rings. The ring(s) of the heterocyclyl is saturated or contains one or more, e.g., one or two, double bonds (i.e., partially unsaturated), but is not fully conjugated and is not a heteroaryl as defined herein. For example, "3-8 membered heterocyclyl" refers to a heterocyclyl having 3-8 ring atoms and containing 1, 2 or 3, preferably 1 or 2 ring heteroatoms independently selected from N, O and S, and is preferably a saturated monocyclic 3-8 membered heterocyclyl. Also, for example, "3-6 membered heterocyclyl" refers to a heterocyclyl having 3-6 ring atoms and containing 1 or 2 ring heteroatoms independently selected from N, O and S, and is preferably a saturated monocyclic 3-6 membered heterocyclyl, e.g., a saturated monocyclic 3-, 4-, 5- or 6-membered heterocyclyl. Examples of heterocyclyl include, but are not limited to, oxiranyl, aziridinyl, oxetanyl, azetidinyl, pyrrolidinyl, tetrahydrofuryl, dioxolaninyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, and tetrahydropyranyl.

[0036] As used herein, the term "aryl" refers to an aryl group having 6 to 14 carbon atoms (C 6-14 ), preferably 6 to 10 carbon atoms (C 6-10 ) and consisting of a single ring or multiple condensed rings, in which at least one ring is aromatic. Examples of aryl include, but are not limited to, phenyl, naphthalenyl, 1,2,3,4-tetrahydronaphthalenyl, phenanthryl, indenyl, indanyl, azulenyl, preferably phenyl and naphthalenyl.

[0037] As used herein, the term "heteroaryl" refers to: monocyclic heteroaryl, i.e. monocyclic aromatic hydrocarbon groups having 5, 6 or 7 ring atoms (5-, 6- or 7-membered), one or more of said ring atoms, for example 1, 2 or 3, preferably 1 or 2, are ring heteroatoms independently selected from N, O and S (preferably N), the remaining ring atoms being carbon; preferably monocyclic aromatic hydrocarbon groups having 5 or 6 ring atoms (5- or 6-membered), one , 2 or 3, preferably 1 or 2, of said ring atoms are heteroatoms independently selected from N, O and S (preferably N); and Bicyclic heteroaryl, i.e., a bicyclic aromatic hydrocarbon group having 8-12 ring atoms (8-12 members), e.g., 8, 9 or 10 ring atoms (8, 9 or 10 members), in which one or more of the ring atoms, e.g., 1, 2, 3 or 4, preferably 2, 3 or 4, are ring heteroatoms independently selected from N, O and S (preferably N), and the remaining ring atoms are carbon, in which at least one ring is aromatic. When the total number of S and O atoms in a heteroaryl group exceeds 1, said S and O heteroatoms are not adjacent to each other. For example, bicyclic heteroaryl includes a 5- or 6-membered heteroaryl ring fused to a 5- or 6-membered cycloalkyl ring.

[0038] Examples of heteroaryl groups include, but are not limited to, pyridyl, pyridyl N-oxide, pyrazinyl, pyrimidinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, 1,2,5-oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl (such as 1,3,4-thiadiazolyl), tetrazolyl, triazolyl (such as 1,2,4-triazolyl), triazinyl (such as 1,3,5-triazinyl), thienyl, furyl, pyranyl, pyrrolyl, pyridazinyl, benzodioxolyl, benzoxazolyl, benzoisoxazolyl, benzothienyl, benzothiazolyl, benzoyl, and benzoyl. These include sothiazolyl, imidazopyridyl, triazolopyridyl, indazolyl, pyrrolopyridyl, pyrrolopyrimidinyl, pyrazolopyridyl, pyrazolopyrimidinyl, tetrazolopydyl, tetrahydropyrazolopyridyl, benzofuryl, benzimidazolinyl, indolyl, 3,4-dihydro-2H-benzo[b][1,4]oxazinyl, indolinyl, purinyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, 2,4,5,6-tetrahydrocyclopentadieno[c]pyrazolyl, and 5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridyl.

[0039] As used herein, the terms "combined ring", "fused ring" or "condensed ring" may be used interchangeably in the present invention and refer to a saturated, partially saturated or aromatic ring system in which two rings share a single ring tangent. In one embodiment, the "combined ring", "fused ring" or "condensed ring" has 8 to 13 ring atoms (8 to 13 members), e.g., 9 to 12 ring atoms (9 to 12 members), 8 to 11 ring atoms (8 to 11 members), or 8, 9 or 10 ring atoms (8, 9 or 10 members), wherein 1, 2 or 3, preferably 1 or 2, of the ring atoms may optionally be ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon.

[0040] The term "spiro ring" as used herein refers to a saturated or partially unsaturated, preferably saturated, ring system in which two rings share a single carbon atom (referred to as a "spiro union"), where one, two or three, preferably one or two, of said ring atoms may optionally be heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon. In one embodiment, a "spiro ring" has 8 to 13 ring atoms (8 to 13 members), e.g., 9 to 12 ring atoms (9 to 12 members), 8 to 11 ring atoms (8 to 11 members), or 8, 9 or 10 ring atoms (8, 9 or 10 members), where one, two or three, preferably one or two, of said ring atoms may optionally be heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon.

[0041] As used herein, the terms "bridged ring" or "bridged ring" are used interchangeably herein and refer to two rings sharing two atoms (called "bridgehead atoms") that are not directly connected, where one, two or three, preferably one or two, of the ring atoms may optionally be ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon. In one embodiment, the "bridged ring" or "bridged ring" has 8 to 13 ring atoms (8 to 13 members), e.g., 9 to 12 ring atoms (9 to 12 members), 8 to 11 ring atoms (8 to 11 members), or 8, 9 or 10 ring atoms (8, 9 or 10 members), where one, two or three, preferably one or two, of the ring atoms may optionally be ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon.

[0042] As used herein, the term "hydroxy" refers to an --OH group. The term "mercapto" as used herein refers to a --SH group. The term "oxo" as used herein refers to the group ═O. As used herein, the term "amino" refers to the group --NH. As used herein, the term "cyano" refers to a -CN group.

[0043] When a structure herein contains an asterisk "*", it means that the chiral center of the compound marked with the "*" is in a single configuration, either the R or S configuration, and the content of the single configuration of the compound marked with the "*" is at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 100%, or any number between those recited values).

[0044] When a structure herein contains "(RS)," it is meant that the chiral center of the compound marked with (RS) includes both the R and S configurations.

[0045] As used herein, the term "optional" or "optionally" refers to the event or circumstance described thereafter that may or may not occur, and the description encompasses both the occurrence and non-occurrence of the event or circumstance. For example, "optionally substituted alkyl" or "alkyl that is optionally substituted with..." encompasses both "unsubstituted alkyl" and "substituted alkyl" as defined herein. With respect to any group that contains one or more substituents, those of skill in the art will understand that such groups are not intended to introduce any substitutions or substitution patterns that are sterically infeasible, chemically defective, synthetically infeasible, and / or inherently unstable.

[0046] As used herein, the term "substituted" or "substituted with" means that one or more hydrogens on the specified atom or group are replaced with one or more substituents selected from the specified group of substituents, but not exceeding the normal valence of the specified atom. When a substituent is oxo (i.e., =O), two hydrogens on a single atom are replaced with oxo. Combinations of substituents and / or variables are permissible only if such combinations result in chemically correct and stable compounds. By chemically correct and stable compounds is meant compounds that are sufficiently robust to survive sufficient separation from a reaction mixture.

[0047] Unless otherwise specified, substituents are named in the core structure. For example, if (cycloalkyl)alkyl is listed as a possible substituent, the point of attachment of that substituent to the core structure is on the alkyl portion.

[0048] As used herein, the term "substituted with one or more substituents" means that one or more hydrogens on a specified atom or group are independently replaced with one or more substituents selected from the group of specified substituents. In some embodiments, "having one or more substituents" means that a specified atom or group is substituted with 1, 2, 3 or 4, preferably 1, 2 or 3, more preferably 1 or 2, substituents independently selected from the group of specified substituents.

[0049] The term "leaving group" refers to an atom or functional group that is displaced in a reaction step. Examples of leaving groups include, but are not limited to, halo, alkoxyl, and sulfonyloxy. Examples of sulfonyloxy include, but are not limited to, alkylsulfonyloxy (e.g., methanesulfonyloxy (also known as methanesulfonyl) and trifluoromethanesulfonyloxy (also known as trifluoromethanesulfonyl) and arylsulfonyloxy (e.g., p-toluenesulfonyloxy (also known as p-tosylate) and p-nitrophenylsulfonyloxy (also known as p-nitrophenylsulfonyl).

[0050] It will be appreciated by those skilled in the art that some of the compounds of formula (I) may contain one or more chiral centers and therefore may exist in two or more stereoisomers. The racemates of these isomers, the individual isomers and mixtures thereof enriched in one enantiomer, as well as diastereomers and mixtures partially enriched in a particular diastereomer when there are two chiral centers, are all within the scope of the present invention. It will be further appreciated by those skilled in the art that the present invention encompasses all of the individual stereoisomers (e.g., enantiomers), racemic mixtures or partially resolved mixtures of the compounds of formula (I), and, where appropriate, the individual tautomeric forms thereof.

[0051] In other words, in some embodiments, the present invention provides compounds of various stereoisomeric purity, i.e., diastereomeric or enantiomeric purity, represented by various "ee" or "de" values. In some embodiments, the compounds of formula (I) or subformulas (I-1), (I-2), (I-3) described herein have an enantiomeric purity of at least 60% ee (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% ee, or any value between those recited values). In some embodiments, the compounds of formula (I) or subformulas (I-1), (I-2), (I-3) described herein have an enantiomeric purity of greater than 99.9% ee. In some embodiments, the compounds of formula (I) or sub-formulas (I-1), (I-2), (I-3) described herein have a diastereomeric purity of at least 60% de (e.g., 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9% de, or any value between the recited values). In some embodiments, the compounds of formula (I) or sub-formulas (I-1), (I-2), (I-3) described herein have a diastereomeric purity of greater than 99.9% de.

[0052] The term "enantiomeric excess" or "ee" indicates how much more of one enantiomer is present relative to the other. In the case of a mixture of R and S enantiomers, the enantiomeric excess is defined as |RS|*100, where R and S are the mole or weight fractions of each enantiomer in the mixture, and R+S=1. With knowledge of the optical rotation of the chiral substance, the enantiomeric excess is defined as ([a]obs / [a]max)*100, where [a]obs is the optical rotation of the mixture of enantiomers, and [a]max is the optical rotation of the pure enantiomer.

[0053] The term "diastereomeric excess" or "de" refers to how much more of one diastereomer is present relative to the other. Thus, for a mixture of diastereomers D1 and D2, diastereomeric excess is defined as |D1-D2|*100, where D1 and D2 are the mole or weight fractions of each diastereomer in the mixture, and D1+D2=1.

[0054] Diastereomeric and / or enantiomeric excess can be determined using a variety of analytical techniques, including NMR spectroscopy, chiral column chromatography, and / or optical polarimetry, following routine protocols well known to those of skill in the art.

[0055] The racemates can be used as is or can be resolved into the individual isomers. Optical resolution can provide stereochemically pure compounds or mixtures enriched in one or more isomers. Methods for separating isomers are well known (see Allinger NL & Eliel EL, "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) and include physical methods such as chromatography using chiral adsorbents. The individual isomers can be prepared in chiral form from chiral precursors. Alternatively, the individual isomers can be chemically separated from the mixture by forming diastereomeric salts with chiral acids (e.g., the individual enantiomers of 10-camphorsulfonic acid, camphoric acid, α-bromocamphoric acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid, etc.), fractional crystallization of the salts, and then freeing one or both of the resolved bases and repeating the process, as desired, to obtain one or both isomers substantially free of the other isomer, i.e., to obtain isomers having an optical purity of >95%. Alternatively, the diastereomers can be produced by covalently binding the racemate to a chiral compound (auxiliary agent), which can be separated by chromatography or fractional crystallization, and then the chiral auxiliary can be chemically removed to obtain the pure enantiomers, as known to those skilled in the art.

[0056] The term "pharmaceutically acceptable salt" refers to acid addition salts formed by compounds of formula (I) or subformulas (I-1), (I-2), (I-3) with inorganic acids, such as hydrochlorides, hydrobromides, carbonates, bicarbonates, phosphates, sulfates, sulfites, nitrates, etc.; as well as acid addition salts formed by compounds of formula (I) or subformulas (I-1), (I-2), (I-3) with organic acids, such as formates, acetates, malates, maleates, fumarates, tartrates, succinates, citrates, lactates, methanesulfonates, p-toluenesulfonates, 2-hydroxyethylsulfonates, benzoates, salicylates, stearates, and salts of the formula HOOC-(CH2) n-COOH (n is 0-4) with alkane-dicarboxylic acids. Also included in the "pharmaceutically acceptable salts" are base addition salts formed by compounds of formula (I) or subformulas (I-1), (I-2), (I-3) bearing an acidic moiety and pharmaceutically acceptable cations such as sodium, potassium, calcium, aluminum, lithium and ammonium.

[0057] In addition, if the compounds described herein are obtained as acid addition salts, the free base can be obtained by basifying a solution of the acid addition salt. Conversely, if the product is a free base, a pharma- ceutically acceptable acid addition salt can be prepared from the base compound by dissolving the free base in a suitable solvent and treating the solution with an acid according to conventional procedures for preparing acid addition salts. Those skilled in the art will recognize a variety of synthetic methodologies that can be used without undue experimentation to prepare non-toxic pharma- ceutically acceptable acid or base addition salts.

[0058] The term "solvate" refers to a solvent addition form that contains either a stoichiometric or non-stoichiometric amount of a solvent. Some compounds have the property of trapping a certain molar ratio of solvent molecules in the solid state, thereby forming a solvate. When the solvent is water, the solvate formed is a hydrate, and when the solvent is alcohol, the solvate formed is an alcoholate. A hydrate is formed by the combination of one or more water molecules with one molecule of a substance, where the water retains its molecular state H2O. Such a combination can form one or more hydrates, for example, hemihydrates, monohydrates, and dihydrates.

[0059] The term "deuterated compound" refers to a compound in which one or more, e.g., one, two or three, hydrogen atoms are replaced by their isotope deuterium, where the content of the deuterium isotope (degree of deuteration) of the deuterium element at the replacement position must be at least higher than the content of the natural deuterium isotope. In some embodiments, the deuterated compound of formula (I) or its subformulas (I-1), (I-2), (I-3) has a degree of deuteration of at least 50% (e.g., 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or any value between these recited values). In some embodiments, the compounds of formula (I) or subformulas (I-1), (I-2), (I-3) thereof have a degree of deuteration of greater than 99.9% up to 100%.

[0060] As used herein, the terms "group," "residue," and "moiety" are synonymous and are meant to refer to a functional group or molecular fragment that can be attached to another molecular fragment.

[0061] The terms "treating," "treat," or "treatment" in relation to a disease or disorder refer to the administration of one or more medicinal substances, particularly a compound of formula (I) or a pharma- ceutically acceptable salt thereof as described herein, to a subject having a disease or disorder or a subject with symptoms of a disease or disorder, with the intent to cure, treat, alleviate, relieve, alter, modify, ameliorate, ameliorate, or affect the disease or disorder or the symptoms of the disease or disorder. In some embodiments, the disease or disorder is a disease that responds to inhibition of ERK, preferably cancer.

[0062] The term "prevent" or "preventing" in relation to a disease or disorder refers to administering one or more medicinal substances, particularly a compound of formula (I) or a pharma- ceutically acceptable salt thereof, to a subject susceptible to or at risk of suffering from a disease or disorder, with the purpose of preventing or delaying the onset of the disease or disorder in the subject. In some embodiments, the disease or disorder is a disease that responds to the inhibition of ERK, preferably cancer.

[0063] The terms "treating," "contacting," and "reacting" in the context of chemical reactions refer to the addition or mixing of two or more reagents under conditions appropriate to produce a specified and / or desired product. The reaction that produces a specified and / or desired product does not necessarily result directly from the combination of two reagents initially added, i.e., it may be one or more intermediates that are produced in the mixture and ultimately lead to the formation of the specified and / or desired product.

[0064] The term "effective amount" as used herein refers to an amount of a compound of formula (I) or a pharma- ceutically acceptable salt thereof, as described herein, that is effective in "treating" or "preventing" a disease or disorder that responds to inhibition of ERK in a subject. An effective amount can cause any observable or measurable change in a subject, as described in the above definitions of "treating", "treating", "treatment", "preventing" or "preventing". For example, in the case of cancer, an effective amount can reduce the number of cancer cells or tumor cells; reduce tumor size; inhibit or stop the invasion of tumor cells into peripheral organs, for example, prevent or stop the spread of tumors to soft tissue and bone; inhibit and stop tumor metastasis; inhibit and stop tumor growth; relieve to some extent one or more symptoms associated with cancer; reduce morbidity and mortality; improve quality of life; or achieve a combination of such effects. An effective amount may be an amount sufficient to reduce the symptoms of a disease that responds to inhibition of ERK. The term "effective amount" may refer to an amount of a compound of Formula (I) described herein, or a pharma- ceutically acceptable salt thereof, effective to inhibit the activity of ERK in a subject.

[0065] The term "inhibition" or "inhibiting" refers to a decrease in the baseline activity of a biological activity or process. "Inhibition of ERK" refers to a decrease in the activity of ERK as a direct or indirect response to the presence of a compound of formula (I) or a pharma- ceutically acceptable salt thereof as described herein, compared to the activity of ERK in the absence of the compound of formula (I) or a pharma- ceutically acceptable salt thereof. The decrease in activity may be due to a direct interaction of the compound of formula (I) or a pharma- ceutically acceptable salt thereof as described herein with ERK, or may be due to an interaction of the compound of formula (I) or a pharma- ceutically acceptable salt thereof as described herein with one or more other factors that in turn affect ERK activity. For example, the presence of a compound of formula (I) or a pharma- ceutically acceptable salt thereof as described herein may decrease ERK activity by direct binding to ERK, by directly or indirectly causing another factor to decrease ERK activity, or by directly or indirectly decreasing the amount of ERK present in a cell or organism.

[0066] The term "subject" as used herein refers to mammals and non-mammals. Mammals refer to any member of the class Mammalia, including, but not limited to, humans; non-human primates, such as chimpanzees and other ape and monkey species; domestic animals, such as cows, horses, sheep, goats and pigs; farm animals, such as rabbits, dogs and cats; laboratory animals, including rodents, such as rats, mice, guinea pigs, etc. Examples of non-mammals include, but are not limited to, birds, etc. The term "subject" does not denote a particular age or sex.

[0067] The term "pharmaceutical acceptable" means that the material which follows this term is useful in preparing pharmaceutical compositions and is generally safe, non-toxic, and not biologically or otherwise undesirable, particularly for human pharmaceutical use.

[0068] The term "about" is used herein to mean approximately, in the region of, roughly, or in the vicinity. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values ​​set forth. In general, the term "about" is used to modify a numerical value above and below the stated value by a deviation of 20%.

[0069] Technical and scientific terms used herein but not specifically defined have the meaning commonly understood by one of ordinary skill in the art to which this disclosure belongs. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0070] Embodiment 1. A compound of formula (I):

[0071] [ka]

[0072] [In the above formula, Z1 and Z2 are independently N or C, and

[0073] [ka]

[0074] is a 5-membered heteroaryl containing 1, 2, 3 or 4 ring heteroatoms selected from N, O or S; said 5-membered heteroaryl is selected from deuterium, halo, hydroxy, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -CN, Mercapto, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-OH, and -(C 1-6 Alkyl)-O-(C 1-6alkyl), wherein the C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 Each haloalkyl may be optionally substituted with one or more deuterium atoms; L is absent or L is -NR c , O, or S; R c is hydrogen or C 1-6 is alkyl; Ar is deuterium, halo, hydroxy, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -CN, Mercapto, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), C 3-8 Heteroaryl optionally substituted with one or more substituents independently selected from cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl, wherein 1-6 Alkyl, C 1-6 Alkoxyl, C 1-6 Haloalkyl, C 3-8 Each of cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl may be optionally substituted with one or more deuterium atoms; R1 is hydrogen; C optionally substituted with one or more deuterium atoms; 1-6 Alkyl;C 2-6 Alkenyl; C 2-6 Alkynyl; C 1-6 Haloalkyl;-(C 1-6 alkyl)-OH;-(C 1-6 Alkyl)-O-(C 1-6 Alkyl);-(C 1-6 Alkyl)-(C 3-8 Cycloalkyl);-(C 1-6alkyl)-(3-8 membered heterocyclyl);-(C 1-6 alkyl)-phenyl;-(C 1-6 Alkyl)-heteroaryl;C 3-8 cycloalkyl; 3- to 8-membered heterocyclyl; phenyl; and heteroaryl, wherein said C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Each of cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl is selected from the group consisting of deuterium, halo, -CN, hydroxy, mercapto, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), C 3-8 Cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, heteroaryl, C optionally substituted with one or more deuterium atoms 1-6 Alkyl, C 1-6 Alkoxyl, and C 1-6 haloalkyl; R2 is hydrogen, deuterium, halo, hydroxy, amino, -NH(C 1-6 alkyl), -N(C 1-6 alkyl), -CN, mercapto, C optionally substituted with one or more deuterium 1-6 Alkyl;C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 alkyl), -(C 1-6 Alkyl)-(C 3-8 Cycloalkyl), -(C 1-6 alkyl)-(3-8 membered heterocyclyl), -(C 1-6 alkyl)-phenyl, -(C 1-6 Alkyl)-heteroaryl, C 3-8cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl, 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Each of cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl is selected from the group consisting of deuterium, halo, -CN, hydroxy, mercapto, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), C 1-6 Alkyl, C 1-6 Alkoxyl, C 1-6 optionally substituted with one or more substituents independently selected from haloalkyl, and oxo;

[0075] R a and R b are independently hydrogen, deuterium, halo, hydroxy, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), -CN, Mercapto, C 1-6 Alkyl, C 1-6 Alkoxyl, and C 1-6 haloalkyl; or R a and R b together with the carbon atom to which they are attached, 3-6 cycloalkyl or 4- to 6-membered heterocyclyl, 3-6 Each of the cycloalkyl and 4- to 6-membered heterocyclyl groups may be selected from the group consisting of deuterium, halo, -CN, hydroxy, mercapto, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), C 1-6 Alkyl, C 1-6Alkoxyl, and C 1-6 optionally substituted with one or more substituents independently selected from haloalkyl;

[0076] [ka] is a double bond or a single bond, and

[0077] [ka] is a double bond, then R3 and R5 are absent;

[0078] R3, R4, R5, R6, R7 and R8 are hydrogen, deuterium, halo, hydroxy, -CN, mercapto, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), C 1-6 Alkyl, -(C 1-6 Alkyl)-phenyl, C 1-6 Alkoxy and C 1-6 haloalkyl; or any two of R3, R4, R5, R6, R7 and R8 together with the carbon atom to which they are attached and the B ring may form an 8-13 membered spiro, fused or bridged ring, optionally containing 1-3 ring heteroatoms independently selected from N, O or S; wherein said spiro, fused or bridged ring is selected from deuterium, halo, -CN, hydroxy, mercapto, amino, -NH(C 1-6 alkyl), -N(C 1-6 Alkyl)2, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6optionally substituted with one or more substituents independently selected from haloalkyl; or R3 and R4 taken together, R5 and R6 taken together, or R7 and R8 taken together represent oxo; n is 0, 1 or 2; m is 0, 1, 2, 3, 4 or 5. or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

[0079] Embodiment 2.

[0080] [ka] but

[0081] [ka]

[0082] is selected from Here, R 10 and R 11 is hydrogen, deuterium, halo, hydroxy, amino, -CN, mercapto, C 1-6 Alkyl, C 1-6 Alkoxyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-OH, and -(C 1-6 Alkyl)-O-(C 1-6 alkyl), wherein said C 1-6 Alkyl, C 1-6 Alkoxyl, and C 1-6 A compound according to embodiment 1, a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof, wherein each haloalkyl is optionally substituted with one or more deuterium atoms.

[0083] Embodiment 3.

[0084] [ka] but

[0085] [ka]

[0086] is selected from Here, R 10 and R 11 is hydrogen, halo, -CN, C 1-6 Alkyl, C 1-6 Alkoxy and C 1-6 haloalkyl; or a pharma- ceutically acceptable salt thereof; or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof, as described in embodiment 1.

[0087] Embodiment 4.

[0088] [ka] but

[0089] [ka]

[0090] and R 10 and R 11 are hydrogen, halo, and C 1-6 or a pharma- ceutically acceptable salt thereof; or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof, as described in embodiment 3, wherein:

[0091] Embodiment 5. Ar is a monocyclic heteroaryl having 5 or 6 ring atoms, 1, 2 or 3 of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon; each of which is deuterium, halo, hydroxy, amino, -CN, mercapto, C 1-6 Alkyl, C 1-6 Alkoxyl, C 1-6 Haloalkyl, -(C 1-6 alkyl)-OH, -(C 1-6 Alkyl)-O-(C 1-6 Alkyl), C 3-8 and optionally substituted by one or more substituents independently selected from cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl, wherein 1-6 Alkyl, C 1-6 Alkoxyl, C 1-6 Haloalkyl, C 3-8 A compound according to any one of embodiments 1-4, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof, wherein each of cycloalkyl, 3-8 membered heterocyclyl, phenyl, and heteroaryl may be optionally substituted with one or more deuterium atoms.

[0092] Embodiment 6. Ar is selected from pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazolyl and thiazolyl (more preferably, Ar is selected from pyridyl, pyrimidinyl and 1,3,5-triazinyl), each of which is optionally substituted by halo; -CN; C optionally substituted by one or more deuteriums. 1-6 Alkyl;C 1-6 Alkoxyl; and C 1-6 haloalkyl, a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof, as described in embodiment 5.

[0093] Embodiment 7. Ar

[0094] [ka]

[0095] where R 20 , R 21 , R 22 , R 23 , and R 24 is hydrogen; halo; -CN; C optionally substituted with one or more deuterium atoms; 1-6 Alkyl;C 1-6 Alkoxyl; and C 1-6 haloalkyl, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof, as described in embodiment 6.

[0096] Embodiment 8. R1 is C 1-6 Alkyl;-(C 1-6 Alkyl)-OH;Saturated monocyclic C 3-8 a cycloalkyl; a saturated monocyclic 3- to 8-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from N, O, and S; and a heteroaryl, wherein the heteroaryl is a monocyclic aromatic hydrocarbon having 5 or 6 ring atoms, 1, 2, 3, or 4 of which are ring heteroatoms independently selected from N, O, and S, and the remaining ring atoms are carbon, or a bicyclic aromatic hydrocarbon having 8, 9, or 10 ring atoms, 1, 2, or 3 of which are ring heteroatoms independently selected from N, O, and S, and the remaining ring atoms are carbon, wherein at least one of the rings is aromatic, and when the total number of S and O atoms in the heteroaryl group exceeds 1, the S and O atoms are not adjacent to one another, and the C 3-8 Each of cycloalkyl, 3- to 8-membered heterocyclyl, and heteroaryl is selected from the group consisting of halo; -(C 1-6alkyl)-OH;-(C 1-6 Alkyl)-O-(C 1-6 alkyl; 3- to 6-membered heterocyclyl; C optionally substituted with one or more deuterium 1-6 Alkyl;C 1-6 Alkoxyl; or C 1-6 haloalkyl, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof, as defined in any one of embodiments 1-7, optionally substituted by one or more substituents independently selected from:

[0097] Embodiment 9. R1 is a heteroaryl selected from pyrazolyl, pyridyl, isoxazolyl, 1,2,4-triazolyl, 1,3,4-thiadiazolyl, 2,4,5,6-tetrahydrocyclopentadieno[c]pyrazolyl, and 5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridyl, each of which is optionally substituted with one or more deuterium atoms. 1-6 Alkyl;C 1-6 Haloalkyl;C 1-6 Alkoxyl;Halo;-(C 1-6 alkyl)-OH;-(C 1-6 Alkyl)-O-(C 1-6 or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof, as defined in embodiment 8, optionally substituted by one or more substituents independently selected from: (a) aryl, (b) aryl, (c) aryl, (d) aryl, (e) aryl, (f) aryl, (g) aryl, (h) aryl, (i) aryl, (j ...

[0098] Embodiment 10. R1 is pyrazolyl, which is a C optionally substituted with one or more deuterium atoms. 1-6 Alkyl;C 1-6 Haloalkyl;C 1-6 Alkoxyl;Halo;-(C 1-6 alkyl)-OH;-(C1-6 Alkyl)-O-(C 1-6 10. The compound of formula (I) as defined in embodiment 9, optionally substituted with one or more substituents independently selected from: alkyl; aryl; and oxetanyl; or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

[0099] Embodiment 11. R2 is halo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, saturated monocyclic C 3-8 and selected from cycloalkyl, phenyl, and heteroaryl, wherein said heteroaryl is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, one, two or three of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, or a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, one, two, three or four of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, wherein at least one of the rings is aromatic, and when the total number of S and O atoms in said heteroaryl group exceeds 1, said S and O heteroatoms are not adjacent to one another, and said C 3-8 Cycloalkyl, phenyl and heteroaryl are not limited to halo, -CN, C 1-6 Alkyl, C 1-6 Alkoxyl, C 1-6 A compound of formula (I) as defined in any one of embodiments 1 to 10, optionally substituted with one or more substituents independently selected from haloalkyl and oxo, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

[0100] Embodiment 12. R2 is phenyl, wherein said phenyl is selected from halo, -CN and C 1-6A compound of formula (I), as defined in embodiment 11, optionally substituted with one or more substituents independently selected from alkoxyl, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

[0101] Embodiment 13. R2 is a heteroaryl selected from 1,2,5-oxadiazolyl, indolyl, indolinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, pyrazolyl, oxazolyl, isoxazolyl, pyridyl, thiazolyl, isothiazolyl, benzo[d]isoxazolyl, thienyl, indazolyl, and pyrrolyl, each of which is selected from C 1-6 A compound of formula (I) as defined in embodiment 11, optionally substituted with one or more substituents independently selected from alkyl, halo, oxo, and -CN, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

[0102] Embodiment 14. R2 is C 1-6 A saturated monocyclic C ring optionally substituted with one or more substituents independently selected from haloalkyl 3-8 A compound of formula (I) as defined in embodiment 11, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof, wherein R is cycloalkyl.

[0103] Embodiment 15. A compound of formula (I) as defined in any one of embodiments 1 to 14, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof, wherein m is 0, 1, or 2.

[0104] Embodiment 16.R a and Rb are hydrogen, halo, hydroxy, and C 1-6 alkyl; or R a and R b together with the carbon atom to which they are attached form a saturated monocyclic C 3-6 forming a cycloalkyl or a 3- to 6-membered heterocyclyl, wherein said 3- to 6-membered heterocyclyl has 3 to 6 ring atoms, one or two of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon; wherein said saturated monocyclic C 3-6 A compound of formula (I) according to any one of embodiments 1 to 15, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof, wherein cycloalkyl or 3- to 6-membered heterocyclyl is optionally substituted with one or more substituents selected from halo.

[0105] Embodiment 17. A compound of formula (I) according to any one of embodiments 1 to 16, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof, wherein L is absent or L is NH, O or S.

[0106] Embodiment 18. A compound of formula (I) as defined in embodiment 1, or a pharma- ceutically acceptable salt thereof, wherein the compound of formula (I) is selected from compounds 1-322.

[0107] 19. n is 0,

[0108] [ka]

[0109] is a double bond, R3 and R5 are absent, R4 and R6 are hydrogen and C 1-6or a pharma- ceutically acceptable salt thereof; or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof, as described in embodiment 1, wherein:

[0110] Embodiment 20. The compound of formula (I) is a compound of formula (I-1):

[0111] [ka]

[0112] where R1 is a heteroaryl, which is optionally substituted with one or more deuterium atoms. 1-6 Alkyl;C 1-6 Haloalkyl;C 1-6 Alkoxyl;Halo; -(C 1-6 alkyl)-OH;-(C 1-6 Alkyl)-O-(C 1-6 alkyl), and 3- to 6-membered heterocyclyl; Ar is heteroaryl, the heteroaryl being halo; -CN; C optionally substituted with one or more deuterium atoms. 1-6 Alkyl;C 1-6 Alkoxyl; and C 1-6 haloalkyl; R2 is halo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, saturated monocyclic C 3-8 cycloalkyl, phenyl, and heteroaryl, wherein the saturated monocyclic C 3-8 Each of cycloalkyl, phenyl or heteroaryl is selected from halo, -CN, C 1-6 Alkyl, C 1-6 Alkoxyl, C 1-6optionally substituted with one or more substituents independently selected from haloalkyl, and oxo; R4 and R6 are hydrogen and C 1-6 independently selected from alkyl; R 10 and R 11 is hydrogen, halo, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, and -(C 1-6 alkyl)-OH; m is 0, 1 or 2; R a and R b is hydrogen, halo, hydroxy or C 1-6 alkyl; or R a and R b together with the carbon atom to which they are attached form a saturated monocyclic C 3-6 forming a cycloalkyl or a 3- to 6-membered heterocyclyl, wherein said 3- to 6-membered heterocyclyl has 3 to 6 ring atoms, one or two of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon; wherein said saturated monocyclic C 3-6 The cycloalkyl or 3- to 6-membered heterocyclyl may be optionally substituted with one or more substituents selected from halo; L is absent or L is NH, O or S; The compound of formula (I) according to embodiment 19, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof, wherein the heteroaryl is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, of which 1, 2 or 3 are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, or a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, of which 1, 2, 3 or 4 are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, wherein at least one of the rings is aromatic, and when the total number of S and O atoms in the heteroaryl group exceeds 1, the S and O heteroatoms are not adjacent to one another.

[0113] EMBODIMENT 21. R1 is C 1-6 pyrazolyl optionally substituted with one or more substituents independently selected from alkyl; Ar is pyrimidinyl, which is optionally substituted with one or more deuterium atoms; 1-6 optionally substituted with one or more substituents independently selected from alkyl, halo, and aryl; R2 is C 1-6 haloalkyl or phenyl, wherein said phenyl is optionally substituted with one or more substituents independently selected from halo; R 10 and R 11 is hydrogen; m is 0 or 1; R a and R b is hydrogen or C 1-6 alkyl; or R a and R b together with the carbon to which they are attached form a saturated monocyclic C 3-6 forming a cycloalkyl; and L is absent or L is NH or O; A compound of formula (I) as defined in embodiment 20, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

[0114] Embodiment 22. The compound of formula (I) is:

[0115] [Table 1-1] [Table 1-2]

[0116] or a pharma- ceutically acceptable salt thereof.

[0117] 23. n is 0,

[0118] [ka]

[0119] is a single bond; R3, R4, R5 and R6 are hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -(C 1-6 Alkyl)-O-(C 1-6 alkyl), and -(C 1-6 or any pair of R3 and R4, or R5 and R6, together with the carbon atom to which they are attached, form a saturated monocyclic C 3-6A compound of formula (I) as defined in embodiment 1, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof, wherein R1 is 0 or 1; R2 is 1 or 2; and R3 is 2 or 3.

[0120] Embodiment 24. The compound of formula (I) is a compound of formula (I-2),

[0121] [ka]

[0122] In the above formula, R1 is C 1-6 Alkyl, -(C 1-6 Alkyl)-OH, saturated monocyclic C 3-8 cycloalkyl, saturated 3-8 membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from N, O and S, and heteroaryl; 3-8 Each of cycloalkyl, 3- to 8-membered heterocyclyl, and heteroaryl is selected from the group consisting of halo; -(C 1-6 alkyl)-OH;-(C 1-6 Alkyl)-O-(C 1-6 alkyl; saturated 3- to 6-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from N, O and S; C optionally substituted with 1 or 2 deuterium 1-6 Alkyl;C 1-6 Alkoxyl; and C 1-6 haloalkyl; Ar is heteroaryl, halo; -CN; C optionally substituted with one or more deuterium atoms. 1-6 Alkyl;C 1-6 Alkoxyl; and C 1-6haloalkyl; heteroaryl optionally substituted with one or more substituents independently selected from; R2 is halo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, saturated monocyclic C 3-8 cycloalkyl, phenyl or heteroaryl, 3-8 Each of cycloalkyl, phenyl or heteroaryl is selected from halo, -CN, C 1-6 Alkyl, C 1-6 Alkoxyl, C 1-6 optionally substituted with one or more substituents independently selected from haloalkyl, and oxo; The Z3 is a CR 10 or N; R3, R4, R5 and R6 are hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -(C 1-6 Alkyl)-O-(C 1-6 alkyl), and -(C 1-6 or any pair of R and R, or R and R, together with the carbon atom to which they are attached, are selected from saturated monocyclic C 3-6 forming a cycloalkyl or a saturated monocyclic 3- to 6-membered heterocyclyl having 1 or 2 ring heteroatoms selected from N, O and S, thereby forming a spiro ring together with ring B; R 10 and R 11 is hydrogen, halo, C 1-6 Alkyl, C 1-6 Alkoxyl, C 1-6 Haloalkyl, and -(C 1-6 alkyl)-OH; m is 0, 1 or 2;

[0123] R a and R b is hydrogen, halo, hydroxy, or C 1-6 alkyl; or R a and R btogether with the carbon to which they are attached form a saturated monocyclic C 3-6 forming a cycloalkyl or a 3- to 6-membered heterocyclyl, wherein said 3- to 6-membered heterocyclyl has 3 to 6 ring atoms, one or two of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon; wherein said saturated monocyclic C 3-6 The cycloalkyl or 3- to 6-membered heterocyclyl may be optionally substituted with one or more substituents selected from halo; L is absent or L is NH, O or S; said heteroaryl is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, one, two or three of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, or a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, one, two, three or four of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, wherein at least one of the rings is aromatic, and when the total number of S and O atoms in the heteroaryl group exceeds 1, said S and O atoms are not adjacent to one another; A compound of formula (I) as defined in embodiment 23, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

[0124] 25. R1 is selected from saturated monocyclic 3-8 membered heterocyclyl containing 1 or 2 heteroatoms independently selected from N, O and S, and heteroaryl; wherein said heteroaryl is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, 1, 2 or 3 of which are 1 or 2 heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, or a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, 1, 2, 3 or 4 of which are ... 1-6 Alkyl, C 1-6 Haloalkyl, halo, -(C 1-6 Alkyl)-OH, C 1-6 Alkoxyl, -(C 1-6 Alkyl)-O-(C 1-6 alkyl), and saturated monocyclic 3- to 6-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from N, O and S; Ar is a heteroaryl having 5 or 6 ring atoms, one, two or three of which are ring heteroatoms independently selected from N, O and S, the remaining ring atoms are carbon, and if the total number of S and O atoms in the heteroaryl group exceeds 1, the S and O atoms are not adjacent to one another, and the heteroaryl is optionally substituted with one or more deuterium atoms. 1-6 optionally substituted with one or more substituents independently selected from alkyl, halo, and aryl; R2 is halo, C 1-6 Alkyl, C 1-6and wherein said heteroaryl is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, one, two or three of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon; or a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, one, two, three or four of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, wherein at least one of said rings is aromatic, and when the total number of S and O atoms in the heteroaryl group exceeds 1, said S and O atoms are not adjacent to one another, and wherein each of said phenyl and heteroaryl is selected from halo, C 1-6 Alkyl, C 1-6 optionally substituted with 1 or 2 substituents independently selected from alkoxyl, and oxo; Z3 is CR 10 or N; R3, R4, R5 and R6 are hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -(C 1-6 Alkyl)-O-(C 1-6 alkyl), and -(C 1-6 or any pair of R and R, or R and R, together with the carbon atom to which they are attached, are selected from saturated monocyclic C 3-6 forming a cycloalkyl or a monocyclic 3- to 6-membered heterocyclyl having 1 or 2 ring heteroatoms selected from N, O and S, thereby forming a spiro ring together with ring B; m is 1 or 2; R a and R b are independently selected from hydrogen and halo; or R a and R b together with the carbon to which they are attached form a saturated monocyclic C 3-6 Forming a cycloalkyl; R 10 and R 11 is hydrogen; L is absent or L is O, A compound of formula (I) as defined in embodiment 24, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

[0125] Embodiment 26. R1 is selected from morpholinyl, thiomorpholinyl, and heteroaryl, wherein said heteroaryl is selected from pyrazolyl, 2,4,5,6-tetrahydrocyclopentadieno[c]pyrazolyl, 1,2,4-triazolyl, 5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridyl, 1,3,4-thiadiazolyl, and pyridyl, and said heteroaryl is C 1-6 Alkyl, C 1-6 Haloalkyl, halo, -(C 1-6 Alkyl)-OH, C 1-6 Alkoxyl, -(C 1-6 Alkyl)-O-(C 1-6 26. The compound of formula (I) as defined in embodiment 25, optionally substituted with one or more substituents independently selected from: alkyl, aryl, aryloxy ...

[0126] Embodiment 27. Ar is a heteroaryl selected from pyridyl, pyrimidinyl, and 1,3,5-triazinyl; wherein said heteroaryl is a C optionally substituted with one or more deuterium atoms. 1-6 A compound of formula (I) as defined in embodiment 24, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or a pharma- ceutically acceptable salt thereof, each optionally substituted with one or more substituents selected from alkyl, and halo.

[0127] Embodiment 28. Ar

[0128] [ka]

[0129] where R 20 , R 21 , R 22 , R 23 , and R 24 is optionally substituted with hydrogen, halo, and one or more deuteriums; 1-6 28. The compound of formula (I) as defined in embodiment 27, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or a pharma- ceutically acceptable salt thereof, wherein:

[0130] Embodiment 29. R2 is halo, C 1-6 Alkyl, C 1-6 and wherein said heteroaryl is selected from isoxazolyl, 1,2,5-oxadiazolyl, pyrazolyl, oxazolyl, pyridyl, thiazolyl, isothiazolyl, thienyl, and benzo[d]isoxazolyl; and wherein each of said phenyl and heteroaryl is selected from halo, C 1-6 Alkyl, C 1-6 A compound of formula (I), as defined in embodiment 24, optionally substituted with one or more substituents independently selected from alkoxyl, and oxo, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

[0131] Embodiment 30. A compound of formula (I)

[0132] [Table 2-1] [Table 2-2]

Table 2-3

Table 2-4

Table 2-5

Table 2-6

Table 2-7

Table 2-8

Table 2-9

Table 2-10

Table 2-11

Table 2-12

Table 2-13

Table 2-14

Table 2-15

Table 2-16

Table 2-17

Table 2-18

Table 2-19

[0133] or a pharma- ceutically acceptable salt thereof.

[0134] 31. n is 1,

[0135] [ka]

[0136] is a single bond, and R3, R4, R5, R 6、 R7 and R8 are hydrogen, halo, hydroxy, C 1-6 Alkyl, and C 1-6 alkoxyl; 1-6 Alkyl is hydroxy and C 1-6 or any two of R3, R4, R5, R6, R7 and R8 together with the carbon atom to which they are attached and the B ring form a 9-12 membered spiro, fused or bridged ring which optionally contains 1-3 ring heteroatoms selected from N, O or S; wherein said spiro, fused or bridged ring is selected from halo, hydroxy, amino, C 1-6 2. A compound of formula (I) according to claim 1, optionally substituted with one or more substituents independently selected from alkyl and -CN, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

[0137] Embodiment 32. The compound of formula (I) is a compound of formula (I-3),

[0138] [ka]

[0139] Where: R1 is C 1-6 Alkyl, -(C 1-6 Alkyl)-OH, saturated monocyclic C 3-8 cycloalkyl, saturated monocyclic 3- to 8-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from N, O and S, and heteroaryl; 3-8 Each of cycloalkyl, 3- to 8-membered heterocyclyl, and heteroaryl is optionally substituted with halo; 1-6 Alkyl;C 1-6 Alkoxyl; and C 1-6 haloalkyl; Ar is heteroaryl, halo; -CN; C optionally substituted with one or more deuterium atoms. 1-6 Alkyl;C 1-6 Alkoxyl; and C 1-6 haloalkyl; heteroaryl optionally substituted with one or more substituents independently selected from; R2 is halo, -CN, C 1-6 Alkyl, C 1-6 Haloalkyl, saturated monocyclic C 3-8 cycloalkyl, phenyl, or heteroaryl, wherein the saturated monocyclic C 3-8 Each of cycloalkyl, phenyl, or heteroaryl is selected from halo, -CN, C 1-6 Alkyl, C 1-6 Alkoxyl, C 1-6 optionally substituted with one or more substituents independently selected from haloalkyl, and oxo; R3, R4, R5, R6, R7 and R8 are hydrogen, halo, hydroxy, C 1-6 Alkyl and C 1-6 alkoxyl; wherein said C 1-6 Alkyl is hydroxy and C 1-6or any two of R, R, R, R, R, R, and R, together with the carbon atom to which they are attached and the B ring, are

[0140] [ka]

[0141] where R d is selected from hydrogen or halo; t is 0, 1, 2 or 3; R 10 and R 11 is hydrogen, halo, C 1-6 Alkyl, C 1-6 Alkoxyl, C 1-6 Haloalkyl, and -(C 1-6 alkyl)-OH; m is 0, 1 or 2; R a and R b is hydrogen, halo, hydroxy, or C 1-6 alkyl; or R a and R b together with the carbon to which they are attached form a saturated monocyclic C 3-6 forming a cycloalkyl or a 4- to 6-membered heterocyclyl, wherein said 4- to 6-membered heterocyclyl has 4 to 6 ring atoms, one or two of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon; wherein said saturated C 3-6 Each cycloalkyl or 4- to 6-membered heterocyclyl may be optionally substituted with one or more substituents selected from halo; L is absent or L is NH, O or S; said heteroaryl is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, one, two or three of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, or a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, one, two, three or four of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, wherein at least one of the rings is aromatic, and when the total number of S and O atoms in said heteroaryl group exceeds 1, said S and O atoms are not adjacent to one another; A compound of formula (I) as defined in embodiment 31, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

[0142] Embodiment 33. R1 is C 1-6 Alkyl, -(C 1-6 Alkyl)-OH, saturated monocyclic C 3-8 cycloalkyl, saturated monocyclic 3- to 8-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from N, O and S, and heteroaryl; 3-8 Each of cycloalkyl, 3- to 8-membered heterocyclyl and heteroaryl is selected from halo, C 1-6 Alkoxyl, C 1-6 Haloalkyl and C optionally substituted with one or more deuterium atoms 1-6 optionally substituted with one or more substituents independently selected from alkyl; Ar is a heteroaryl having 5 or 6 ring atoms, one, two or three of which are ring heteroatoms independently selected from N, O and S, the remaining ring atoms are carbon, and if the total number of S and O atoms in the heteroaryl group exceeds 1, the S and O atoms are not adjacent to one another; wherein the heteroaryl is a C optionally substituted with halo; -CN; 1-6 Alkyl;C 1-6Alkoxyl; and C 1-6 haloalkyl; R2 is -CN, C 1-6 Haloalkyl, saturated monocyclic C 3-8 cycloalkyl, phenyl, or heteroaryl, wherein said heteroaryl is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, one, two or three of which are 1 or 2 ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, or a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, one, two, three or four of which are 1, 2, three or four ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, wherein at least one of said rings is aromatic, and when the total number of S and O atoms in the heteroaryl group exceeds 1, said S and O atoms are not adjacent to one another; 3-8 Each of cycloalkyl, phenyl or heteroaryl is selected from halo, -CN, C 1-6 Alkyl and C 1-6 optionally substituted with one or more substituents independently selected from haloalkyl; R3, R4, R5, R6, R7 and R8 are hydrogen, halo, hydroxy, C 1-6 Alkyl and C 1-6 alkoxyl; wherein said C 1-6 Alkyl is hydroxy and C 1-6 or any two of R, R, R, R, R, R, R, and R, together with the carbon atom to which they are attached and the B ring, are

[0143] [ka]

[0144] where R d is selected from hydrogen and halo, and t is 0, 1, 2, or 3; R 10 and R 11 is hydrogen, halo, and C 1-6 independently selected from alkyl; m is 0, 1 or 2; R a and R b is hydrogen, halo, hydroxy, and C 1-6 alkyl; or R a and R b together with the carbon to which they are attached form a saturated monocyclic C 3-6 forming a cycloalkyl or a 3- to 6-membered heterocyclyl, wherein said 3- to 6-membered heterocyclyl has 3 to 6 ring atoms, one or two of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon; wherein said saturated monocyclic C 3-6 Each cycloalkyl or 3- to 6-membered heterocyclyl may be optionally substituted with one or more substituents selected from halo; L is absent or L is NH or O A compound of formula (I) as defined in embodiment 32, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

[0145] Embodiment 34. R1 is selected from the group consisting of (1) C 1-6 Alkyl, (2)-(C 1-6 (3) halo and C 1-6 A saturated monocyclic C optionally substituted with one or more substituents independently selected from alkoxyl 3-8 (4) saturated monocyclic 6-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from N, O and S; and (5) heteroaryl selected from pyrazolyl, pyridyl and isoxazolyl, wherein said heteroaryl is selected from C 1-6 Alkoxyl, C 1-6 Haloalkyl and C optionally substituted with one or more deuterium atoms 1-633. The compound of formula (I), as defined in embodiment 32, optionally substituted with one or more substituents independently selected from: alkyl, aryl, aryloxy ...

[0146] Embodiment 35. Ar is a heteroaryl selected from pyridyl and pyrimidinyl, wherein said heteroaryl is halo; -CN; C optionally substituted with one or more deuterium atoms. 1-6 A compound of formula (I) as described in embodiment 32, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or a pharma- ceutically acceptable salt thereof, each of which may be optionally substituted with one or more substituents independently selected from alkyl, C1-6 alkoxyl, C1-6 haloalkyl.

[0147] Embodiment 36. Ar

[0148] [ka]

[0149] where R 20 , R 21 , R 22 , R 23 and R 24 is hydrogen; halo; -CN; C optionally substituted with one or more deuterium atoms; 1-6 Alkyl;C 1-6 Alkoxyl; and C 1-6 haloalkyl; or a pharma- ceutically acceptable salt thereof; or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof, as recited in embodiment 35.

[0150] Embodiment 37. R2 is (1) -CN, (2) C 1-6Haloalkyl, (3)C 1-6 A saturated monocyclic C ring optionally substituted with one or more substituents selected from haloalkyl 3-8 (4) phenyl optionally substituted with one or more substituents independently selected from halo and -CN; and (5) heteroaryl selected from 1,2,5-oxadiazolyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, pyrazolyl, indazolyl, and pyrrolyl, wherein said heteroaryl is selected from halo, -CN, and C. 1-6 A compound of formula (I), as defined in embodiment 32, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof, each optionally substituted with one or more substituents independently selected from alkyl.

[0151] Embodiment 38. The compound of formula (I) is

[0152] [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] [Table 3-8] [Table 3-9] [Table 3-10] [Table 3-11] [Table 3-12] [Table 3-13] [Table 3-14] [Table 3-15]

[0153] or a pharma- ceutically acceptable salt thereof.

[0154] Embodiment 39. A pharmaceutical composition comprising a compound according to any one of embodiments 1 to 38, or a pharma- ceutically acceptable salt thereof, and optionally a pharma- ceutically acceptable carrier.

[0155] Embodiment 40. A method for inhibiting the activity of ERK in vivo or in vitro, comprising contacting ERK with an effective amount of a compound according to any one of embodiments 1 to 38, or a pharma- ceutically acceptable salt thereof.

[0156] Embodiment 41 Use of a compound according to any one of embodiments 1 to 38, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a disease responsive to inhibition of ERK.

[0157] Embodiment 42. The use according to embodiment 41, wherein the medicament is used to treat cancer or an autoimmune disease.

[0158] Embodiment 43. The use of embodiment 42, wherein the cancer is a solid tumor or a hematological malignancy, such as leukemia, lymphoma, colorectal cancer, melanoma, glioma, pancreatic cancer, breast cancer, lung cancer (such as non-small cell lung cancer), thyroid cancer (such as papillary thyroid carcinoma), or ovarian cancer.

[0159] Embodiment 44. A method for treating or preventing a disease responsive to inhibition of ERK, comprising administering to a subject in need thereof an effective amount of a compound according to any one of embodiments 1 to 38 or a pharma- ceutically acceptable salt thereof.

[0160] Embodiment 45. A compound according to any one of embodiments 1 to 38, or a pharma- ceutically acceptable salt thereof, for use in the treatment or prevention of a disease responsive to inhibition of ERK.

[0161] Embodiment 46. A compound according to any one of embodiments 1 to 38, or a pharma- ceutically acceptable salt thereof, for use as a medicament.

[0162] Embodiment 47. A compound according to embodiment 46, or a pharma- ceutically acceptable salt thereof, for use as a medicament for treating or preventing a disease responsive to the inhibition of ERK.

[0163] Embodiment 48. A compound according to embodiment 47, or a pharma- ceutically acceptable salt thereof, for use as a medicament for treating or preventing cancer or an autoimmune disease.

[0164] Embodiment 49. The compound of claim 48, or a pharmaceutically acceptable salt thereof, wherein the cancer is a solid tumor or a hematological malignancy, such as leukemia, lymphoma, colorectal cancer, melanoma, glioma, pancreatic cancer, breast cancer, lung cancer (non-small cell lung cancer), thyroid cancer (such as papillary thyroid cancer), or ovarian cancer.

[0165] Embodiment 50. A combination comprising a compound according to any one of embodiments 1 to 38, or a pharma- ceutically acceptable salt thereof, and at least one additional therapeutic agent.

[0166] Embodiment 51. The combination of embodiment 50, wherein the additional therapeutic agent is an anti-tumor agent, such as a radiotherapeutic agent, a chemotherapy agent, an immunotherapy agent, or a targeted therapy agent.

[0167] Embodiment 52. A compound of formula (II):

[0168] [ka]

[0169] or a racemic mixture or enantiomer thereof, R9 being a leaving group; R 10 and R 11 are hydrogen, halo, and C 1-6 alkyl; R3, R4, R5, R6, R7 and R8 are independently selected from hydrogen, halo, C 1-6 Alkyl, C 1-6 Alkoxyl, or C 1-6 haloalkyl; or any two of R, R, R, R, R, R and R, together with the carbon atom to which they are attached and the B ring, are

[0170] [ka]

[0171] where R d is selected from hydrogen and halo, and t is 0, 1, 2, or 3; 10 and R 11 are hydrogen, then R3, R4, R5, R6, R7 and R8 may not all be hydrogen, and when one of R3, R4, R5, R6, R7 and R8 is methyl, the others may not all be hydrogen, or a racemic mixture or enantiomer thereof.

[0172] EMBODIMENT 53.

[0173] [ka]

[0174] The compound of embodiment 52, selected from:

[0175] Embodiment 54. A compound of formula (III):

[0176] [ka]

[0177] or a racemic mixture or enantiomer thereof, R9 is a leaving group; R 10 and R 11 are independently hydrogen, halo and C 1-6 alkyl; R3, R4, R5 and R6 are independently hydrogen, halo, C 1-6 Alkyl, C 1-6 Alkoxyl, C 1-6 C optionally substituted with haloalkyl, or phenyl 1-6 alkyl; or any pair of R and R, or R and R, together with the carbon atom to which they are attached, are selected from saturated C 3-6 cycloalkyl or a saturated 3-4 membered heterocyclyl having one or two heteroatoms selected from N, O and S, thereby forming a spiro ring together with ring B; provided that R3, R4, R5 and R6 cannot all be hydrogen, and one or two of R3, R4, R5 and R6 are C; 1-6 A compound, or a racemic mixture or enantiomer thereof, with the proviso that if it is alkyl, the others cannot all be hydrogen.

[0178] Embodiment 55. The following:

[0179] [ka]

[0180] The compound of formula (III) as defined in embodiment 54, selected from: General synthesis method for compounds

[0181] The compounds of formula (I) and / or pharma- ceutically acceptable salts thereof described herein can be synthesized from commercially available starting materials by methods well known in the art and disclosed in patent applications. The synthetic route shown in Figure 1 outlines a general method for preparing the compounds disclosed herein, where X is halo; Z1, Z2,

[0182] [ka]

[0183] , L, R1, R2, R3, R4, R5, R6, R7, R8, R a , R b , m and n are as defined for compounds of formula (I) and subformulas (I-1), (I-2), (I-3); R9 is as defined for compounds of formula (II), (III).

[0184] As shown in FIG. 1, there are mainly three important reactions in the synthesis of these compounds: introduction of amino substituents in the Ar ring; coupling reaction between the fragment of the Ar ring and the tricyclic system; and condensation of the triazole ring to the tricyclic system. Therefore, the synthesis of the target compounds can be carried out in different reaction priorities according to the actual situation. As shown in Route 1, some compounds can be obtained in the order of coupling reaction first, then introducing amino, and finally constructing triazole, for example, Example 8. As shown in Route 2, some compounds can be obtained in the order of synthesizing triazole first to give the tricyclic fragment, then carrying out coupling reaction, and finally introducing amino, for example, Examples 13 and 14. As shown in Route 3, some compounds can be obtained in the order of introducing amino first, then carrying out coupling reaction, and finally constructing triazole, for example, Examples 1 and 7. As shown in Route 4, some compounds can be obtained by combining the methods of Route 2 and Route 3, with coupling reaction proceeding last, for example, Example 12.

[0185] The compounds obtained by the above methods can be further modified at the periphery to provide other desired compounds. Synthetic chemical transformations are described, for example, in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); TW Greene & PGM Wuts, Protective Groups in Organic Synthesis, 3rd Edition, John Wiley and Sons (1999); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) and subsequent editions.

[0186] Prior to use, the compounds of formula (I) described herein and / or pharma- ceutically acceptable salts thereof may be purified by column chromatography, high performance liquid chromatography, crystallization or other suitable methods. Pharmaceutical Compositions and Uses

[0187] The compositions comprising the compounds of formula (I) or pharma- ceutically acceptable salts thereof described herein can be administered in a variety of known ways, for example orally, parenterally, by inhalation, or by implantation. As used herein, the term "parenteral" includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion.

[0188] Oral compositions can be any orally administrable dosage form, including tablets, capsules, pills, powders, emulsions, and aqueous suspensions, dispersions, and solutions. Commonly used carriers for tablets include lactose and cornstarch. Lubricants such as magnesium stearate are also typically added to tablets. For oral administration in capsule form, useful diluents include lactose and dry cornstarch. When aqueous suspensions or emulsions are orally administered, the active ingredient can be suspended or dissolved in the oil phase with the aid of emulsifiers or suspending agents. If desired, certain sweeteners, flavors, or colorants can be added.

[0189] Sterile injectable compositions (e.g., aqueous or oleaginous suspensions) can be formulated using suitable dispersants or wetting agents (e.g., Tween® 80) and suspending agents according to techniques known in the art. Sterile injectable compositions can also be sterile injectable solutions or suspensions in non-toxic parenterally administrable diluents or solvents, for example, as a solution in 1,3-butanediol. Among the pharmaceutically acceptable vehicles (excipients) or solvents that can be used are mannitol, water, Ringer's solution, and isotonic saline. In addition, sterile, fixed oils are conventionally used as solvents or suspending media, for example, synthetic mono- or di-glycerides. Fatty acids such as oleic acid and its glyceride derivatives, as well as natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated forms, are useful in the preparation of injectable compositions. These oily solutions or suspensions can also contain long-chain alcohol diluents or dispersants, or carboxymethylcellulose or similar dispersing agents.

[0190] Inhalation compositions may be prepared according to techniques well known in the pharmaceutical art using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other solubilizing or dispersing agents known in the art, and may also be prepared as solutions in saline.

[0191] The topical composition can be formulated in the form of oils, creams, lotions, ointments, and the like. Suitable carriers for the composition include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats, and high molecular weight alcohols (i.e., alcohols with more than 12 carbon atoms). In some embodiments, the pharma- ceutically acceptable carrier is one in which the active ingredient is soluble. Optionally, the composition may include emulsifiers, stabilizers, humectants, and antioxidants, as well as agents that impart color and fragrance. Additionally, transdermal penetration enhancers may be added to the topical formulation. Examples of such enhancers can be found in U.S. Pat. Nos. 3,989,816 and 4,444,762.

[0192] Creams can be formulated from a mixture of mineral oil, self-emulsifying beeswax and water, in which the active ingredient dissolved in a small amount of oil, such as almond oil, is mixed. An example of such a cream is one that contains about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil, and about 1 part almond oil by weight. Ointments can be formulated by mixing a solution of the active ingredient in a vegetable oil, such as almond oil, with warm soft paraffin and allowing the mixture to cool. An example of such an ointment is one that contains about 30% by weight almond oil and about 70% by weight white soft paraffin.

[0193] A pharma-ceutically acceptable carrier is one that is compatible with the active ingredient of the composition (in some embodiments, can stabilize the active ingredient) and is not harmful to the subject to be treated.For example, solubilizing agents such as cyclodextrins (which can form specific, easily soluble complexes with the compound of formula (I) and / or its pharma-ceutically acceptable salts described herein) can be used as pharmaceutical excipients for the delivery of active ingredients.Other examples of carriers include colloidal silicon dioxide, magnesium stearate, cellulose, sodium lauryl sulfate, and pigments such as D&C Yellow No. 10 (FDA name) (yellow No. 203).

[0194] The efficacy of the compound of formula (I) and / or its pharmaceutically acceptable salt as described herein in inhibiting ERK activity can be preliminarily evaluated using a suitable in vitro assay. For example, the compound of formula (I) and / or its pharmaceutically acceptable salt as described herein can be contacted with ERK kinase or cells, and its inhibition rate on ERK activity can be determined. The compound of formula (I) and / or its pharmaceutically acceptable salt can be further examined for additional efficacy in treating or preventing cancer or autoimmune disease by in vivo assay. For example, the compound of formula (I) and / or its pharmaceutically acceptable salt as described herein can be administered to animals (e.g., mouse models) with cancer or autoimmune disease, and its therapeutic effect can be evaluated. Based on the results, the appropriate dose range and administration route for animals, such as humans, can also be determined.

[0195] The compounds of formula (I) and / or pharma- ceutically acceptable salts thereof described herein can be used to achieve beneficial therapeutic or prophylactic effects, for example, in subjects bearing cancer.

[0196] As used herein, the term "cancer" refers to a cellular disorder characterized by uncontrolled or deregulated cell proliferation, impaired cell differentiation, inappropriate ability to invade surrounding tissues, and / or ability to establish new growths at other sites. The term "cancer" includes, but is not limited to, solid tumors and hematological malignancies. The term "cancer" encompasses cancers of the skin, tissues, organs, bone, cartilage, blood, and blood vessels. The term "cancer" further encompasses primary and metastatic cancers.

[0197] Non-limiting examples of solid tumors include pancreatic cancer; bladder cancer; colorectal cancer; breast cancer, including metastatic breast cancer; prostate cancer, including androgen-dependent and independent prostate cancer; renal cancer, including, for example, metastatic renal cell carcinoma; hepatocellular carcinoma; lung cancer, including, for example, non-small cell lung cancer (NSCLC), bronchioloalveolar carcinoma (BAC) and lung adenocarcinoma; ovarian cancer, for example, advanced epithelial carcinoma or primary peritoneal carcinoma; cervical cancer; gastric cancer; esophageal cancer; head and neck cancer, for example, squamous cell carcinoma of the head and neck; skin cancer, including, for example, melanoma; neuroendocrine carcinoma, including metastatic neuroendocrine tumors; brain tumors, for example, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma; osteosarcoma; sarcoma of soft tissue; thyroid cancer, such as papillary thyroid carcinoma.

[0198] Non-limiting examples of hematological malignancies include acute myeloid leukemia (AML); chronic myeloid leukemia (CML), including aggressive CML and CML blast phases (CML-BP); acute lymphocytic leukemia (ALL); chronic lymphocytic leukemia (CLL); Hodgkin's lymphoma; non-Hodgkin's lymphoma (NHL), including follicular lymphoma and mantle cell lymphoma (MCL); B-cell lymphoma; T-cell lymphoma; multiple myeloma (MM); Waldenstrom's macroglobulinemia; myelodysplastic syndromes (MDS) with refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), and transitional type of RAEB (RAEB-T); and myeloproliferative syndromes.

[0199] The compounds of formula (I) and / or pharma- ceutically acceptable salts thereof described herein can be used to achieve beneficial therapeutic or prophylactic effects, for example, in subjects with autoimmune diseases.

[0200] The term "autoimmune disease" refers to a disease or condition resulting from damage to an individual's own tissues or organs caused by the body's immune response to self-antigens. Autoimmune diseases include chronic obstructive pulmonary disease (COPD), allergic rhinitis, lupus erythematosus, myasthenia gravis, multiple sclerosis (MS), rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD), asthma, idiopathic thrombocytopenic purpura, and myeloproliferative disorders such as myelofibrosis, polycythemia vera / essential thrombocythemia myelofibrosis (PV / post-ET myelofibrosis).

[0201] Furthermore, in the treatment of cancer, the compounds of formula (I) described herein (e.g., compounds of subformula (I-1), (I-2) or (I-3), and compounds 1-321) and / or pharma- ceutically acceptable salts thereof can be used in combination with an additional therapeutic agent. The additional therapeutic agent may be administered separately from the compounds of formula (I) described herein and / or pharma- ceutically acceptable salts thereof, or may be formulated together with the compounds of formula (I) described herein and / or pharma- ceutically acceptable salts thereof in a pharmaceutical composition, e.g., a fixed-dose combination drug product, in accordance with the present disclosure. In some embodiments, the additional therapeutic agent is one known or recognized to be effective in the treatment of diseases mediated by ERK, e.g., another ERK inhibitor, or a compound that antagonizes another target associated with the particular disease. Such combinations may serve to enhance the efficacy, reduce one or more side effects, or reduce the required dosage of the compounds of formula (I) and / or pharma- ceutically acceptable salts thereof described herein (e.g., by including in the composition a compound that enhances the efficacy or efficacy of the compounds of formula (I) and / or pharma- ceutically acceptable salts thereof described herein).

[0202] In some embodiments, the compounds of formula (I) described herein (e.g., compounds of subformulas (I-1), (I-2) or (I-3), and compounds 1-321) and / or pharma- ceutically acceptable salts thereof are administered in combination with an anti-tumor agent. As used herein, "anti-tumor agent" refers to any agent administered to a subject suffering from cancer for the purpose of treating the cancer. Anti-tumor agents include, but are not limited to, radiotherapy agents, chemotherapy agents, immunotherapy agents, and targeted therapy agents.

[0203] Non-limiting examples of chemotherapeutic agents include topoisomerase I inhibitors (e.g., irinotecan, topotecan, camptothecin and their analogs or metabolites, and doxorubicin); topoisomerase II inhibitors (e.g., etoposide, teniposide, mitoxantrone, idarubicin, and daunorubicin); alkylating agents (e.g., melphalan, chlorambucil, busulfan, thiotepa, ifosfamide, carmustine, lomustine, semustine, streptozocin, decarbazine, methotrexate, mitomycin C, and cyclophosphamide); DNA intercalating agents (e.g., cisplatin, oxaliplatin, and carboplatin; DNA intercalators and free radical generators such as bleomycin; nucleoside mimetics (e.g., 5-fluorouracil, capecitabine, gemcitabine, fludarabine, cytarabine, azacitidine (VIDAZA®), mercaptopurine, thioguanine, pentostatin, and hydroxyurea); paclitaxel, docetaxel, and related analogues; vincristine, vinblastine, and related analogues; thalidomide and related analogues (e.g., CC-5013 and CC-4047).

[0204] Non-limiting examples of immunotherapeutics or targeted therapeutics include MEK inhibitors, RAF inhibitors, mTOR inhibitors, PAK inhibitors, CDK inhibitors, VEGFR inhibitors, PARP inhibitors, ERBB inhibitors, PI3K inhibitors, AKT inhibitors, autophagy inhibitors, immune checkpoint inhibitors such as PD-1 inhibitors, PD-L1 inhibitors, and the like. For example, Trametinib, Cobimetinib, Vemurafenib, Dabrafenib, Rapamycin, Temsirolimus, Everolimus, Palbociclib, Ribociclib, Fruquintinib, Olaparib, Niraparib, Neratinib, Chloroquine, Hydroxychloroquine, LXH254, Selumetinib, LY3214996, Abemaciclib, P1446A- 05 (voruciclib), LGX818 (encorafenib), ARRY-162 (binimetinib), cetuximab, gefitinib, panitumumab, BYL719 (alpelisib), bevacizumab, pembrolizumab, and atezolizumab , PDR001 (Spartalizumab), Durvalumab, Nivolumab, Avelumab, Libtayo (Cemiplimab), Tislelizumab, Toripalimab (JS001), Sintilimab, Camrelizumab, etc. EXAMPLES

[0205] The following examples are intended to be purely illustrative of the present invention and should not be construed as limiting in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperatures, etc.), but some experimental error and deviation should be accounted for.

[0206] Unless indicated otherwise, parts are parts by weight, temperature is in degrees Celsius (° C.), and pressure is at or near atmospheric. All MS (mass spectrometry) data was measured on an Agilent 6120 and / or Agilent 1100. 1 H-NMR spectra were recorded on a nuclear magnetic resonance spectrometer operating at 400 MHz. NMR spectra were obtained as CDCl3 solutions (reported in ppm) with chloroform (7.26 ppm) as the reference standard or with internal standard tetramethylsilane (0.00 ppm) as required. Other NMR solvents were used as required. When reporting peak multiplicities, the following abbreviations are used: s (singlet), d (doublet), t (triplet), m (multiplet), q (quartet), br (broad), dd (doublet of doublets) and dt (doublet of triplets). Coupling constants, when given, are reported in Hertz (Hz).

[0207] All reagents used in this invention, except for the intermediates, are commercially available.

[0208] All compound names, except for reagents, were generated by Chemdraw software. In case of any discrepancy between the structure and the name of a compound given in this invention, the structure takes precedence unless the context indicates that the structure is incorrect and the name is correct.

[0209] If any atom disclosed herein has an open valence (zero valence), the open valence is a hydrogen atom and is omitted for convenience.

[0210] In the following examples, the following abbreviations are used: Boc: tert-butoxycarbonyl BPIN: Bis(pinacolato)diboron CDI: N,N′-carbonyldiimidazole DCM: dichloromethane DIAD: Diisopropyl azodicarboxylate DIBAL-H: Diisobutylaluminum hydride DIPEA: N,N-diisopropylethylamine DMF: N,N-dimethylformamide EA: Ethyl acetate EDCI: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride Et: Ethyl h: time HATU: O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate HOBT: 1-hydroxybenzotriazole ISCO: TELEDYNE ISCO CombiFlash RF+ Chromatography System LDA: Lithium diisopropylamide min: minutes MeOH: Methanol Ms: Methanesulfonyl NBS: N-bromosuccinimide NaHMDS: Sodium bis(trimethylsilyl)amide PE: Petroleum Ether PdCl2(PPh3)2: Bis(triphenylphosphine)palladium(II) dichloride Pd2(dba)3: Tris(dibenzylideneacetone)dipalladium(0) Pd(dppf)Cl2·CH2Cl2: 1,1′-Bis(diphenylphosphino)ferrocene-palladium(II) dichloride·dichloromethane complex Pd(OAc)2: Palladium(II) acetate Pd(PPh3)4: Tetrakis(triphenylphosphine)palladium(0) PMB: p-Methoxybenzyl PPh3: Triphenylphosphine PTLC: Preparative thin layer chromatography SEM: 2-(trimethylsilyl)ethoxymethyl THF: Tetrahydrofuran TBDPS: tert-butyldiphenylsilyl TFA: Trifluoroacetic acid Ts: p-Toluenesulfonyl Xantphos: 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene

[0211] Intermediate 1 4-Chloro-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine

[0212] [ka]

[0213] (A) 2-Chloro-4-((4-methoxybenzyl)oxy)pyrimidine To a solution of (4-methoxyphenyl)methanol (40.8 g, 295.3 mmol) in THF (200 mL) was added NaH (16.1 g, 402.5 mmol, 60% dispersion in paraffin liquid) portionwise at 0° C. The mixture was stirred at the same temperature for 30 min under nitrogen atmosphere. Then, the mixture was slowly added to a solution of 2,4-dichloropyrimidine (40.0 g, 268.5 mmol) in THF (200 mL) at 0° C. After addition, the mixture was stirred at room temperature overnight. The reaction was quenched with ice water (200 mL). The mixture was separated and the aqueous layer was extracted with THF (200 mL). The combined organic layers were washed with brine and dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated to give an off-white solid (73.0 g), which was used directly in the next step.

[0214] (B) 4-((4-methoxybenzyl)oxy)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine To a solution of 2-chloro-4-((4-methoxybenzyl)oxy)pyrimidine (73.0 g, obtained in the previous step) and 1-methyl-1H-pyrazol-5-amine (56.6 g, 582.4 mmol) in 1,4-dioxane (730 mL) was added Pd(OAc)2 (3.27 g, 14.6 mmol), Xantphos (16.8 g, 29.1 mmol) and KOAc (85.7 g, 873.6 mmol). The mixture was purged and then stirred overnight at 90° C. under nitrogen atmosphere. After cooling, the mixture was filtered and the filter cake was washed with EA (200 mL). The combined filtrate was washed with brine. After separation, the organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by ISCO (eluted with 0% to 100% methanol in water) to give a slightly yellow solid (38.5 g, 42.4% yield). MS (m / z): 312.1 (M+H). + .

[0215] (C) 4-Chloro-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine In a three-necked round-bottom flask, 4-((4-methoxybenzyl)oxy)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine (38.5 g, 123.7 mmol) and TFA (150 mL) were added. The mixture was then stirred at room temperature for 3 h. Then the mixture was concentrated to give a brown solid, which was suspended in POCl3 (150 mL). The mixture was stirred at 100 °C for 3 h and then concentrated. The residue was poured into ice water and adjusted to PH = 8-9 with a saturated solution of NaHCO3. The mixture was extracted with EA. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to give a brown solid (23.3 g, 89.6% yield). MS (m / z): 210.0 (M+H) + .

[0216] The following intermediates were prepared following the procedure of Intermediate 1 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one skilled in the art.

[0217] [Table 4]

[0218] Intermediate 3 5-Chloro-4-iodo-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine

[0219] [ka]

[0220] (A) 5-Chloro-4-iodo-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine To a solution of 1-methyl-1H-pyrazol-5-amine (39.4 g, 406 mmol) in anhydrous THF (1500 mL) was added NaHMDS (406 mL, 406 mmol, 1M in THF) at 0° C. under nitrogen atmosphere, and the solution was stirred for 30 min. Then, 5-chloro-2-fluoro-4-iodopyridine (87 g, 338 mmol) was added, and the resulting mixture was refluxed overnight. The reaction was quenched with methanol / water (40 mL, 1:1) and concentrated under vacuum. The residue was purified by silica gel chromatography (PE:EA=1:1) and ISCO (eluted with 0% to 100% methanol in water) to give the title compound as a pale yellow solid (39.8 g, 35% yield). MS(m / z): 334.9 (M+H) + .

[0221] The following intermediates were prepared following the procedure of Intermediate 3 using the corresponding intermediates and reagents under appropriate conditions recognized by one skilled in the art.

[0222] [Table 5]

[0223] Intermediate 5 5-Fluoro-4-iodo-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine

[0224] [ka]

[0225] (A) N-(1-methyl-1H-pyrazol-5-yl)acetamide To a solution of 1-methyl-1H-pyrazol-5-amine (87 g, 90 mmol) and acetic anhydride (101 g, 99 mmol) in EA (1000 mL) was added NaOAc (81 g, 99 mmol) at room temperature. The mixture was stirred at room temperature overnight. Then the mixture was filtered and the cake was washed with EA. The filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (DCM:MeOH=25:1) to give the title compound as a pale yellow solid (98 g, 78% yield). MS(m / z): 140.1 (M+H) + .

[0226] (B) 5-Fluoro-4-iodo-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine To a solution of N-(1-methyl-1H-pyrazol-5-yl)acetamide (53 g, 380 mmol) in anhydrous THF / DMF (800 mL, 7:1) was added NaHMDS (354 mL, 354 mmol, 1M in THF) under nitrogen atmosphere at 0° C. and the solution was stirred at room temperature for 30 min. 2,5-difluoro-4-iodopyridine (61 g, 253 mmol) was then added and the solution was refluxed. The reaction was quenched with methanol / water (200 mL, 1:1) and concentrated under vacuum. The residue was dissolved in methanol / water (200 mL, 1:1), lithium hydroxide monohydrate (11 g, 253 mmol) was added and the solution was stirred at room temperature for 1 h. The solvent was removed by rotary evaporation, and the residue was purified by silica gel chromatography (PE:EA = 1:1) and ISCO (eluting with 0% to 100% methanol in water) to give the title compound as a pink solid (30 g, 37.5% yield). MS (m / z): 319.0 (M+H). + .

[0227] Intermediate 6 4-Iodo-N-(1-methyl-1H-pyrazol-5-yl)-5-(trifluoromethyl)pyridin-2-amine

[0228] [ka]

[0229] (A) 2-Bromo-4-iodo-5-(trifluoromethyl)pyridine To a solution of diisopropylamine (3.1 g, 30 mmol) in anhydrous THF (150 mL) was added n-butyllithium (12.5 mL, 30 mmol, 2.4 mol / L in THF) at -70°C under nitrogen atmosphere. The solution was stirred at -10°C for 30 min. The solution was cooled again to -70°C and 2-bromo-5-(trifluoromethyl)pyridine (5.6 g, 25 mmol) was added. The resulting dark brown solution was stirred at -70°C for 2 h. Iodine (6.4 g, 25 mmol) was added in portions and the solution was stirred for an additional 1 h. The reaction was quenched with 10% HOAc (50 mL) and a saturated solution of sodium thiosulfate. The mixture was extracted with EA. The organic phases were combined and concentrated under vacuum. The residue was purified by silica gel chromatography (PE:EA=50:1) to give the title compound as a yellow solid (6.1 g, 69% yield). MS(m / z): 351.7, 353.7 (M+H) + .

[0230] (B) 4-iodo-N-(1-methyl-1H-pyrazol-5-yl)-5-(trifluoromethyl)pyridin-2-amine To a solution of N-(1-methyl-1H-pyrazol-5-yl)acetamide (1.1 g, 4 mmol) in anhydrous THF (50 mL) was added sodium hydride (320 mg, 8 mmol, 60% dispersion in paraffin liquid) portionwise at room temperature under nitrogen atmosphere. The mixture was stirred for 30 min. 2-Bromo-4-iodo-5-(trifluoromethyl)pyridine (556 mg, 4 mmol) was added and the mixture was refluxed overnight. The reaction was quenched with methanol. The solvent was removed on a rotary evaporator and the residue was purified by ISCO (eluting with 0% to 100% methanol in water) and silica gel chromatography (DCM:MeOH=25:1) to give the title compound as a brown gum (640 mg, 44% yield). MS(m / z): 368.9 (M+H) + .

[0231] The following intermediates were prepared following the procedure of Intermediate 6 using the corresponding intermediates and reagents under appropriate conditions recognized by one of skill in the art.

[0232] [Table 6]

[0233] Intermediate 8 N-Cyclopropyl-4-iodo-5-(trifluoromethyl)pyridin-2-amine

[0234] [ka]

[0235] (A) N-Cyclopropyl-4-iodo-5-(trifluoromethyl)pyridin-2-amine To a solution of 2-bromo-4-iodo-5-(trifluoromethyl)pyridine (352 mg, 1 mmol) and cyclopropanamine (114 mg, 2 mmol) in anhydrous THF (10 mL) was added DIPEA (390 mg, 3 mmol). The solution was refluxed overnight. The solvent was removed on a rotary evaporator and the residue was purified by ISCO (eluting with 0% to 100% methanol in water) to give the title compound as a yellow solid (184 mg, 56% yield). MS (m / z): 328.9 (M+H). + .

[0236] The following intermediates were prepared following the procedure of Intermediate 8 using the corresponding intermediates and reagents under appropriate conditions as would be recognized by one of skill in the art.

[0237] [Table 7]

[0238] Intermediate 11 5-Ethyl-4-iodo-N-(1-methyl-1H-pyrazol-5-yl)pyrimine-2-amine

[0239] [ka]

[0240] (A) 5-Ethyl-2-fluoropyridine To a solution of 5-bromo-2-fluoropyridine (5.5 g, 31.3 mmol) and triethylborane (1 M) (62.6 mL, 62.6 mmol) in DMF (30 mL) was added K2CO3 (12.9 g, 94 mmol) and Pd(PPh3)4 (1.8 g, 1.6 mmol). The mixture was degassed and stirred overnight at 80 °C under nitrogen atmosphere, diluted with water, extracted with hexane, washed with water and brine, dried over anhydrous Na2SO4, concentrated, and purified by ISCO (eluted with DCM in PE 0%-100%) to give the title compound as a yellow liquid (3 g, 77% yield). MS (m / z): 126.0 (M+H). + .

[0241] (B) 5-Ethyl-2-fluoro-3-iodopyridine To a solution of 5-ethyl-2-fluoropyridine (1 g, 8 mmol) in THF (20 mL) was added dropwise LDA (6 mL, 12 mmol, 2M in THF) at -78 °C under nitrogen atmosphere. After stirring at -78 °C for 1 h, iodine (3 g, 12 mmol) was added. The mixture was stirred at -78 °C under nitrogen atmosphere for 2 h, quenched with HOAc and aqueous Na2SO3, and extracted with EA. The organic layer was washed with water and brine, dried over anhydrous Na2SO4, concentrated, and purified by ISCO (eluted with EA in PE 0%-100%) to give the title compound as a yellow oil (1.1 g, 55% yield). MS (m / z): 251.9 (M+H). + .

[0242] (C) 5-Ethyl-2-fluoro-4-iodopyridine To a solution of 5-ethyl-2-fluoro-3-iodopyridine (1.1 g, 4.4 mmol) in THF (20 mL) was added LDA (3.3 mL, 6.6 mmol, 2 M in THF) dropwise under nitrogen at −78° C. The mixture was stirred at −78° C. for 2 h under nitrogen, quenched with a saturated solution of ammonium chloride, extracted with EA, the organic layer was washed with water and brine, dried over anhydrous Na2SO4, concentrated and purified by ISCO (eluted with EA in PE 0%-100%) to give the title compound as a yellow oil (860 mg, 78% yield).

[0243] (D) 5-Ethyl-4-iodo-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine To a solution of 1-methyl-1H-pyrazol-5-amine (648 mg, 6.6 mmol) in THF (40 mL) was added NaHMDS (6.6 mL, 6.6 mmol, 1 M in THF) under nitrogen atmosphere. After mixing at room temperature for 1 h, 5-ethyl-2-fluoro-4-iodopyridine (830 mg, 3.3 mmol) was added. The mixture was refluxed overnight, quenched with water and MeOH, concentrated, and purified by ISCO (eluting with 0% to 100% methanol in water) to give the title compound as a yellow solid (100 mg, 9% yield). MS (m / z): 328.9 (M+H). + .

[0244] Intermediate 12 2-Bromo-4-iodo-5-methoxypyridine

[0245] [ka]

[0246] (A) 2-Bromo-5-methoxypyridine To a solution of 6-bromopyridin-3-ol (1.7 g, 10 mmol) in anhydrous DMF (20 mL) was added NaH (600 mg, 15 mmol, 60% dispersion in paraffin liquid) portionwise under nitrogen atmosphere at 0° C. The mixture was stirred for 30 min. Iodomethane (2.1 g, 15 mmol) was added and then the mixture was stirred at room temperature for 1 h. The reaction was quenched with saturated ammonium chloride solution. The mixture was extracted with EA. The organic phases were combined and concentrated under vacuum. The residue was purified by silica gel chromatography (PE:EA=5:1) to give the title compound as a yellow solid (1.7 g, 91% yield). MS (m / z): 188.0, 190.0 (M+H). + .

[0247] (B) 2-Bromo-4-iodo-5-methoxypyridine To a solution of 2-bromo-5-methoxypyridine (1.5 g, 8 mmol) in anhydrous THF (50 mL) was added LDA (4 mL, 8 mmol, 2 M in THF) at -70°C under nitrogen atmosphere. The solution was stirred at -70°C for 2 h. Iodine (2.1 g, 8 mmol) was added in portions and the solution was stirred for an additional 1 h. The reaction was quenched with a saturated solution of 10% HOAc and sodium thiosulfate. The mixture was extracted with DCM. The organic phases were combined and concentrated under vacuum. The residue was purified by silica gel chromatography (PE:EA = 5:1) to give the title compound as a pale yellow solid (900 mg, 39% yield). MS (m / z): 313.8, 315.8 (M+H). + .

[0248] Intermediate 13 8-Bromo-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

[0249] [ka]

[0250] (A) 4-Bromo-1-(3-((tert-butylbutoxycarbonyl)amino)propyl)-1H-pyrrole-2-carboxylate methyl To methyl 4-bromo-1H-pyrrole-2-carboxylate (100 grams, 0.49 moles) and tert-butyl (3-bromopropyl)carbamate (122 g, 0.51 moles) in DMF (500 mL) was added K2CO3 (169 g, 1.23 moles). The mixture was stirred at room temperature overnight. Then, K2CO3 was filtered off and the filtrate was diluted with water and extracted with EA. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated to give the title compound as a yellow solid (166 g, 93.9 yield). %). MS(m / z):261.0, 263.0 (M+H) + .

[0251] (B) 1-(3-aminopropyl)-4-bromo-1H-pyrrole-2-carboxylate methyl Methyl 4-bromo-1-(3-((tert-butoxycarbonyl)amino)propyl)-1H-pyrrole-2-carboxylate (166 g, 0.46 mol) and TFA (200 mL) were heated at 60° C. for 3 h. The mixture was concentrated and the residue was partitioned between a saturated solution of NaHCO3 and EA. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated to give the title compound as a yellow solid (114.37 g, 95.2% yield). MS (m / z): 261.0, 263.0 (M+H). + .

[0252] (C) 8-Bromo-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one To a mixture of methyl 1-(3-aminopropyl)-4-bromo-1H-pyrrole-2-carboxylate (114 g, 0.44 mol) in MeOH (800 mL) was added K2CO3 (151 g, 1.10 mol). The mixture was stirred at 80° C. for 3 h. Then, K2CO3 was filtered off and the filtrate was concentrated. The residue was diluted with water and extracted with EA. The organic layer was washed with brine, dried over anhydrous Na2SO4, concentrated and recrystallized to give the title compound as a white solid (70.0 g, 69.9% yield). MS (m / z): 228.9 / 230.9 (M+H). + .

[0253] Intermediate 14 8-Bromo-9-chloro-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

[0254] [ka]

[0255] (A) 4-Bromo-3-chloro-1H-pyrrole-2-carboxylate methyl To a mixture of methyl 4-bromo-3-chloro-1H-pyrrole-2-carboxylate (10 g, 62.7 mmol) in DMF (400 mL) was added Br2 (3.2 mL, 62.7 mmol) dropwise at room temperature. The mixture was stirred at room temperature for 8 h. The mixture was then diluted with water (2.0 L) and extracted with EA (3×1.5 L). The organic layer was concentrated and the residue was then purified by ISCO (eluted with methanol in water (0%-100%)) to give the title compound as a yellow solid (7.0 g, 46.9% yield). MS (m / z): 237.8, 239.8 (M+H). + .

[0256] (B) 4-Bromo-1-(3-bromopropyl)-3-chloro-1H-pyrrole-2-carboxylate methyl A mixture of methyl 4-bromo-3-chloro-1H-pyrrole-2-carboxylate (6 g, 25.2 mmol), 1,3-dibromopropane (50.9 g, 252 mmol) and K2CO3 (7.0 g, 50.4 mmol) in CH3CN (150 mL) was heated at 70 °C for 3 h. The reaction mixture was concentrated and partitioned between water (200 mL) and EA (200 mL). The aqueous layer was further extracted with EA (2 x 200 mL). The combined organic layers were concentrated and purified by ISCO (eluted with 0% to 100% methanol in water) to give the title compound as a white solid (4.2 g, 46.3% yield). MS (m / z): 359.8 (M+H). + .

[0257] (C) 8-Bromo-9-chloro-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one A mixture of methyl 4-bromo-1-(3-bromopropyl)-3-chloro-1H-pyrrole-2-carboxylate (500 mg, 1.39 mmol) in ammonium hydroxide (6 mL) and MeOH (10 mL) was heated at 120° C. for 3 h under microwave. The reaction mixture was concentrated and washed with EA (1 mL) to give the crude title compound as a white solid (500 mg, used directly in next step). MS (m / z): 262.9, 264.9 (M+H). + .

[0258] The following intermediates were prepared following the procedure of Intermediate 14 using the corresponding intermediates and reagents under appropriate conditions that would be recognized by one of skill in the art.

[0259] [Table 8]

[0260] Intermediate 16 8-Bromo-9-fluoro-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

[0261] [ka]

[0262] (A) 1-(3-((tert-butoxycarbonyl)amino)propyl)-3-fluoro-1H-pyrrole-2-carboxylate ethyl A mixture of ethyl 3-fluoro-1H-pyrrole-2-carboxylate (3.14 g, 20 mmol), tert-butyl (3-bromopropyl)carbamate (7.14 g, 30 mmol) and Cs2CO3 (9.75 g, 30 mmol) in DMF (20 mL) was heated at 80° C. overnight. After cooling to room temperature, the mixture was extracted with EA. The organic phase was washed with water and brine, concentrated and purified by ISCO (eluted with methanol in water 0% to 100%) to give the title compound as a yellow solid (6.28 g). MS (m / z): 315.1 (M+H). + .

[0263] (B) 4-Bromo-1-(3-((tert-butoxycarbonyl)amino)propyl)-3-fluoro-1H-pyrrole-2-carboxylate ethyl To a solution of ethyl 1-(3-((tert-butoxycarbonyl)amino)propyl)-3-fluoro-1H-pyrrole-2-carboxylate (6.28 g, 20 mmol) in DMF (15 mL) was added NBS (3.56 g, 20 mmol) portionwise at room temperature. The mixture was stirred for 4 h, quenched with aqueous Na2SO3, extracted with EA and concentrated to give the crude title compound. MS (m / z): 414.9, 416.9 (M+23). + .

[0264] (C) 8-Bromo-9-fluoro-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one To a solution of ethyl 4-bromo-1-(3-((tert-butoxycarbonyl)amino)propyl)-3-fluoro-1H-pyrrole-2-carboxylate (6.1 g, 15.5 mmol) in methanol (10 mL) was added concentrated hydrochloric acid (3 mL). The resulting mixture was stirred at room temperature for 3 h. The mixture was concentrated under vacuum. The residue was adjusted to pH=8 with aqueous NaHCO3 and extracted with DCM. The organic phase was concentrated and the residue was dissolved in MeOH (25 mL) to which K2CO3 (6.42 g, 46.5 mmol) was added. The mixture was stirred at 80 °C for 48 h. Then K2CO3 was filtered off and the filtrate was concentrated. The residue was purified via ISCO (eluted with EA in PE 50%-100%) to give the title compound as a white solid (3 g, 78.7% yield). MS(m / z): 247.0, 249.0 (M+H) + .

[0265] Intermediate 17 7-Bromo-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one

[0266] [ka]

[0267] (A) 4-Bromo-1-(cyanomethyl)-1H-pyrrole-2-carboxylate methyl To a solution of methyl 4-bromo-1H-pyrrole-2-carboxylate (4 g, 19.6 mmol) in DMF (15 mL) was added K2CO3 (5.4 g, 39.2 mmol) and 2-bromoacetonitrile (2.4 g, 19.6 mmol). The mixture was then stirred at 80° C. for 3 h, poured into water and extracted with EA. The organic phase was washed with water and brine, dried over anhydrous Na2SO4 and concentrated to give the title compound as a yellow solid (5.1 g). MS (m / z): 243.0 / 245.0 (M+H) + .

[0268] (B) 1-(2-aminoethyl)-4-bromo-1H-pyrrole-2-carboxylate methyl To a solution of methyl 4-bromo-1-(cyanomethyl)-1H-pyrrole-2-carboxylate (5.1 g, 19.6 mmol) in THF (20 mL) was added BH3·Me2S (10 mL, 19.6 mmol, 2 M in THF) dropwise at room temperature. The mixture was then stirred at 60 °C overnight, quenched with cold aqueous NaHCO3 at 0 °C and extracted with EA. The organic phase was washed with water and brine, dried over anhydrous Na2SO4 and concentrated to give the title compound as a yellow solid (4.5 g, 93% yield). MS (m / z): 246.9 / 248.9 (M+H). + .

[0269] (C) 7-Bromo-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one To a solution of methyl 1-(2-aminoethyl)-4-bromo-1H-pyrrole-2-carboxylate (4.5 g, 18.2 mmol) in MeOH (20 mL) was added ammonium hydroxide (3 mL). The mixture was stirred at room temperature overnight, concentrated, and purified via ISCO (eluted with MeOH 0%-15% in DCM) to give the title compound as a brown solid (3.2 g, 82% yield). MS (m / z): 214.9 / 216.9 (M+H). + .

[0270] Intermediate 18 8'-Bromo-2',3'-dihydro-1'H,5'H-spiro[cyclopropane-1,4'-pyrrolo[1,2-a][1,4]diazepine]-1'-one

[0271] [ka]

[0272] (A) tert-Butyl ((1-(hydroxymethyl)cyclopropyl)methyl)carbamate To a solution of (1-(aminomethyl)cyclopropyl)methanol (5 g, 49.5 mmol) in DCM (40 mL) was added BocO (10.8 g, 49.5 mmol) and DIPEA (12.8 g, 99 mmol). The mixture was stirred at room temperature for 2 h, concentrated, and purified by ISCO (eluted with 0% to 100% methanol in water) to give the title compound as a yellow solid (9.4 g, 94% yield).

[0273] (B) 4-Bromo-1-((1-(((tert-butoxycarbonyl)amino)methyl)cyclopropyl)methyl)-1H-pyrrole-2-carboxylate methyl To a solution of tert-butyl ((1-(hydroxymethyl)cyclopropyl)methyl)carbamate (4.9 g, 24.5 mmol), methyl 4-bromo-1H-pyrrole-2-carboxylate (5 g, 24.5 mmol) and PPh3 (9.6 g, 36.8 mmol) in THF (20 mL) was added DIAD (7.4 g, 36.8 mmol) dropwise under nitrogen at 0° C. The mixture was stirred at room temperature overnight, concentrated and purified by ISCO (eluted with EA in PE 0% to 100%) to give the title compound as a yellow oil (9.2 g, crude).

[0274] (C) 8′-Bromo-2′,3′-dihydro-1′H,5′H-spiro[cyclopropane-1,4′-pyrrolo[1,2-a][1,4]diazepine]-1′-one A mixture of methyl 4-bromo-1-((1-(((tert-butoxycarbonyl)amino)methyl)cyclopropyl)methyl)-1H-pyrrole-2-carboxylate (9.2 g, 23.8 mmol) in TFA (10 mL) was stirred at room temperature for 2 h. The mixture was concentrated under vacuum. The residue was dissolved in MeOH (30 mL) and to it was added K2CO3 (9.8 g, 71.3 mmol) and Et3N (7.2 g, 71.3 mmol). The mixture was stirred at room temperature overnight, concentrated and purified by ISCO (eluted with methanol in water 0% to 100%) to give the title compound as a yellow solid (4.5 g, 74% yield). MS (m / z): 255.0 / 257.0 (M+H). + .

[0275] The following intermediates were prepared following the procedure of Intermediate 18 using the corresponding intermediates and reagents under appropriate conditions as would be recognized by one skilled in the art.

[0276] [Table 9-1] [Table 9-2]

[0277] Intermediate 37 (R)-8-Bromo-4-methoxy-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one

[0278] [ka]

[0279] (A) (R)-8-Bromo-4-hydroxy-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one To a solution of methyl 4-bromo-1H-pyrrole-2-carboxylate (60.0 g, 0.294 mol) and (S)-2-(chloromethyl)oxirane (68.0 g, 0.735 mol) in EtOH (600 mL) was added Cs2CO3 (115.0 g, 0.352 mol). After stirring at 80 °C for 2 h, the mixture was diluted with water and extracted with EA. The organic layer was concentrated and the residue was treated with EtOH (1000 mL) and ammonium hydroxide (100 mL, 25-28 WT% in water). The mixture was stirred at 80 °C for 16 h. The mixture was concentrated and the residue was recrystallized (EA and EtOH) to give the title compound as a white solid (25 g, 34.7% yield for two steps). MS (m / z): 245.1 / 247.1 (M+H) + .

[0280] (B) (R)-8-Bromo-4-methoxy-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one To a solution of (R)-8-bromo-4-hydroxy-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one (20.0 g, 0.082 mol) in DCM (300 mL) was added CF3SO3Me (20.0 g, 0.122 mol). After stirring at 40°C for 16 h, the mixture was concentrated. The residue was dissolved in DMF (250 mL) and cooled to 0°C. NaH (10.0 g, 0.255 mol, 60% dispersion in paraffin liquid) was added at 0°C and the mixture was stirred at 0°C for 30 min, followed by the addition of iodomethane (24.0 g, 0.17 mol). After stirring at room temperature for 3 h, the mixture was diluted with water and extracted with EA. The organic layer was washed with brine and water and concentrated to give a yellow oil, which was dissolved in MeOH (300 mL). After adding concentrated hydrochloric acid (60 mL), the mixture was stirred at 60° C. for 3 h. The mixture was concentrated and dissolved in MeOH (400 mL) again. To it was added K2CO3 (40.0 g, 0.289 mol) and the mixture was stirred at 60° C. for 4 h. The mixture was filtered through Celite. The filtrate was concentrated and the residue was purified by ISCO (eluted with methanol in water 0% to 100%) to give the title compound as a white solid (10.0 g, 47.7% yield for 4 steps). MS (m / z): 259.0 / 261.0 (M+H). + .

[0281] Intermediate 38 8'-Bromo-2',3'-dihydro-1'H,5'H-spiro[cyclobutane-1,4'-pyrrolo[1,2-a][1,4]diazepine]-1'-one

[0282] [ka]

[0283] (A) Cyclobutane-1,1-diyldimethanol To a suspension of LiAlH4 (2.3 g, 60 mmol) in THF (30 mL) was added diethyl cyclobutane-1,1-dicarboxylate (8 g, 40 mmol) in THF (40 mL) dropwise at 0° C. under nitrogen atmosphere. The mixture was stirred overnight at room temperature, poured into water, adjusted to pH=3 with 2 N HCl, extracted with EA, washed with water and brine, dried over anhydrous Na2SO4, and concentrated to give the title compound as a yellow oil (2.9 g, 63% yield). MS (m / z): 117.1 (M+H). + .

[0284] (B) 1,1-bis(4-methylsulfonyloxymethyl)cyclobutane To a solution of cyclobutane-1,1-diyldimethanol (2.9 g, 25 mmol) in DCM (30 mL) was added TsCl (10.5 g, 55 mmol) and Et3N (7.6 g, 75 mmol) at 0° C. The mixture was stirred at room temperature for 3 h, poured into water, extracted with DCM, washed with water and brine, dried over anhydrous Na2SO4, concentrated, and purified by ISCO (eluted with EA in PE 0%-100%) to give the title compound as a white solid (3.5 g, 33% yield).

[0285] (C) 8′-Bromo-2′,3′-dihydro-1′H,5′H-spiro[cyclobutane-1,4′-pyrrolo[1,2-a][1,4]diazepine]-1′-one To a solution of methyl 4-bromo-1H-pyrrole-2-carboxylate (1.7 g, 8.2 mmol) in DCM (10 mL) was added K2CO3 (3.4 g, 24.7 mmol) and 1,1-bis(4-methylsulfonyloxymethyl)cyclobutane (3.5 g, 8.2 mmol). The mixture was stirred at 100° C. for 5 h, poured into water, and extracted with DCM. The organic layer was washed with water and brine, dried over anhydrous Na2SO4, and concentrated. The resulting yellow oil was dissolved in DMF (10 mL) and NaN3 (1.1 g, 16.4 mmol) was added. The mixture was stirred at 100° C. overnight, poured into water, extracted with EA, dried over anhydrous Na2SO4, and concentrated. The residue was dissolved in EA (30 mL) and to it was added PPh3 (2.2 g, 8.2 mmol). The mixture was stirred at room temperature for 1 h, and then concentrated. The residue was dissolved in MeOH (3 mL) and hydrochloric acid (10 mL) was added. The mixture was refluxed for 3 h, concentrated and redissolved in MeOH (10 mL). To it was added K2CO3 (3.4 g, 24.7 mmol) and Et3N (4.2 g, 41.1 mmol). The mixture was refluxed overnight, concentrated and purified by ISCO (eluted with 0% to 100% methanol in water) to give the title compound as a yellow solid (1.2 g, 54.1% yield). MS (m / z): 269.0 / 271.0 (M+H). + .

[0286] Intermediate 39 (R)-7-Bromo-3-(fluoromethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one

[0287] [ka]

[0288] (A) Ethyl N-(tert-butoxycarbonyl)-O-(tert-butyldiphenylsilyl)-L-serine To a solution of L-ethyl serine hydrochloride (8.0 g, 47.2 mmol) and Et3N (9.5 g, 94.3 mmol) in DCM (80 mL) was added (Boc)2O (20.6 g, 94.3 mmol). The resulting mixture was stirred at room temperature overnight, then diluted with water (100 mL) and extracted with DCM (3×100 mL). The combined organic layers were concentrated and redissolved in DCM (100 mL). 1H-imidazole (4.7 g, 68.6 mmol) and TBDPSCl (8.3 g, 30.2 mmol) were added at 0° C. The mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (100 mL) and extracted with DCM (3×100 mL). The combined organic layers were concentrated and the residue was purified by ISCO (eluted with 0% to 100% methanol in water) to give the title compound as an oil (5.8 g, 26.1% yield). MS (m / z): 372.1 (M+H-100). + .

[0289] (B) (R)-(1-((tert-butyldiphenylsilyl)oxy)-3-hydroxypropan-2-yl)carbamic acid tert-butyl To a solution of N-(tert-butoxycarbonyl)-O-(tert-butyldiphenylsilyl)-L-ethyl serinate (5.4 g, 11.4 mmol) in DCM (40 mL) was added DIBAL-H (22.9 mL, 22.9 mmol, 1M in hexanes) slowly at -78°C. The mixture was stirred at -78°C for 30 min and then at room temperature overnight. The reaction mixture was cooled to 0°C and quenched with 1 mL of water, 1 mL of 15% NaOH solution and 3 mL of water. The mixture was stirred at room temperature for 15 min, filtered and the cake was washed with DCM (100 mL). The combined filtrate was concentrated and purified by ISCO (eluted with EA in PE 0%-100%) to give the title compound as an oil (3.1 g, 63.3% yield). MS (m / z): 330.1 (M+H-100). + .

[0290] (C) (R)-4-bromo-1-(2-((tert-butoxycarbonyl)amino)-3-((tert-butyldiphenylsilyl)oxy)propyl)-1H-pyrrole-2-carboxylate methyl To a solution of (R)-(1-((tert-butyldiphenylsilyl)oxy)-3-hydroxypropan-2-yl)tert-butylcarbamate (2.5 g, 5.8 mmol), methyl 4-bromo-1H-pyrrole-2-carboxylate (1.2 g, 5.8 mmol) and PPh3 (2.3 g, 8.7 mmol) in anhydrous THF (100 mL) was added DIAD (1.8 g, 8.7 mmol) slowly at 0 °C. The mixture was then warmed to room temperature and stirred overnight. The reaction mixture was concentrated and partitioned between water (100 mL) and DCM (100 mL). The aqueous layer was extracted with DCM (2 x 100 mL). The combined organic layers were concentrated and purified by ISCO (eluted with EA in PE 0% to 100%) to give the title compound as a white solid (2.0 g, 55.8% yield). MS (m / z):515.1 / 517.1 (M+H-100) + .

[0291] (D) (R)-7-Bromo-3-(hydroxymethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one A solution of (R)-4-bromo-1-(2-((tert-butoxycarbonyl)amino)-3-((tert-butyldiphenylsilyl)oxy)propyl)-1H-pyrrole-2-methyl carboxylate (2.0 g, 3.2 mmol) in TFA (40 mL) was stirred at room temperature for 2 h. Volatiles were removed under reduced pressure. The residue was dissolved in MeOH (50 mL) and to it was added Et3N (1.6 g, 16.2 mmol) and K2CO3 (2.2 g, 16.2 mmol). The resulting mixture was refluxed for 4 h. The reaction mixture was concentrated and partitioned between water (100 mL) and DCM (100 mL). The aqueous layer was further extracted with DCM (2×100 mL). The combined organic layers were concentrated and purified by ISCO (eluted with 0% to 100% methanol in water) to give the title compound as a white solid (0.35 g, 44.2% yield). MS (m / z): 245.0 / 247.0 (M+H). + .

[0292] (E) (R)-7-Bromo-3-(fluoromethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one To a mixture of (R)-7-bromo-3-(hydroxymethyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (450 mg, 1.84 mmol) in DCM (5 mL) was slowly added diethylaminosulfur trifluoride (593 mg, 3.68 mmol) at 0° C. The mixture was allowed to warm to room temperature and stirred overnight under nitrogen atmosphere. The mixture was then quenched with saturated NaHCO3 solution and extracted with EA. The organic layer was dried over anhydrous Na2SO4, concentrated and purified by ISCO (eluted with methanol in water 0% to 100%) to give the title compound as a yellow solid (228 mg, 50.2% yield). MS (m / z): 246.9 / 248.9 (M+H) + .

[0293] The following intermediates were prepared following the procedure of Intermediate 39 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one skilled in the art.

[0294] [Table 10]

[0295] Intermediate 41 7'-Bromo-4'H-spiro[cyclobutane-1,3'-pyrrolo[1,2-a]pyrazine]-1'(2'H)-one

[0296] [ka]

[0297] (A) tert-Butyl (1-(hydroxymethyl)cyclobutyl)carbamate To a solution of (1-aminocyclobutyl)methanol hydrochloride (2 g, 0.015 mol) and Et3N (6.2 mL, 0.044 mol) in DCM (40 mL) was added (Boc)2O (3.5 g, 0.016 mol) at 0° C. The reaction was stirred at room temperature for 16 h. The reaction mixture was partitioned between DCM (30 mL) and saturated aqueous ammonium chloride solution (30 mL). The organic layer was washed with brine (30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and recrystallized with PE / EA to give the title compound as a white solid (2.4 g, 87.8% yield). 1 H NMR (400 MHz, DMSO-d6)δ6.57 (s, 1H), 4.64 (t, J=5.9 Hz, 1H), 3.39 (d, J=5.9 Hz, 2H), 2.17 - 2.02 (m, 2H), 1.97 - 1.85 (m, 2H), 1.75 - 1.52 (m, 2H), 1.35 (s, 9H).

[0298] (B) 4-Bromo-1-((1-((tert-butoxycarbonyl)amino)cyclobutyl)methyl)-1H-pyrrole-2-carboxylate methyl To a solution of tert-butyl (1-(hydroxymethyl)cyclobutyl)carbamate (2.1 g, 0.010 mol) in DCM (50 mL) was added dropwise at 0 °C followed by MsCl (0.93 mL, 0.012 mol). The mixture was stirred at room temperature for 2 h. The reaction mixture was partitioned between DCM (30 mL) and saturated ammonium chloride solution (30 mL). The organic layer was washed with brine (30 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was dissolved in DMF (40 mL) and methyl 4-bromo-1H-pyrrole-2-carboxylate (2 g, 0.0096 mol) and Cs2CO3 (6.3 g, 0.0192 mol) were added. The resulting mixture was stirred at 80 °C for 8 h. The reaction mixture was partitioned between EA (200 mL) and brine (300 mL). The aqueous layer was further extracted with EA (200 mL×2). The combined organic layers were concentrated and purified by ISCO (PE / EA) to give the title compound as an oil (1.6 g, 41% yield). MS (m / z): 287.0 / 289.0 (M+H-100). + .

[0299] (C) 7′-Bromo-4′H-spiro[cyclobutane-1,3′-pyrrolo[1,2-a]pyrazine]-1′(2′H)-one A mixture of methyl 4-bromo-1-((1-((tert-butoxycarbonyl)amino)cyclobutyl)methyl)-1H-pyrrole-2-carboxylate (1.6 g, 0.0041 mol) in TFA (10 mL) was stirred at room temperature for 2 h. The volatiles were removed under reduced pressure. The residue was dissolved in MeOH (20 mL) and to it was added Et3N (3 mL) and K2CO3 (2 g, 0.0144 mol). The mixture was refluxed for 6 h and then concentrated. The residue was purified by ISCO (eluted with 0%-100% methanol in water) to give the title compound as a white solid (0.7 g, 66.8% yield). MS (m / z): 255.9 / 257.9 (M+H) + .

[0300] The following intermediates were prepared following the procedure of Intermediate 41 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one skilled in the art.

[0301] [Table 11]

[0302] Intermediate 45 7'-Bromo-4'H-spiro[cyclopropane-1,3'-pyrrolo[1,2-a]pyrazine]-1'(2'H)-one

[0303] [ka]

[0304] (A) 4-Bromo-1-(cyanomethyl)-1H-pyrrole-2-carboxylate methyl A mixture of methyl 4-bromo-1H-pyrrole-2-carboxylate (10 g, 49.0 mmol), 2-bromoacetonitrile (6.17 g, 51.5 mmol) and K2CO3 (10.1 g, 73.5 mmol) in CH3CN (100 mL) was heated at 80° C. for 3.5 h. The reaction mixture was concentrated and partitioned between water (150 mL) and EA (150 mL). The aqueous layer was further extracted with EA (2×150 mL). The combined organic layers were concentrated to give the title compound as a white solid (11.0 g, 92.4% yield). MS (m / z): 242.9 / 244.9 (M+H). + .

[0305] (B) 7′-Bromo-4′H-spiro[cyclopropane-1,3′-pyrrolo[1,2-a]pyrazine]-1′(2′H)-one Methyl 4-bromo-1-(cyanomethyl)-1H-pyrrole-2-carboxylate (3.0 g, 12.3 mmol) and Ti(O iTo a mixture of 2,4-dichloromethane (5.2 g, 18.2 mmol), ethylmagnesium bromide (11 mL, 33 mmol, 3 M in THF) was added dropwise at room temperature. After the addition, the mixture was stirred at room temperature for 1 h. Hydrochloric acid (1 N, 50 mL) was added, THF was evaporated under reduced pressure, and the aqueous layer was extracted with DCM (3×50 mL). The combined organic layers were concentrated, and the residue was purified by ISCO (PE / EA) to give the title compound as a white solid (0.4 g, 10.1% yield). MS (m / z): 241.0 / 243.0 (M+H) + . 1H NMR (400 MHz, DMSO-d6) δ 8.01 (brs, 1H), 7.11 (d, J = 1.8 Hz, 1H), 6.68 (d, J = 1.8 Hz, 1H), 4.01 (s, 2H), 0.84 - 0.79 (m, 4H).

[0306] The following intermediates were prepared following the procedure of Intermediate 45 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one skilled in the art.

[0307] [Table 12]

[0308] Intermediate 47 7-Bromo-3-methylpyrrolo[1,2-a]pyrazin-1(2H)-one

[0309] [ka]

[0310] (A) 4-Bromo-1-(2-oxopropyl)-1H-pyrrole-2-carboxylate methyl To a solution of methyl 4-bromo-1H-pyrrole-2-carboxylate (2.0 g, 0.010 mol) in DMF (10 mL) was added NaH (0.6 g, 0.015 mol, 60% dispersion in paraffin liquid) at 0° C. The mixture was stirred at 0° C. for 30 min, then 1-bromopropan-2-one (1.4 g, 0.010 mol) was added. The mixture was stirred at room temperature for 4 h, diluted with water and extracted with EA. The organic layer was washed with water and brine and concentrated to give the title compound as a yellow oil (2.5 g). MS (m / z): 259.9 / 261.9 (M+H) + .

[0311] (B) 7-Bromo-3-methylpyrrolo[1,2-a]pyrazin-1(2H)-one To a solution of methyl 4-bromo-1-(2-oxopropyl)-1H-pyrrole-2-carboxylate (2.5 g, 0.001 mol) in MeOH (10 mL) was added a solution of ammonium nitrate (10 mL, 7 M) in MeOH (10 mL). The mixture was sealed in an autoclave and stirred at 120° C. for 16 h. The mixture was concentrated and the residue was purified by ISCO (eluting with 0% to 100% methanol in water) to give the title compound as a yellow solid (0.5 g, 22.0% for two steps). MS (m / z): 227.0 / 229.0 (M+H) + .

[0312] Intermediate 48 1-(Trifluoromethyl)cyclobutane-1-carbohydrazide

[0313] [ka]

[0314] (A) 1-(trifluoromethyl)cyclobutane-1-carbohydrazide To a solution of 1-(trifluoromethyl)cyclobutane-1-carboxylic acid (20 g, 119 mmol) in MeOH (30 mL) was added concentrated H2SO4 (0.75 mL). The mixture was refluxed overnight. Hydrazine hydrate (85%, 30 mL) was added. The mixture was refluxed again overnight. The mixture was diluted with EA, washed with water and brine, dried over anhydrous Na2SO4, and concentrated to give the title compound as a yellow solid (19 g, 68% yield). MS (m / z): 183.0 (M+H) + .

[0315] Prepared according to the procedure of Intermediate 48 using the corresponding intermediates and reagents under suitable conditions recognized by one skilled in the art.

[0316] [Table 13]

[0317] Intermediate 54 1-(Trifluoromethyl)cyclopropane-1-carbohydrazide

[0318] [ka]

[0319] (A) 1-(trifluoromethyl)cyclopropane-1-carbohydrazide To a solution of 1-(trifluoromethyl)cyclopropane-1-carboxylic acid (5.0 g, 0.033 mol) and tert-butyl hydrazinecarboxylate (5.5 g, 0.033 mol) in DCM (50 mL) was added EDCI (6.3 g, 0.033 mol), HOBT (4.4 g, 0.033 mol) and Et3N (6.6 g, 0.066 mol). The resulting mixture was stirred at room temperature for 16 h and then washed with saturated NaHCO3 solution and water. The organic layer was concentrated in vacuo. The residue was dissolved in THF (80 mL) and concentrated hydrochloric acid (10 mL) was added. The resulting mixture was stirred at room temperature overnight. The mixture was then concentrated to give the crude title compound as a yellow solid (5.0 g). MS (m / z): 169.1 (M+H) + .

[0320] Intermediate 55 1-(Difluoromethyl)-3,3-difluorocyclobutane-1-carbohydrazide

[0321] [ka]

[0322] (A) 1-Formyl-3,3-dimethoxycyclobutane-1-carboxylate isopropyl To a mixture of isopropyl 3,3-dimethoxycyclobutane-1,1-dicarboxylate (5.0 g, 17.34 mmol) in DCM (50 mL) was added DIBAL-H (35 mL, 35.0 mmol) slowly at -78 °C. The mixture was stirred at -78 °C under nitrogen atmosphere for 0.5 h. The reaction mixture was then quenched with 2N HCl and extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO, concentrated and purified by ISCO (eluted with PE in PE 0% to 100%) to give the title compound as a colorless oil (1.83 g, 45.8% yield). 1H NMR (400 MHz, CDCl3)δ9.67 (s, 1H), 5.11-5.03 (m, 1H), 3.14 (s, 3H), 3.11 (s, 3H), 2.65-2.58 (m, 4H), 1.24 (d, J = 6.3 Hz, 6H).

[0323] (B) 1-Formyl-3-oxocyclobutane-1-carboxylate isopropyl A mixture of isopropyl 1-formyl-3,3-dimethoxycyclobutane-1-carboxylate (1.83 g, 7.95 mmol) in 6N HCl (10 mL, 60 mmol) was stirred at room temperature for 24 h. The mixture was then extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated to give the title compound as a colorless oil (950 mg). MS (m / z): 185.1 (M+H) + .

[0324] (C) 1-(Difluoromethyl)-3,3-difluorocyclobutane-1-carboxylate isopropyl To a mixture of the above isopropyl 1-formyl-3-oxocyclobutane-1-carboxylate (0.95 g) in DCM (5 mL) was slowly added diethylaminosulfur trifluoride (4.46 g, 27.27 mmol) at 0° C. The mixture was then stirred at room temperature under nitrogen atmosphere. The reaction mixture was quenched with a saturated solution of NaHCO3 and extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated to give the title compound as a brown oil (1.2 g). 1 H NMR (400 MHz, CDCl3) δ6.15 (t, J = 56.2 Hz, 1H), 5.15 - 5.07 (m, 1H), 3.01 -2.90 (m, 4H), 1.28 (d, J = 6.3 Hz, 6H).

[0325] (D) 1-(Difluoromethyl)-3,3-difluorocyclobutane-1-carbohydrazide To a solution of the above isobutyl 1-(difluoromethyl)-3,3-difluorocyclobutane-1-carboxylate (1.20 g) in MeOH (10 mL) was added hydrazine hydrate (85%, 3 mL). The mixture was stirred overnight at 75° C. under nitrogen atmosphere. MeOH was then removed and the residue was extracted with EA. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated to give the title compound as a yellow oil (1.0 g). MS (m / z): 201.0 (M+H) + .

[0326] The following intermediates were prepared following the procedure of Intermediate 55 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one skilled in the art.

[0327] [Table 14]

[0328] Example 1: Synthesis of Compounds 1-35 compound 1 4-(3-(2-fluorophenethyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine

[0329] [ka]

[0330] (A) 8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one A mixture of 8-bromo-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one (6 g, 26.19 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (11.97 g, 47.15 mmol), Pd2dba3 (2.4 g, 2.62 mmol), tricyclohexylphosphane (1.47 g, 5.24 mmol) and KOAc (7.71 g, 78.58 mmol) in 1,4-dioxane (120 mL) was stirred at 100° C. for 16 h under nitrogen atmosphere. The mixture was filtered and the filtrate was diluted with EA (200 mL) and washed with water (100 mL) and brine (100 mL). The collected organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by ISCO (methanol in water 0% to 100%) to give the title compound as a white solid (3.55 g, 49.1% yield). MS (m / z): 277.0 (M+H). + .

[0331] (B) 8-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one To a mixture of 8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one (17.76 g, 64.32 mol) and 4-chloro-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine (13.50 g, 64.40 mmol) in 1,4-dioxane / water (380 mL / 70 mL) was added Pd(dppf)Cl2.CH2Cl2 (2.63 g, 3.22 mmol) and cesium carbonate (52.40 g, 160.82 mmol). The mixture was then stirred at 90° C. for 2 h under nitrogen atmosphere. The mixture was filtered and the filtrate was diluted with EA and washed with water and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by ISCO (eluted with 0% to 100% methanol in water) to give the title compound as a yellow solid (16.6 g, 79.8% yield). MS (m / z): 324.1 (M+H). + .

[0332] (C) 4-(1-hydrazinenyl-4,5-dihydro-3H-pyrrolo[1,2-a][1,4]diazepin-8-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine A suspension of 8-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one (8.00 g, 24.74 mmol) in POCl3 (80 mL) was stirred at 100° C. overnight under nitrogen atmosphere. The mixture was concentrated and the residue was poured into cold saturated NaHCO3 solution and extracted with EA. The combined organic layers were washed with water and brine, dried over sodium sulfate and concentrated. The residue was dissolved in THF (50 mL) and hydrazine hydrate (50 mL, 85%) was added. The mixture was then refluxed overnight under nitrogen atmosphere. The mixture was filtered and the filter cake was washed with THF. The organic layer was washed with water and brine, dried over sodium sulfate and concentrated to give a brown solid (3.75 g, 47.7% yield). MS (m / z): 338.1 (M+H) + .

[0333] (D) 4-(3-(2-fluorophenethyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine To a solution of 4-(1-hydrazinenyl-4,5-dihydro-3H-pyrrolo[1,2-a][1,4]diazepin-8-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine (100 mg, 0.30 mmol) and 3-(2-fluorophenyl)propanoic acid (60 mg, 0.35 mmol) in 5 mL of DCM, HATU (113 mg, 0.30 mmol) and Et3N (58 mg, 0.58 mmol) were added. The mixture was stirred at room temperature for 1 h. The volatiles were removed under reduced pressure and the residue was dissolved in 5 mL of 1,4-dioxane and then stirred at 60 °C for 1 h. The mixture was concentrated and the residue was purified by ISCO (eluting with 0% to 100% methanol in water) to give the title compound as a white solid (66.6 mg, 47.1% yield). MS (m / z): 470.3 (M+H) + . 1 H NMR (400 MHz, DMSO-d6) δ9.22 (s, 1H), 8.31 (d, J = 5.2 Hz, 1H), 7.68 (d, J = 2.0 Hz, 1H), 7.40 - 7.32 (m, 3H), 7.28 - 7.23 (m, 1H), 7.18 - 7.09 (m, 3H), 6.27 (d, J = 1.9 Hz, 1H), 4.37 - 4.23 (m, 2H), 4.17 - 4.00 (m, 2H), 3.68 (s, 3H), 3.10 - 2.98 (m, 4H), 2.29 - 2.13 (m, 2H).

[0334] The following compounds were prepared following the procedure for Compound 1 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of ordinary skill in the art.

[0335] [Table 15-1] [Table 15-2] [Table 15-3] [Table 15-4] [Table 15-5] [Table 15-6] [Table 15-7]

[0336] Example 2: Synthesis of Compounds 36-38 compound 36 N-(1-methyl-1H-pyrazol-5-yl)-4-(3-(phenoxymethyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)pyrimidin-2-amine

[0337] [ka]

[0338] (A) 4-(3-(chloromethyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine To a solution of 4-(1-hydradienyl-4,5-dihydro-3H-pyrrolo[1,2-a][1,4]diazepin-8-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine (500 mg, 1.48 mmol) in DCM (50 mL) was slowly added DIPEA (287 mg, 2.22 mmol) followed by 2-chloroacetyl chloride (201 mg, 1.78 mmol) at 0° C. The mixture was then stirred overnight at room temperature and refluxed for 3 h. The mixture was diluted with THF (100 mL) and water (100 mL). The aqueous layer was extracted with THF. The combined organic layers were washed with brine and dried over anhydrous sodium sulfate to give a brown oil (587 mg) which was used directly in the next step. MS (m / z): 454.2 (M+H) + .

[0339] (B) N-(1-methyl-1H-pyrazol-5-yl)-4-(3-(phenoxymethyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)pyrimidin-2-amine To a solution of 4-(3-(chloromethyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine (73.4 mg, 0.19 mmol) in DMF (5 mL) was added cesium carbonate (151 mg, 0.46 mmol) and phenol (34.9 mg, 0.37 mmol). The resulting mixture was stirred at 60° C. for 1 h. After cooling, the reaction mixture was directly purified by ISCO (eluted with 0% to 100% methanol in water) and PTLC (DCM:MeOH=12 / 1) to give the title compound as a pale yellow solid (19.1 mg, 22.7% yield). MS (m / z): 396.2 (M+H) + . 1H NMR (400 MHz, DMSO-d6)δ9.26 (s, 1H), 8.31 (s, 1H), 7.71 (s, 1H), 7.42 (s, 1H), 7.37 - 7.24 (m, 3H), 7.15 - 7.04 (m, 3H), 7.03 - 6.92 (m, 1H), 6.28 (s, 1H), 5.30 (s, 2H), 4.45 - 4.34 (m, 2H), 4.34 - 4.24 (m, 2H), 3.68 (s, 3H), 2.38 - 2.27 (m, 2H).

[0340] The following compounds were prepared following the procedure for Compound 36 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of ordinary skill in the art.

[0341] [Table 16]

[0342] Example 3: Synthesis of Compounds 39-40 compound 39 (S)-4-(3-(1-(2-fluorophenoxy)ethyl)pyrrolo[1,2-a][1,2,4]triazolo[3,4-c]pyrazin-9-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine

[0343] [ka]

[0344] (A) 7-Bromo-2-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[1,2-a]pyrazin-1(2H)-one To a solution of 7-bromopyrrolo[1,2-a]pyrazin-1(2H)-one (21.3 g, 100 mmol) in anhydrous DMF (100 mL) was added NaH (6 g, 150 mmol, 60% dispersion in paraffin liquid) at 0° C. The mixture was stirred at 0° C. for 0.5 h, then 2-(trifluoromethylsilyl)ethoxymethyl chloride (21.6 g, 130 mmol) was added. The mixture was stirred overnight at room temperature, poured into ice water, extracted with EA, concentrated and purified by ISCO (PE / EA=5:1) to give the title compound as a yellow solid (16 g, 47% yield). MS (m / z): 342.9 / 344.9(M+H) + .

[0345] (B) 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[1,2-a]pyrazin-1(2H)-one A mixture of 7-bromo-2-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[1,2-a]pyrazin-1(2H)-one (8.5 g, 24.8 mmol), BPIN (9.44 g, 37.2 mmol), Pd2(dba)3 (0.68 g, 7.44 mmol), KOAc (4.86 g, 49.6 mmol) and tricyclohexylphosphine (0.417 g, 1.488 mmol) in 1,4-dioxane (120 mL) was stirred at 100 °C for 4 h under nitrogen atmosphere. The mixture was diluted with water and extracted with EA. The organic layer was concentrated and purified by ISCO (PE / EA=5:1) to give the title compound as a yellow solid (8.1 g, 84% yield). MS (m / z): 391.1(M+H) + .

[0346] (C) 7-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[1,2-a]pyrazin-1(2H)-one A mixture of 4-chloro-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine (627 mg, 3 mmol), 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[1,2-a]pyran-1(2H)-one (1170 mg, 3 mmol), Pd(dppf)Cl2.CH2Cl2 (122 mg, 0.15 mmol) and Na2CO3 (636 mg, 3 mmol) in 1,4-dioxane (20 mL) and water (2 mL) was stirred at 100 °C under nitrogen atmosphere for 3 h. The mixture was diluted with water and extracted with EA. The organic layer was concentrated and purified by ISCO (DCM / MeOH=20:1) to give the title compound as a brown solid (800 mg, 61% yield). MS (m / z): 438.2 (M+H). + .

[0347] (D) 7-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyrrolo[1,2-a]pyrazin-1(2H)-one A solution of 7-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-2-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[1,2-a]pyrazin-1(2H)-one (800 mg, 1.8 mmol) in TFA (3 mL) was stirred at room temperature for 0.5 h. The volatiles were removed under reduced pressure and ammonium hydroxide was added. Filtration, washing the filter cake with water and drying afforded the title compound as a yellow solid (500 mg). MS (m / z): 380.0 (M+H) + .

[0348] (E) (S)-4-(3-(1-((2-fluorophenoxy)ethyl)pyrrolo[1,2-a][1,2,4]triazolo[3,4-c]pyrazin-9-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine A mixture of 7-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyrrolo[1,2-a]pyrazin-1(2H)-one (93 mg, 0.3 mmol) in POCl3 (2 mL) was stirred at 100 °C for 1 h. The volatiles were removed under reduced pressure and aqueous NaHCO3 was added to adjust pH = 8. The aqueous layer was extracted with DCM. The organic layer was dried over anhydrous Na2SO4 and concentrated. The residue was dissolved in EtOH (5 mL) and to it was added (S)-2-(2-fluorophenoxy)propanehydrazide (59 mg, 0.30 mmol). The resulting mixture was refluxed overnight. The volatiles were concentrated under reduced pressure and the residue was purified by ISCO (eluted with MeOH 0-100% in water) to give the title compound as a yellow solid (85 mg, 60% yield). MS (m / z): 470.1 (M+H) + . 1 H NMR (400 MHz, CD3OD) δ8.31 (d, J = 5.2 Hz, 1H), 8.07 (s, 1H), 7.77 (d, J = 6.0 Hz, 1H), 7.98 (d, J = 6.0 Hz, 1H), 7.60 (s, 1H), 7.42 (d, J = 2.0 Hz, 1H), 7.20 - 6.97 (m, 5H), 6.35 (d, J = 2.0 Hz, 1H), 5.97-5.92 (m,1H), 3.75 (s, 3H), 1.88 (d, J = 6.8 Hz, 3H).

[0349] The following compounds were prepared following the procedure for compound 39 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of ordinary skill in the art.

[0350] [Table 17]

[0351] Example 4: Synthesis of Compounds 41-43 compound 41 N-(2-fluorophenyl)-9-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyrrolo[1,2-a][1,2,4]triazolo[3,4-c]pyrazin-3-amine

[0352] [ka]

[0353] To a solution of 4-(1-chloropyrrolo[1,2-a]pyrazin-7-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine (130 mg, 0.40 mmol) in THF (5 mL) was added hydrazine hydrate (2 mL, 85%) and the mixture was then heated at 80° C. for 4 h. The mixture was then extracted with DCM. The combined organic layers were dried over anhydrous sodium sulfate and concentrated. The residue was dissolved in DCM (5 mL), 1-fluoro-2-isocyanatobenzene (70 mg, 0.51 mmol) and POCl3 (3 mL) were added and the resulting mixture was heated at 60° C. for 3 h. The volatiles were removed under reduced pressure and the residue was adjusted to pH=8 with aqueous NaHCO3. The aqueous layer was extracted with DCM. The organic layer was dried over anhydrous Na2SO4 and concentrated. The residue was purified by ISCO (eluting with MeOH in water 0% to 100%) to give the title compound as a yellow solid (15.0 mg, 10.0% yield). MS (m / z): 441.1 (M+H). + . 1H NMR (400 MHz, DMSO-d6) δ 9.32 (s, 1H), 8.41 (d, J = 5.2 Hz, 1H), 8.17 (d, J = 1.2 Hz, 1H), 7.89-7.85 (m,1H), 7.84 (d, J = 6.4 Hz, 1H), 7.66 (d, J = 6.4 Hz, 1H), 7.50 (s, 1H), 7.34 (d, J = 2.0 Hz, 1H), 7.31 (d, J = 5.2 Hz, 1H), 7.21-7.18 (m, 1H), 7.11-7.07 (m, 1H), 6.91 - 6.86 (m, 1H), 6.30 (d, J = 2.0 Hz, 1H), 3.69 (s, 3H).

[0354] The following compounds were prepared following the procedure for compound 41 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of ordinary skill in the art.

[0355] [Table 18]

[0356] Example 5: Synthesis of Compounds 44-52 (S)-4-(3-(1-(2-fluorophenoxy)ethyl)-6,6-dimethyl-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine

[0357] [ka]

[0358] (A) 4-(1-chloro-4,4-dimethyl-4,5-dihydro-3H-pyrrolo[1,2-a][1,4]diazepin-8-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine The title compound was prepared according to the procedure of Example 1 using the corresponding intermediates and reagents.

[0359] (B) (S)-4-(3-(1-(2-fluorophenoxy)ethyl)-6,6-dimethyl-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine A mixture of 4-(1-chloro-4,4-dimethyl-4,5-dihydro-3H-pyrrolo[1,2-a][1,4]diazepin-8-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine (111 mg, 0.3 mmol) and (S)-2-(2-fluorophenoxy)propanehydrazide (59 mg, 0.3 mmol) in EtOH (10 mL) was refluxed overnight. The mixture was concentrated and the residue was purified by ISCO (eluted with MeOH 0-100% in water) to give the title compound as a yellow solid (40 mg, 26% yield). MS (m / z): 514.2 (M+H) + . 1 H NMR (400 MHz, CD3OD) δ 8.26 (d, J = 5.2 Hz, 1H), 7.70 (d, J = 1.6 Hz, 1H), 7.42 (d, J = 2.0 Hz, 1H), 7.38 (d, J = 1.6 Hz, 1H), 7.24-7.20 (m, 1H), 7.17-7.09 (m, 2H), 7.07 - 7.00 (m, 2H), 6.33 (d, J = 2.0 Hz, 1H), 5.81-5.76 (m, 1H), 4.00 (s, 2H), 3.92 (s, 2H), 3.74 (s, 3H), 1.81 (d, J = 6.8 Hz, 3H), 1.11 (s,3H), 1.16 (s,3H).

[0360] The following compounds were prepared following the procedure for compound 44 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of skill in the art.

[0361] [Table 19-1] [Table 19-2]

[0362] Example 6: Synthesis of Compounds 53-54 compound 53 5-Chloro-4-(3-(indolin-1-yl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine

[0363] [ka]

[0364] (A) 5-chloro-4-(1-chloro-4,5-dihydro-3H-pyrrolo[1,2-a][1,4]diazepin-8-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine The title compound was prepared according to the procedure of Example 1 using the corresponding intermediates and reagents.

[0365] (B) Indoline-1-carbohydrazide To a solution of indoline (500 mg, 4.2 mmol) and DIPEA (0.76 mL, 4.6 mmol) in DMF (5 mL) was added CDI (750 mg, 4.6 mmol) in small portions at 0° C. The reaction mixture was stirred at room temperature for 2 h, diluted with water (100 mL) and extracted with EA (200 mL×2). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and concentrated. The residue was dissolved in THF (10 mL) and hydrazine hydrate (20 mL, 85%) was added thereto. The reaction mixture was stirred at room temperature for 1 h. The solvent was evaporated and the residue was partitioned between EA (50 mL) and brine (30 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to give the title compound (600 mg, crude), which was used directly in the next step without further purification. MS (m / z): 178.1 (M+H) + .

[0366] (C) 5-chloro-4-(3-(indolin-1-yl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine A mixture of 5-chloro-4-(1-chloro-4,5-dihydro-3H-pyrrolo[1,2-a][1,4]diazepin-8-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine (60 mg, 0.16 mmol) and indoline-1-carbohydrazide (43 mg, 0.24 mmol) in POCl3 (5 mL) was stirred at 60 °C for 3 h, followed by stirring at 90 °C for 4 h. The volatiles were removed under reduced pressure and the residue was adjusted to pH = 10 with 2M NaOH solution and extracted with DCM (30 mL x 2). The combined organic layer was washed with brine (30 mL), concentrated and purified by PTLC (DCM / MeOH = 13 / 1) to give the title compound as a yellow solid (12 mg, 15% yield). MS (m / z): 498.2 (M+H) + . 1H NMR (400 MHz, DMSO-d6) δ 8.83 (s, 1H), 8.13 (s, 1H), 7.64 (d, J = 2.0 Hz, 1H), 7.32 (d, J = 1.9 Hz, 1H), 7.25 - 7.21 (m, 2H), 7.04 (t, J = 7.7 Hz, 1H), 6.99 (s, 1H), 6.80 (t, J = 7.4 Hz, 1H), 6.68 (d, J = 7.9 Hz, 1H), 6.23 (d, J = 1.9 Hz, 1H), 4.49 - 4.40 (m, 2H), 4.14 - 4.05 (m, 2H), 3.93 (t, J = 8.3 Hz, 2H), 3.66 (s, 3H), 3.13 (t, J = 8.2 Hz, 2H), 2.34 - 2.30 (m, 2H).

[0367] The following compounds were prepared following the procedure for compound 53 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of skill in the art.

[0368] [Table 20]

[0369] Example 7: Synthesis of Compounds 55-210 compound 55 5-Chloro-N-(1-methyl-1H-pyrazol-5-yl)-4-(3'-(1-(trifluoromethyl)cyclobutyl)-5'H,7'H-spiro[cyclobutane-1,6'-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine]-10'-yl)pyridin-2-amine

[0370] [ka]

[0371] (A) 8'-(5-chloro-2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)-2',3'-dihydro-1'H,5'H-spiro[cyclobutane-1,4'-pyrrolo[1,2-a][1,4]diazepine]-1'-one The title compound was prepared according to the procedure in Example 1 using the corresponding intermediates and reagents.

[0372] (B) 5-chloro-N-(1-methyl-1H-pyrazol-5-yl)-4-(3′-(1-(trifluoromethyl)cyclobutyl)-5′H,7′H-spiro[cyclobutane-1,6′-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine]-10′-yl)pyridin-2-amine A mixture of 8'-(5-chloro-2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)-2',3'-dihydro-1'H,5'H-spiro[cyclobutane-1,4'-pyrrolo[1,2-a][1,4]diazepin]-1'-one (55 mg, 0.14 mmol) and 1-(trifluoromethyl)cyclobutane-1-carbohydrazide (25 mg, 0.14 mmol) in POCl3 (3 mL) was stirred at 100 °C for 30 min. The volatiles were removed under reduced pressure and the residue was adjusted to pH = 8 with NaHCO3 solution and extracted with EA. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was dissolved in EtOH (3 mL) and acetic acid (2 drops) and the resulting mixture was stirred in a microwave at 100 °C for 1.5 h. The mixture was then concentrated and the residue was purified by ISCO (eluted with MeOH 0-100% in water) and PTLC (DCM / MeOH=15:1) to give the title compound as a yellow solid (20 mg, 27% yield). MS (m / z): 543.1 (M+H). + . 1H NMR (400 MHz, DMSO-d6) δ 8.85 (s, 1H), 8.12 (s, 1H), 7.72 (d, J = 1.6 Hz, 1H), 7.31 (d, J = 1.6 Hz, 1H), 7.20 (d, J = 2.0 Hz, 1H), 6.97 (s, 1H), 6.22 (d, J = 1.6 Hz, 1H), 4.40 (s, 2H), 4.06 (s, 2H), 3.64 (s, 3H), 2.92 - 2.85 (m, 2H), 2.80 - 2.74 (m, 2H), 2.20 - 2.13 (m, 1H), 2.03 - 1.96 (m, 2H), 1.89 - 1.79 (m, 5H).

[0373] The following compounds were prepared following the procedure for compound 55 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of skill in the art.

[0374] [Table 21-1] [Table 21-2] [Table 21-3] [Table 21-4] [Table 21-5] [Table 21-6] [Table 21-7] [Table 21-8] [Table 21-9]

Table 21-10

Table 21-11

Table 21-12

Table 21-13

Table 21-14

Table 21-15

Table 21-16

Table 21-17

Table 21-18

Table 21-19

Table 21-20

Table 21-21

Table 21-22

Table 21-23

Table 21-24

Table 21-25

Table 21-26

[0375] Example 8: Synthesis of Compounds 211-214 compound 211 5-Chloro-4-(3-((2-fluorophenoxy)methyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine

[0376] [ka]

[0377] (A) 8-(2,5-dichloropyrimidin-4-yl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one A mixture of 8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one (2.70 g, 9.78 mmol), Pd(dppf)Cl2.CH2Cl2 (799 mg, 0.98 mmol), 2,4,5-trichloropyrimidine (1.97 g, 10.76 mmol) and cesium carbonate (9.56 g, 29.33 mmol) in 1,4-dioxane / water (120 mL / 30 mL) was degassed and stirred at 80° C. under nitrogen atmosphere for 3 h. The mixture was diluted with DCM and washed with water and brine. The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was suspended in EA and stirred for 30 min, then filtered and the filter cake was dried in vacuum to give the title compound as a yellow solid (2.85 g). MS (m / z): 296.9 (M+H). + .

[0378] (B) 8-(5-chloro-2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one A mixture of 8-(2,5-dichloropyrimidin-4-yl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one (2.80 g, 9.46 mmol), 1-methyl-1H-pyrazol-5-amine (4.59 g, 47.28 mmol), Pd2dba3 (0.87 g, 0.95 mmol), Xantphos (1.09 g, 1.89 mmol) and cesium carbonate (9.24 g, 28.36 mmol) in 1,4-dioxane (140 mL) was degassed and stirred at 100° C. for 6 h under nitrogen atmosphere. The mixture was filtered and the filtrate was extracted with EA and water. The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate and concentrated. The residue was purified by ISCO (eluted with 0% to 100% methanol in water) to give the title compound as a yellow solid (1.52 g, 45.0% yield). MS (m / z): 358.0 (M+H). + .

[0379] (C) 5-chloro-4-(3-((2-fluorophenoxy)methyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine The title compound was prepared according to the procedure of Example 1 using the corresponding intermediates and reagents. MS (m / z): 506.2 (M+H) + . 1 H NMR (400 MHz, DMSO-d6) δ 9.48 (s, 1H), 8.43 (s, 1H), 7.97 (d, J = 2.0 Hz, 1H), 7.60 (d, J = 2.0 Hz, 1H), 7.44-7.39 (m, 1H), 7.36 (d, J = 1.9 Hz, 1H), 7.25-7.20 (m, 1H), 7.19 - 7.13 (m, 1H), 7.04 - 6.96 (m, 1H), 6.26 (d, J = 1.9 Hz, 1H), 5.40 (s, 2H), 4.50 - 4.41 (m, 2H), 4.37 - 4.30 (m, 2H), 3.68 (s, 3H), 2.40 - 2.30 (m, 2H).

[0380] The following compounds were prepared following the procedure for compound 211 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of ordinary skill in the art.

[0381] [Table 22]

[0382] Example 9: Synthesis of Compounds 215-216 compound 215 (S)-10-(5-chloro-2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-6-ol

[0383] [ka]

[0384] (A) (R)-8-Bromo-1-oxo-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-4-yl acetate To a solution of (R)-8-bromo-4-hydroxy-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one (1.5 g, 0.006 mol) and Ac2O (0.7 g, 0.006 mol) in THF (50 mL) was added Et3N (1.3 g, 0.012 mol) and N,N-dimethylpyridin-4-amine (40 mg, 0.300 mmol). After stirring at 50 °C for 1 h, the mixture was concentrated and the residue was dissolved in DCM. The organic layer was then washed with NaHCO3 saturated solution and water and concentrated to give the title compound as a yellow oil (1.5 g, 88.2% yield). MS (m / z): 287.0 / 289.0 (M+H) + .

[0385] (B) (R)-1-Oxo-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-4-yl acetate A mixture of (R)-8-bromo-1-oxo-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-4-ylacetic acid ester (200 mg, 0.669 mmol), Pd2(dba)3 (32 mg, 0.035 mmol), tricyclohexylphosphane (10 mg, 0.035 mmol), BPIN (178 mg, 0.669 mmol) and KOAc (137 mg, 1.398 mmol) in 1,4-dioxane (10 mL) was stirred at 100 °C under nitrogen atmosphere for 16 h. The mixture was filtered and the filtrate was concentrated. The residue was purified by ISCO (eluted with methanol in water 0% to 100%) to give the title compound as a white solid (150 mg, 64.2% yield). MS (m / z): 335.1 (M+H) + .

[0386] (C) (R)-8-(5-chloro-2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)-4-hydroxy-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one A mixture of (R)-1-oxo-8-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-4-ylacetic acid ester (150 mg, 0.449 mmol), Pd(dppf)Cl2 (16 mg, 0.023 mmol), Na2CO3 (95 mg, 0.898 mmol) and 5-chloro-4-iodo-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine (150 mg, 0.449 mmol) in 1,4-dioxane (5 mL) and water (1 mL) was stirred at 80° C. for 2 h under nitrogen atmosphere. The mixture was diluted with water and extracted with DCM. The organic layer was concentrated and the residue was purified by ISCO (methanol in water 0% to 100%) to give the title compound as a white solid (100 mg, 59.9% yield). MS (m / z): 373.1 (M+H). + .

[0387] (D) (S)-10-(5-chloro-2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-6-ol A mixture of (R)-8-(5-chloro-2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)-4-hydroxy-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one (100 mg, 0.269 mmol), 1-(trifluoromethyl)cyclobutane-1-carbohydrazide (49 mg, 0.269 mmol) in POCl3 (5 mL) was stirred at 80 °C for 2 h. The mixture was concentrated and the residue was dissolved in DCM and MeOH. The organic layer was then washed with saturated NaHCO3 solution and water, concentrated and the residue was dissolved in NMP (5 mL). To it was added a drop of HOAc and the mixture was stirred at 130 °C for 30 min in a microwave. The mixture was then directly purified by ISCO (eluting with 0% to 100% methanol in water) to give the title compound as a yellow solid (20 mg, 14.4% yield). MS (m / z): 519.0 (M+H). + . 1 H NMR (400 MHz, DMSO-d6) δ 8.85 (s, 1H), 8.12 (s, 1H), 7.70 (s, 1H), 7.31 (s, 1H), 7.07 (s, 1H), 6.96 (s, 1H), 6.21 (s, 1H), 4.45 - 4.28 (m, 2H), 4.14 - 4.01 (m, 2H), 3.82-3.7 (m, 1H), 3.03 - 2.86 (m, 2H), 2.73-2.69 (m, 2H), 2.16-2.12 (m, 1H), 2.03-2.00 (m, 1H).

[0388] The following compounds were prepared following the procedure for Compound 215 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of ordinary skill in the art.

[0389] [Table 23]

[0390] Example 10: Synthesis of Compounds 217-219 compound 217 1-((10-(5-chloro-2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)-6,6-difluoro-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-3-yl)methyl)-1H-pyrrole-2-carbonitrile

[0391] [ka]

[0392] (A) 8-(5-chloro-2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)-4,4-difluoro-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one The title intermediate was prepared according to the procedure of Example 1 using the corresponding intermediates and reagents.

[0393] (B) 2-((4-methoxybenzyl)oxy)acetohydrazide To a solution of ethyl 2-hydroxyacetate (3.1 g, 30 mmol) in anhydrous DMF (50 mL) was added NaH (1.5 g, 36 mmol, 60% dispersion in paraffin liquid) in small portions under nitrogen atmosphere at 5° C. The mixture was stirred for 1 h. 1-(Chloromethyl)-4-methoxybenzene (5.6 g, 36 mmol) was added dropwise and the mixture was stirred at room temperature for 12 h. The reaction mixture was quenched with saturated ammonium chloride solution and then concentrated in vacuo. The residue was purified by silica gel chromatography (PE: EA=4:1) to give a yellow oil. The oil was dissolved in ethanol (100 mL) and hydrazine hydrate (4.5 g, 85%) was added. The solution was refluxed for 2 h. The solvent was removed by rotary evaporation and the residue was purified by ISCO (eluting with 0% to 100% methanol in water) to give the title compound as a yellow oil (3.7 g, 59% yield). MS (m / z): 121.1 (M+H). + .

[0394] (C) 5-chloro-4-(3-(chloromethyl)-6,6-difluoro-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine A mixture of 8-(5-chloro-2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)-4,4-difluoro-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one (784 mg, 2 mmol) and 2-((4-methoxybenzyl)oxy)acetohydrazide (841 mg, 4 mmol) in POCl3 (10 mL) was stirred at 100° C. under nitrogen atmosphere for 2 h. The solvent was removed by rotary evaporation, the residue was dissolved in DCM and washed with saturated aqueous sodium bicarbonate. The aqueous phase was extracted with DCM. The organic phases were combined, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was dissolved in a solution of acetic acid (2 drops) in n-BuOH (20 mL). The solution was stirred at 130° C. for 2 h and then concentrated under reduced pressure. The residue was purified by ISCO (eluted with 0% to 100% methanol in water) to give the title compound as a yellow solid (380 mg, 41% yield). MS (m / z): 465.1, 467.1 (M+H). + .

[0395] (D) 1-((10-(5-chloro-2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)-6,6-difluoro-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-3-yl)methyl)-1H-pyrrole-2-carbonitrile A mixture of 5-chloro-4-(3-(chloromethyl)-6,6-difluoro-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine (80 mg, 0.17 mmol), 1H-pyrrole-2-carbonitrile (19 mg, 0.21 mmol) and cesium carbonate (166 mg, 0.51 mmol) in acetonitrile (10 mL) was stirred overnight at room temperature under nitrogen atmosphere. The reaction mixture was quenched with dilute aqueous HCl and then adjusted to pH=8 with saturated aqueous sodium bicarbonate. The mixture was extracted with DCM / MeOH (10:1). The organic phases were combined and then concentrated in vacuo. The residue was purified by ISCO (eluted with 0% to 100% methanol in water) and PTLC (DCM / MeOH=10:1) to give the title compound as a pale yellow solid (19.1 mg, 22% yield). MS (m / z): 521.1 (M+H). + . 1 H NMR (400 MHz, DMSO-d6) δ 8.87 (s, 1H), 8.14 (s, 1H), 7.87 (d, J = 1.9 Hz, 1H), 7.31 (d, J = 1.9 Hz, 1H), 7.25 (dd, J = 2.7, 1.6 Hz, 1H), 7.13 (d, J = 1.9 Hz, 1H), 6.98 (dd, J = 4.0, 1.6 Hz, 1H), 6.96 (s, 1H), 6.23 (dd, J = 4.0, 2.7 Hz, 1H), 6.21 (d, J = 1.9 Hz, 1H), 5.60 (s, 2H), 4.80 -4.69 (m, 4H), 3.64 (s, 3H).

[0396] The following compounds were prepared following the procedure for Compound 217 using the corresponding intermediates and reagents under conditions recognized by one of ordinary skill in the art.

[0397] [Table 24]

[0398] Example 11: Synthesis of Compounds 220-228 compound 220 (R)-4-(3-((2-chlorophenyl)difluoromethyl)-5-(methoxymethyl)-5,6-dihydroimidazolo[1,2-a][1,2,4]triazolo[3,4-c]pyrazin-9-yl)-5-methyl-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine

[0399] [ka]

[0400] (A) 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carboxylate methyl To a solution of methyl 1H-imidazole-2-carboxylate (10 g, 79.3 mmol) and K2CO3 in acetone (300 mL) was added (2-(chloromethoxy)ethyl)trimethylsilane (14.3 g, 85.6 mmol). The resulting mixture was stirred at room temperature for 16 h. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by silica gel chromatography (PE:EA=2:1) ​​to give the title compound as a yellow oil (11.9 g, 58.5% yield). MS (m / z): 257.0 (M+H) + .

[0401] (B) 4-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-2-carboxylate methyl To a mixture of methyl 1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carboxylate (16.6 g, 64.7 mmol), BPIN (32.8 g, 129.2 mmol), (1,5-cyclooctadiene)(methoxy)iridium(I) dimer (2.2 g, 3.3 mmol) and 3,4,7,8-tetramethyl-1,10-phenanthroline (1.5 g, 6.5 mmol) was added anhydrous THF (110 mL) and the resulting mixture was degassed with nitrogen three times. The mixture was then refluxed overnight under a nitrogen atmosphere. The mixture was filtered and the filtrate was concentrated. The residue was dissolved in DMF (400 mL) and Pd(PPh3)4 (3.8 g, 3.3 mmol), CuI (1.3 g, 6.5 mmol), Cs2CO3 (15.8 g, 97.0 mmol) and 2,4-dichloro-5-methylpyrimidine (15.8 g, 97.0 mmol) were added. The resulting mixture was degassed with nitrogen three times. The mixture was then refluxed at 90° C. overnight under nitrogen atmosphere. The mixture was filtered and the filtrate was concentrated. The residue was dissolved in TFA (100 mL) and refluxed for 2 h. The volatiles were evaporated and the residue was neutralized with saturated NaHCO3 solution and then with DCM / MeOH (10:1). The combined organic layers were concentrated and the residue was purified by silica gel chromatography (DCM:MeOH=10:1) to give the title compound as an off-white solid (15.2 g, 92.9% yield). MS (m / z): 253.0 (M+H). + .

[0402] (C) (R)-1-(2-((tert-butoxycarbonyl)amino)-3-methoxypropyl)-4-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-2-carboxylate methyl To a solution of methyl 4-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-2-carboxylate (2.5 g, 9.9 mmol), (R)-tert-butyl (1-hydroxy-3-methoxypropan-2-yl)carbamate (2.3 g, 12.0 mmol) and PPh3 (5.3 g, 20.0 mmol) in anhydrous THF (100 mL) was added DIAD (4.6 g, 20.0 mmol) dropwise at 0° C. The resulting mixture was stirred overnight at room temperature under nitrogen atmosphere. The mixture was concentrated and the residue was purified by silica gel chromatography (PE:EA=2:1) ​​to give the title compound as a yellow gum (2.5 g, 57.4% yield). MS (m / z): 440.0 (M+H) + .

[0403] (D) (R)-2-(2-chloro-5-methylpyrimidin-4-yl)-6-(methoxymethyl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5H)-one A mixture of (R)-1-(2-((tert-butoxycarbonyl)amino)-3-methoxypropyl)-4-(2-chloro-5-methylpyrimidin-4-yl)-1H-imidazole-2-carboxylate (2.5 g, 5.7 mmol) and TFA (15 mL) in DCM (20 mL) was stirred at room temperature for 3 h. The mixture was concentrated and the residue was dissolved in MeOH (10 mL) and to it was added ammonium chloride solution (30 mL, 7M) in MeOH. The resulting mixture was stirred at room temperature for 2 h. The mixture was concentrated and the residue was purified by silica gel chromatography (DCM:MeOH=20:1) to give the title compound as a yellow compound (1.21 g, 69.2% yield). MS (m / z): 308.0 (M+H) + .

[0404] (E) (R)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5H)-one To a solution of 1-methyl-1H-pyrazol-5-amine (0.12 g, 1.24 mmol) in THF (10 mL) was added NaHMDS (0.5 mL, 1.0 mmol, 2 M in THF) at room temperature, and the resulting mixture was stirred for another 20 min under nitrogen atmosphere. (R)-2-(2-chloro-5-methylpyrimidin-4-yl)-6-(methoxymethyl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5H)-one (0.12 g, 0.39 mmol) was added. The mixture was refluxed overnight. The reaction was quenched with 4N HCl. The volatiles were evaporated and the residue was neutralized with saturated NaHCO3 solution. The solvent was evaporated and the residue was purified by silica gel chromatography (DCM:MeOH=10:1) to give the title compound as a yellow solid (0.118 g, 82.1% yield). MS (m / z): 369.2 (M+H) + .

[0405] (F) (R)-4-(3-((2-chlorophenyl)difluoromethyl)-5-(methoxymethyl)-5,6-dihydroimidazo[1,2-a][1,2,4]triazolo[3,4-c]pyrazin-9-yl)-5-methyl-N-(1-methyl-1H-pyrazol-5-yl)pyrimidin-2-amine The title compound was prepared using the corresponding intermediates and reagents according to the procedure of Example 7. MS (m / z): 553.0 (M+H) + . 1H NMR (400 MHz, DMSO-d6) δ 9.22 (s, 1H), 8.32 (s, 1H), 8.12 (s, 1H), 7.89 (d, J = 7.5 Hz, 1H), 7.70 - 7.64 (m, 2H), 7.62 - 7.54 (m, 1H), 7.32 (d, J = 1.8 Hz, 1H), 6.30 (d, J = 1.8 Hz, 1H), 5.38 - 5.32 (m, 1H), 4.87 (d, J = 14.0 Hz, 1H), 4.69 (dd, J = 14.0, 5.1 Hz, 1H), 3.69 (s, 3H), 3.62 - 3.51 (m, 2H), 3.13 (s, 3H), 2.52 (s, 3H).

[0406] The following compounds were prepared following the procedure for Compound 220 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of skill in the art.

[0407] [Table 25-1] [Table 25-2]

[0408] Example 12: Synthesis of Compounds 229-274, 322 compound 229 (S)-2-((5-chloro-4- (3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)pyridin-2-yl)amino)propan-1-ol

[0409] [ka]

[0410] (A) 10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine The title compound was prepared using the corresponding intermediates and reagents according to the procedure of Example 1. MS (m / z): 423.1 (M+H) + .

[0411] (B) (S)-2-((5-chloro-4-(3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)pyridin-2-yl)amino)propan-1-ol A mixture of 10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine (85 mg, 0.2 mmol), (S)-2-((5-chloro-4-iodopyridin-2-yl)amino)propan-1-ol (94 mg, 0.3 mmol), Pd(PPh3)4 (23 mg, 0.02 mmol) and Na2CO3 (63 mg, 0.6 mmol) in 1,4-dioxane / water (10 mL, 4:1) was stirred at 80 °C for 2 h under nitrogen atmosphere. The solvent was removed by rotary evaporation, and the residue was purified by ISCO (eluted with 0% to 100% methanol in water) and PTLC (DCM:MeOH=10:1) to give the title compound as a pale yellow solid (39 mg, 41% yield). MS (m / z): 481.1 (M+H). + . 1H NMR (400 MHz, DMSO-d6) δ 7.95 (s, 1H), 7.61 (d, J = 2.0 Hz, 1H), 7.18 (d, J = 2.0 Hz, 1H), 6.71 (s, 1H), 6.32 (d, J = 7.8 Hz, 1H), 4.69 (t, J = 5.5 Hz, 1H), 4.32 (t, J = 6.0 Hz, 2H), 4.05 (t, J = 6.0 Hz, 2H), 3.92 - 3.86 (m, 1H), 3.49 - 3.43 (m, 1H), 3.30 - 3.24 (m, 1H), 2.95 - 2.87 (m, 2H), 2.79 - 2.68 (m, 2H), 2.35 - 2.26 (m, 2H), 2.23 - 2.10 (m, 1H), 2.05 - 1.96 (m, 1H), 1.11 (d, J = 6.6 Hz, 3H).

[0412] The following compounds were prepared following the procedure for Compound 229 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of ordinary skill in the art.

[0413] [Table 26-1] [Table 26-2] [Table 26-3] [Table 26-4] [Table 26-5] [Table 26-6] [Table 26-7] [Table 26-8] [Table 26-9] [Table 26-10] [Table 26-11]

[0414] Example 13: Synthesis of Compounds 275-280 compound 275 (S)-2-((5-methyl-4-(3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)pyrimidin-2-yl)amino)propan-1-ol

[0415] [ka]

[0416] (A) 10-(2-chloro-5-methylpyrimidin-4-yl)-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine A mixture of 10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine (2.0 g, 4.7 mmol), 2,4-dichloro-5-methylpyrimidine (620 mg, 3.8 mmol), Pd(dppf)Cl2·CH2Cl2 (300 mg, 0.40 mmol) and Na2CO3 (1.0 g, 9.4 mmol) in 1,4-dioxane (40 mL) and water (8 mL) was stirred at 90 °C for 4 h. The resulting mixture was concentrated and purified by ISCO (eluting with 0% to 100% methanol in water) to give the title compound as a white solid (500 mg, 25.0% yield). MS (m / z): 423.0.

[0417] (B) (S)-2-((5-methyl-4-(3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)pyrimidin-2-yl)amino)propan-1-ol A mixture of 10-(2-chloro-5-methylpyrimidin-4-yl)-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine (50 mg, 0.12 mmol), (S)-2-aminopropan-1-ol (44 mg, 0.59 mmol) and DIPEA (76 mg, 0.59 mmol) in NMP (2 mL) was stirred at 180° C. for 2.5 h under microwave. The resulting mixture was directly purified by ISCO (eluted with 0% to 100% methanol in water) and PTLC (DCM:MeOH=15:1) to give the title compound as a white solid (8.0 mg, 14.7% yield). MS (m / z): 462.1 (M+H) + . 1H NMR (400 MHz, DMSO-d6) δ 8.03 (s, 1H), 7.62 (d, J = 1.7 Hz, 1H), 7.40 (d, J = 1.7 Hz, 1H), 6.15 (d, J = 8.1 Hz, 1H), 4.58 (s, 1H), 4.37 - 4.29 (m, 2H), 4.09 - 3.95 (m, 3H), 3.53 - 3.45 (m, 1H), 3.40 - 3.32 (m, 2H), 2.97 - 2.86 (m, 2H), 2.74 - 2.71 (m, 2H), 2.35 - 2.28 (m, 2H), 2.25 (s, 3H), 2.21 - 2.11 (m, 1H), 2.04 - 1.94 (m, 1H), 1.14 (d, J = 6.6 Hz, 3H).

[0418] The following compounds were prepared following the procedure for Compound 275 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of ordinary skill in the art.

[0419] [Table 27-1] [Table 27-2]

[0420] Example 14: Synthesis of Compounds 281-298 compound 281 5-Methyl-N-(2-methylpyridin-4-yl)-4-(3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)pyrimidin-2-amine

[0421] [ka]

[0422] A mixture of 10-(2-chloro-5-methylpyrimidin-4-yl)-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine (30 mg, 0.07 mmol), 2-methylpyridin-4-amine (15 mg, 0.14 mmol), Pd2(dba)3 (16 mg, 0.007 mmol), Xantphos (4.1 mg, 0.007 mmol) and Cs2CO3 (69 mg, 0.21 mmol) in 1,4-dioxane (2 mL) was stirred at 150 °C for 30 min under microwave. The mixture was concentrated and partitioned between water (10 mL) and DCM (10 mL). The aqueous layer was extracted with DCM (10 mL x 2). The combined organic layers were concentrated and purified by PTLC (DCM:MeOH=15:1) to give the title compound as a white solid (8.5 mg, 24.2% yield). MS (m / z): 495.1 (M+H). + . 1 H NMR (400 MHz, DMSO-d6) δ 9.63 (s, 1H), 8.34 (s, 1H), 8.19 (d, J = 5.7 Hz, 1H), 7.73 (d, J = 6.0 Hz, 2H), 7.59 - 7.54 (m, 1H), 7.55 - 7.52 (m, 1H), 4.42 - 4.35 (m, 2H), 4.11 - 4.05 (m, 2H), 2.98 - 2.89 (m, 2H), 2.76 - 2.72 (m, 2H), 2.41 (s, 3H), 2.38 (s, 3H), 2.34 - 2.30 (m, 2H), 2.23 - 2.12 (m, 1H), 2.05 - 1.95 (m, 1H).

[0423] The following compounds were prepared following the procedure for Compound 281 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of ordinary skill in the art.

[0424] [Table 28-1] [Table 28-2] [Table 28-3] [Table 28-4]

[0425] Example 15: Synthesis of Compound 299 compound 299 (10-(5-chloro-2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-6-yl)methanol

[0426] [ka]

[0427] (A) 8-Bromo-1-oxo-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepine-4-carboxylic acid To a mixture of methyl 4-bromo-1H-pyrrole-2-carboxylate (5.0 g, 24.5 mmol) in DMF (100 mL) was added NaH (3.43 g, 85.7 mmol, 60% dispersion in paraffin liquid) slowly at 0° C. The reaction mixture was stirred for 0.5 h, and then 3-bromo-2-(bromomethyl)propanoic acid was added to it. The reaction was stirred at room temperature under nitrogen atmosphere for 2 h. The reaction was then quenched with saturated ammonium chloride solution, adjusted to pH<4 with dilute HCl, and extracted with EA. The organic layer was washed with brine, dried, and concentrated. To the residue was added ammonium hydroxide (50 mL), and the resulting mixture was stirred at 100° C. overnight. The mixture was concentrated and purified by ISCO (eluted with 0% to 100% methanol in water) to give the title compound as a yellow solid (1.30 g, 16.1% yield). MS (m / z): 273.0 / 275.0 (M+H)+ .

[0428] (B) 8-Bromo-4-(hydroxymethyl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one To a solution of 8-bromo-1-oxo-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepine-4-carboxylic acid (800 mg, 2.93 mmol) in THF (10 mL) was added BH3·Me2S (4.5 mL, 9.0 mmol) at 0° C. The reaction mixture was stirred at 50° C. under nitrogen atmosphere for 3 h. The reaction mixture was then quenched with MeOH, concentrated, and purified by ISCO (eluting with 0% to 100% methanol in water) to give the title compound as a yellow solid (250 mg, 32.8% yield). MS (m / z): 259.0 / 261.0 (M+H) + .

[0429] (C) (10-Bromo-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-6-yl)methyl acetate To a mixture of 8-bromo-4-(hydroxymethyl)-2,3,4,5-tetrahydro-1H-pyrrolo[1,2-a][1,4]diazepin-1-one (250 mg, 0.96 mmol) in DCM (10 mL) was added Et3N (194.3 mg, 1.92 mmol), Ac2O (148 mg, 1.44 mmol) and N,N-dimethylpyridin-4-amine (12 mg, 0.096 mmol) at 0° C. The reaction mixture was stirred at room temperature under nitrogen atmosphere for 2 h. The reaction mixture was then quenched with water and extracted with DCM. The organic layer was washed with brine, dried and concentrated. The residue was mixed with 1-(trifluoromethyl)cyclobutane-1-carbohydrazide (210 mg, 1.15 mmol) and POCl3 (5 mL). The resulting mixture was stirred at 70° C. for 2 h. The volatiles were evaporated and the residue was dissolved in DCM and MeOH. The organic layer was then washed with saturated NaHCO3 solution, dried over anhydrous Na2SO4 and concentrated. The residue was dissolved in NMP (5 mL) to which 2 drops of HOAc were added. The resulting mixture was stirred at 130 °C under microwave for 0.5 h. The reaction mixture was then directly purified by ISCO (eluted with methanol in water 0%-100%) to give the title compound as a yellow solid (220 mg, 51.0% yield). MS (m / z): 447.0 / 449.0 (M+H). + .

[0430] (D) (10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-6-yl)methyl acetate A mixture of (10-bromo-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-6-yl)methyl acetate (80 mg, 0.18 mmol) and BPIN (91 mg, 0.36 mmol), Pd2(dba)3 (16 mg, 0.018 mmol), tricyclohexylphosphane (10 mg, 0.036 mmol) and potassium acetate (53 mg, 0.54 mmol) in 1,4-dioxane (8 mL) was stirred at 100° C. for 5 h under nitrogen atmosphere. The reaction mixture was diluted with water and extracted with DCM. The organic layer was dried, concentrated in vacuo and purified by ISCO (eluting with 0% to 100% methanol in water) to give the title compound as a white solid (10 mg, 11.1% yield). MS (m / z): 495.1 (M+H). + .

[0431] (E) (10-(5-chloro-2-((1-methyl-1H-pyrazol-5-yl)amino)pyridin-4-yl)-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-6-yl)methanol A mixture of (10-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-6-yl)methyl acetate (10 mg, 0.02 mmol), 5-chloro-4-iodo-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine (9 mg, 0.024 mmol), Pd(dppf)Cl2·CH2Cl2 (2 mg, 0.002 mmol) and sodium carbonate (6.4 mg, 0.06 mmol) in 1,4-dioxane (8 mL) and water (2 mL) was degassed and stirred at 80 °C under nitrogen atmosphere for 1 h. The mixture was then concentrated and the residue was purified by ISCO (eluted with 0% to 100% methanol in water) to give the title compound as a pale yellow solid (3.0 mg, 28.0% yield). MS (m / z): 533.0(M+H). + . 1 H NMR (400 MHz, DMSO-d6) δ 8.86 (s, 1H), 8.14 (s, 1H), 7.70 (s, 1H), 7.33 (s, 1H), 7.14 (s, 1H), 6.98 (s, 1H), 6.24 (s, 1H), 5.06 (t, J = 5.0 Hz, 1H), 4.32 - 4.17 (m, 2H), 4.14 - 4.09 (m, 1H), 3.75 -3.69 (m, 1H), 3.67 (s, 3H), 3.50 - 3.36 (m, 3H), 2.97 - 2.89 (m, 2H), 2.77 - 2.72 (m, 2H), 2.19 - 2.14 (m, 1H), 2.08 - 1.94 (m, 1H).

[0432] Example 16: Synthesis of Compounds 300 to 303 compound 300 5-Chloro-4-(6-(methoxymethyl)-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine

[0433] [ka]

[0434] (A) 10-Bromo-6-(methoxymethyl)-3-(1-(trifluoromethyl)cyclobutyl-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine A mixture of (10-bromo-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-6-yl)methyl acetate (140 mg, 0.31 mmol) and Na2CO3 (99 mg, 0.93 mmol) in THF (3 mL) and water (3 mL) was stirred at room temperature for 0.5 h. The mixture was then diluted with water and extracted with DCM. The organic layer was washed with brine, dried and concentrated. The residue was dissolved in THF (10 mL) and cooled to 0 °C. To it was added NaH (20 mg, 0.50 mmol, 60% dispersion in paraffin liquid) and the mixture was stirred for an additional 20 min. Iodomethane was added and the reaction was stirred at room temperature for 0.5 h. The reaction was then quenched with saturated ammonium chloride and extracted with DCM. The organic layer was concentrated and purified by ISCO (eluting with 0% to 100% methanol in water) to give the title compound as a white solid (110 mg, 83.8% yield). MS (m / z): 419.0 / 421.0 (M+H). + .

[0435] (B) 5-chloro-4-(6-(methoxymethyl)-3-(1-(trifluoromethyl)cyclobutyl)-6,7-dihydro-5H-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepin-10-yl)-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine The title compound was prepared using the corresponding intermediates and reagents according to the procedure of Example 15. MS (m / z): 547.1 (M+H) + . 1 H NMR (400 MHz, DMSO-d6) δ 8.83 (s, 1H), 8.12 (s, 1H), 7.67 (s, 1H), 7.31 (s, 1H), 7.12 (s, 1H), 6.96 (s, 1H), 6.21 (s, 1H), 4.23 (d, J = 4.3 Hz, 2H), 4.08 - 4.05 (m, 1H), 3.82 - 3.72 (m, 1H), 3.64 (s, 3H), 3.36 -3.30 (m, 2H), 3.24 (s, 3H), 2.93 - 2.85 (m, 2H), 2.75 - 2.68 (m, 3H), 2.18 - 2.13 (m, 1H), 2.03 - 1.97 (m, 1H).

[0436] The following compounds were prepared following the procedure for compound 300 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of ordinary skill in the art.

[0437] [Table 29]

[0438] Example 17: Synthesis of Compounds 304-321 Compound 304 5-Chloro-N-(1-methyl-1H-pyrazol-5-yl)-4-(3'-(1,1,2,2-tetrafluoroethyl)-5'H,7'H-spiro[oxetane-3,6'-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine]-10'-yl)pyridin-2-amine

[0439] [ka]

[0440] (A) 10′-Bromo-3′-(1,1,2,2-tetrafluoroethyl)-5′H,7′H-spiro[oxetane-3,6′-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine] To a solution of 8'-bromo-2',3'-dihydro-1'H,5'H-spiro[oxetane-3,4'-pyrrolo[1,2-a][1,4]diazepin]-1'-one (400 mg, 1.48 mmol) in DCM (30 mL) was added CF3SO3Me (291 mg, 1.77 mmol), and the mixture was then stirred at reflux temperature under nitrogen atmosphere overnight. The reaction mixture was quenched with water and extracted with DCM. The combined organic layers were washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The residue was dissolved in propan-2-ol (20 mL), to which was added 2,2,3,3-tetrafluoropropanehydrazide (283 mg, 1.77 mmol) and HOAc (2 drops). The mixture was then purged with nitrogen and stirred at 70°C for 3 h, followed by stirring at 90°C for 3 h. The mixture was concentrated and the residue was purified by ISCO (eluted with 0% to 100% methanol in water) to give an off-white solid (203 mg, 34.7% yield). MS (m / z): 394.9 / 396.9 (M+H). + .

[0441] (B) 5-chloro-N-(1-methyl-1H-pyrazol-5-yl)-4-(3′-(1,1,2,2-tetrafluoroethyl)-5′H,7′H-spiro[oxetane-3,6′-pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine]-10′-yl)pyridin-2-amine The title compound was prepared using the corresponding intermediates and reagents according to the procedure of Example 15. MS (m / z): 523.0 (M+H) + . 1 H NMR (400 MHz, DMSO-d6) δ 8.83 (s, 1H), 8.15 (s, 1H), 7.89 (s, 1H), 7.62 - 7.14 (m, 3H), 6.98 (s, 1H), 6.23 (s, 1H), 4.73 (s, 2H), 4.66 (s, 2H),4.51 - 4.42 (m, 2H), 4.41 - 4.31(m, 2H), 3.64 (s, 3H).

[0442] The following compounds were prepared following the procedure for Compound 304 using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of ordinary skill in the art.

[0443] [Table 30]

[0444] The following compounds were prepared following the procedures of the above examples using the corresponding intermediates and reagents under suitable conditions that would be recognized by one of ordinary skill in the art.

[0445] [Table 31-1] [Table 31-2]

[0446] Example 18: Z-lyte kinase assay of ERK2 1. Materials and Reagents:

[0447] [Table 32]

[0448] 2.Reaction process Plate Map

[0449] [Table 33]

[0450] 3. Solution Preparation 1) 1.33x Kinase Buffer: Dilute 5x Kinase Buffer to 1.33x with ddH2O. 2) 4x Test Compound: Serially dilute test compound to 4x the desired concentration while maintaining DMSO concentration at 8%. Final concentrations are 1, 0.33, 0.11, 0.037, 0.012, 0.004, 0.0014, 0.00046 μM with a final DMSO concentration of 2%. 3) Kinase / peptide mixture (P / K solution): Dilute kinase to 0.6 μg / mL in 1.33× kinase buffer and mix with Z-LYTE TM Prepare the kinase / peptide mix by diluting the ™ Ser / Thr3 peptide to 4 μM. Mix gently by pipetting. 4) Phospho-peptide solution (PP solution): 0.4 μL of Z-LYTE TM The Ser / Thr3 phosphopeptide is added to 99.6 μL of 1.33× kinase buffer. 5) ATP solution: Prepare ATP solution by diluting 10 mM ATP to 100 μM in 1.33× kinase buffer. 6) Color development solution: Dilute color development reagent A 1:1024 with color development buffer.

[0451] 4. Reaction 1) Kinase reaction (volume 10 μl) In a 384-well plate, add 2.5 μL of 4× test compound to each well except wells C1, C2, and C3. Add 2.5 μL of 8% DMSO to wells C1, C2, and C3. b. Place the plate on ice. c. Add 5 μL of P / K mix to each test compound well and to wells C1 and C2. d. Add 5 μL of PP solution to C3 well. e. Add 2.5 μL of 1.33× Kinase Buffer to wells C1 and C3. f. Add 2.5 μL of 4×ATP solution to each test compound well and C2 well respectively. Shake plate for 30 seconds and centrifuge (1500 rpm for 1 minute). g. Seal the plate to protect it from light and incubate the plate at RT (25-30 °C) for 1 h.

[0452] 2) Color reaction Add 5 μL of color developing solution to all wells. b. Shake the plate for 30 seconds and centrifuge (1500 rpm for 1 minute). c. Seal the plate to protect it from light and incubate the plate at RT (25-30 °C) for 1 h.

[0453] 3) Stop and Read Add 5 μL of Stop Reagent to all wells. b. Shake the plate for 30 seconds and centrifuge (1500 rpm, 1 minute). c. Measure the respective values ​​of coumarin (Ex 400 nm, Em 445 nm) and fluorescein (Ex 400 nm, Em 520 nm).

[0454] 5. Data Analysis Emission ratio (ER) = coumarin emission (445 nm) / fluorescein emission (520 nm) % phosphorylation = 1-[ER × C3 520nm - C3 445nm ] / [(C1 445nm - C3 445nm ) + ER × (C3 520nm - C1 520nm )] Inhibition rate (IR) = 1-% phosphorylation 試験化合物 / % Phosphorylation C2

[0455] 6. IC 50 value XLfit is an add-in for Microsoft Excel from ID Business Solutions (Guildford, UK).TM (Version 2.0) using IC 50 was decided.

[0456] Example 19: p-RSK (Thr359) Acumen® Assay in colo205 Cells 1. Cell line colo205 (SIBS)

[0457] 2. Materials and Reagents Phospho-p90RSK (Thr359) (D1E9) Rabbit mAb: Cell Signal, # 8753 Alexa Fluor® 488 Duck Anti-Rabbit IgG: Invitrogen, #A-21206 Propidium iodide: Sigma, # p4170 4% Paraformaldehyde: SCRC, #DF021 10% Triton X-100 (registered trademark): PIERCE, #28314 96-well plate (black plate with clear bottom): BD, #354640 Acumen® eX3 (Multi-Laser Microplate Cytometer for Enhanced High Content Screening (HCS)): TTP LabTech

[0458] 3.Acumen Assay Protocol Seed 4000 cells in 100 μL 10% FBS / well in a 96-well plate and incubate overnight at 37°C, 5% CO2. Dilute compounds to 3, 1, 0.33, 0.11, 0.037, 0.012, 0.004, 0.001 μM while maintaining DMSO concentration at 5%. Add 10 μL of diluted compounds per well and incubate for 1 hour at 37°C, 5% CO2. Add 100 μL of 4% pre-warmed paraformaldehyde (final concentration 2%) and incubate for 45 min at room temperature. Remove the paraformaldehyde solution. Add 100 μL of ice-cold 0.1% Triton and fix the cells for 30 min at room temperature. Wash twice with 150 µL of PBS and incubate with 100 µL of blocking buffer (1% BSA in PBS) for 2–3 h at room temperature. Wash once with PBS and incubate with 35 μL of p-RSK(Thr359) (1:1000 dilution) overnight at 4°C. Seal the plate. Wash twice with PBS and incubate with 35 μL of Alexa Fluor® 488 Duck Anti-Rabbit IgG at a 1:1,000 dilution in Antibody Dilution Buffer (0.1% BSA in PBS) for 1.5 hours at room temperature. Cover the plate with foil and keep it protected from light. Wash twice with 150 μL PBS. Count cells by adding 35 μL of 1.5 μM propidium iodide stock solution to each well and seal the plate. · Incubate at room temperature for 30 minutes. Load the plate into the Acumen Explorer and scan using appropriate instrument settings.

[0459] 4. Data Analysis

[0460]

number

[0461] Note) The ratio in the compound wells represents the positive rate of cells treated with the compound. The ratio of the smallest well represents the positive rate of cells treated with 3 μM GDC0994. The ratio of the maximum well represents the positive rate of cells without compound treatment.

[0462] 5. IC 50 value XLfit is an add-in for Microsoft Excel from ID Business Solutions (Guildford, UK) TM(Version 2.0) using IC 50 It was decided.

[0463] [Table 34-1] [Table 34-2] [Table 34-3]

Claims

1. Compounds of formula (I): 【Chemistry 1】 [In the above formula, Z and Z are independently N or C; and 【Chemistry 2】 is a 5-membered heteroaryl containing 1, 2, 3 or 4 ring heteroatoms selected from N, O or S; said 5-membered heteroaryl may be optionally substituted by one or more substituents independently selected from deuterium, halo, hydroxy, amino, -NH(Ci_6 alkyl), -N(Ci_6 alkyl)2, -CN, mercapto, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 alkoxyl, Ci_6 haloalkyl, -(Ci_6 alkyl)-OH, and -(Ci_6 alkyl)-O-(Ci_6 alkyl), wherein each of said Ci_6 alkyl, Ci_6 alkoxyl, and Ci_6 haloalkyl may be optionally substituted by one or more deuterium; L is absent or L is -NR, O, or S; R is hydrogen or C alkyl; Ar is heteroaryl optionally substituted with one or more substituents independently selected from deuterium, halo, hydroxy, amino, -NH(Ci_6 alkyl), -N(Ci_6 alkyl)2, -CN, mercapto, Ci_6 alkyl, C2_6 alkenyl, C2_6 alkynyl, Ci_6 alkoxyl, Ci_6 haloalkyl, -(Ci_6 alkyl)-OH, -(Ci_6 alkyl)-O-(Ci_6 alkyl), C3_8 cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl, wherein each of said Ci_6 alkyl, Ci_6 alkoxyl, Ci_6 haloalkyl, C3_8 cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl may be optionally substituted with one or more deuterium; R1 is selected from hydrogen; C1-6 alkyl optionally substituted with one or more deuterium atoms; C2-6 alkenyl; C2-6 alkynyl; C1-6 haloalkyl; -(C1-6 alkyl)-OH; -(C1-6 alkyl)-O-(C1-6 alkyl); -(C1-6 alkyl)-(C3-8 cycloalkyl); -(C1-6 alkyl)-(3- to 8-membered heterocyclyl); -(C1-6 alkyl)-phenyl; -(C1-6 alkyl)-heteroaryl; C3-8 cycloalkyl; 3- to 8-membered heterocyclyl; phenyl; and heteroaryl, wherein said C2-6 alkenyl, C2-6 alkynyl , C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, phenyl and heteroaryl may each be optionally substituted with one or more substituents independently selected from deuterium, halo, -CN, hydroxy, mercapto, amino, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, -(C1-6 alkyl)-OH, -(C1-6 alkyl)-O-(C1-6 alkyl), C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, heteroaryl, C1-6 alkyl optionally substituted with one or more deuterium, C1-6 alkoxyl, and C1-6 haloalkyl; R2 is hydrogen, deuterium, halo, hydroxy, amino, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, -CN, mercapto, C1-6 alkyl optionally substituted with one or more deuterium; C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, -(C1-6 alkyl)-OH, -(C1-6 alkyl)-O-(C1-6 alkyl), -(C1-6 alkyl)-(C3-8 cycloalkyl), -(C1-6 alkyl)-(3- to 8-membered heterocyclyl), -(C1-6 alkyl)-phenyl, -(C1-6 alkyl)-heteroaryl, C3-8 cycloalkyl, 3 3-8 membered heterocyclyl, phenyl and heteroaryl, each of said C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, 3-8 membered heterocyclyl, phenyl and heteroaryl may be optionally substituted with one or more substituents independently selected from deuterium, halo, -CN, hydroxy, mercapto, amino, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, -(C1-6 alkyl)-OH, -(C1-6 alkyl)-O-(C1-6 alkyl), C1-6 alkyl, C1-6 alkoxyl, C1-6 haloalkyl, and oxo; R and R are independently selected from hydrogen, deuterium, halo, hydroxy, amino, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, -(C1-6 alkyl)-OH, -(C1-6 alkyl)-O-(C1-6 alkyl), -CN, mercapto, C1-6 alkyl, C1-6 alkoxyl, and C1-6 haloalkyl; or R and R together with the carbon atom to which they are attached are C3-6 cycloalkyl or 3- to 6-membered heterocycloalkyl. wherein each of said C3-6 cycloalkyl or 3- to 6-membered heterocyclyl is optionally substituted with one or more substituents independently selected from deuterium, halo, -CN, hydroxy, mercapto, amino, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, -(C1-6 alkyl)-OH, -(C1-6 alkyl)-O-(C1-6 alkyl), C1-6 alkyl, C1-6 alkoxyl, and C1-6 haloalkyl; 【Chemistry 3】 is a double bond or a single bond, and 【Chemistry 4】 is a double bond, then R and R are absent; R3, R4, R5, R6, R7 and R8 are independently selected from hydrogen, deuterium, halo, hydroxy, -CN, mercapto, amino, -NH(C1-6 alkyl), -N(C1-6 alkyl)2, -(C1-6 alkyl)-OH, -(C1-6 alkyl)-O-(C1-6 alkyl), C1-6 alkyl, -(C1-6 alkyl)-phenyl, C1-6 alkoxyl and C1-6 haloalkyl; or any two of R3, R4, R5, R6, R7 and R8 together with the carbon atom to which they are attached and the B ring form an 8-13 membered spiro, fused or bridged ring and are not limited to N, O or S; wherein said spiro, fused or bridged rings are optionally substituted with one or more substituents independently selected from deuterium, halo, -CN, hydroxy, mercapto, amino, -NH(Ci_6 alkyl), -N(Ci_6 alkyl)2, -(Ci_6 alkyl)-OH, -(Ci_6 alkyl)-O-(Ci_6 alkyl), Ci_6 alkyl, Ci_6 alkoxyl and Ci_6 haloalkyl; or R3 and R4 taken together, R5 and R6 taken together, or R7 and R8 taken together represent oxo; n is 0, 1 or 2; m is 0, 1, 2, 3, 4 or 5. or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof. 【Request 2】 【Chemical 5】 but 【Chemistry 6】 is selected from wherein R10 and R11 are independently selected from hydrogen, deuterium, halo, hydroxy, amino, -CN, mercapto, C1-6 alkyl, C1-6 alkoxyl, C1-6 haloalkyl, -(C1-6 alkyl)-OH, and -(C1-6 alkyl)-O-(C1-6 alkyl), each of said C1-6 alkyl, C1-6 alkoxyl, and C1-6 haloalkyl optionally being substituted with one or more deuterium atoms; or a pharma-ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma-ceutically acceptable salt thereof. 【Request 3】 【Chemical 7】 but 【Chemistry 8】 is selected from 2. A compound of formula (I) according to claim 1, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof, wherein R10 and R11 are independently selected from hydrogen, halo, -CN, C1-6 alkyl, C1-6 alkoxyl, and C1-6 haloalkyl.

4. 【Chemistry 9】 but 【Chemistry 10】 and R and R are independently selected from hydrogen, halo, and C alkyl.

5. Ar is a monocyclic heteroaryl having 5 or 6 ring atoms, one, two or three of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon; each of which is independently selected from deuterium, halo, hydroxy, amino, -CN, mercapto, C1-6 alkyl, C1-6 alkoxyl, C1-6 haloalkyl, -(C1-6 alkyl)-OH, -(C1-6 alkyl)-O-(C1-6 alkyl), C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl; wherein each of said C1-6 alkyl, C1-6 alkoxyl, C1-6 haloalkyl, C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, phenyl, and heteroaryl is optionally substituted by one or more deuterium atoms, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

6. 6. The compound of formula (I) according to claim 5, wherein Ar is selected from pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazolyl and thiazolyl (more preferably, Ar is selected from pyridyl, pyrimidinyl and 1,3,5-triazinyl), each of which is optionally substituted by one or more substituents independently selected from halo; -CN; C1-6 alkyl optionally substituted by one or more deuterium atoms; C1-6 alkoxyl; and C1-6 haloalkyl; or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

7. Ar 【Chemistry 11】 wherein R20, R21, R22, R23, and R24 are independently selected from hydrogen; halo; -CN; C1-6 alkyl optionally substituted with one or more deuterium atoms; C1-6 alkoxyl; and C1-6 haloalkyl; or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

8. R1 is selected from C1-6 alkyl; -(C1-6 alkyl)-OH; saturated monocyclic C3-8 cycloalkyl; saturated monocyclic 3- to 8-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from N, O and S; and heteroaryl, said heteroaryl being a monocyclic aromatic hydrocarbon having 5 or 6 ring atoms, 1, 2 or 3 of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms being carbon, or a bicyclic aromatic hydrocarbon having 8, 9 or 10 ring atoms, 1, 2, 3 or 4 of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms being carbon, wherein at least one of the rings is aromatic, and in the heteroaryl group wherein when the total number of S and O atoms in exceeds 1, said S and O atoms are not adjacent to one another, and each of said C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, and heteroaryl is optionally substituted by one or more substituents independently selected from halo; -(C1-6 alkyl)-OH; -(C1-6 alkyl)-O-(C1-6 alkyl); 3- to 6-membered heterocyclyl; C1-6 alkyl optionally substituted with one or more deuterium atoms; C1-6 alkoxyl; or C1-6 haloalkyl.

9. R1 is a heteroaryl selected from pyrazolyl, pyridyl, isoxazolyl, 1,2,4-triazolyl, 1,3,4-thiadiazolyl, 2,4,5,6-tetrahydrocyclopentadieno[c]pyrazolyl, and 5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridyl, each of which is optionally substituted with one or more deuterium atoms; C1-6 alkyl; C1-6 haloalkyl; C1-6 aryl; 6 alkoxyl; halo; -(C1-6 alkyl)-OH; -(C1-6 alkyl)-O-(C1-6 alkyl); and 3- to 6-membered heterocyclyl. The compound of formula (I) according to claim 8, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

10. 10. The compound of formula (I) according to claim 9, wherein R1 is pyrazolyl, optionally substituted with one or more substituents independently selected from C1-6 alkyl optionally substituted with one or more deuterium; C1-6 haloalkyl; C1-6 alkoxyl; halo; -(C1-6 alkyl)-OH; -(C1-6 alkyl)-O-(C1-6 alkyl); and oxetanyl, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

11. R2 is selected from halo, -CN, C1-6 alkyl, C1-6 haloalkyl, saturated monocyclic C3-8 cycloalkyl, phenyl, and heteroaryl, where said heteroaryl is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms of which 1, 2 or 3 are ring heteroatoms independently selected from N, O and S and the remaining ring atoms are carbon, or a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms of which 1, 2, 3 or 4 are ring heteroatoms independently selected from N, O and S and the remaining ring atoms are carbon, where at least one of said rings is 11. The compound of formula (I) according to any one of claims 1 to 10, wherein one is aromatic and if the total number of S and O atoms in said heteroaryl group exceeds 1, said S and O heteroatoms are not adjacent to one another, and said C3-8 cycloalkyl, phenyl and heteroaryl may be optionally substituted with one or more substituents independently selected from halo, -CN, C1-6 alkyl, C1-6 alkoxyl, C1-6 haloalkyl and oxo, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

12. 12. The compound of formula (I) according to claim 11, wherein R2 is phenyl, wherein said phenyl is optionally substituted with one or more substituents independently selected from halo, -CN and C1-6 alkoxyl, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of the pharma- ceutically acceptable salt.

13. 12. The compound of formula (I) according to claim 11, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof, wherein R2 is heteroaryl selected from 1,2,5-oxadiazolyl, indolyl, indolinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, pyrazolyl, oxazolyl, isoxazolyl, pyridyl, thiazolyl, isothiazolyl, benzo[d]isoxazolyl, thienyl, indazolyl, and pyrrolyl, each of which is optionally substituted by one or more substituents independently selected from C1-6 alkyl, halo, oxo, and -CN.

14. 12. A compound of formula (I) according to claim 11, wherein R2 is a saturated monocyclic C3-8 cycloalkyl optionally substituted with one or more substituents independently selected from C1-6 haloalkyl, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

15. 15. A compound of formula (I) according to any one of claims 1 to 14, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof, wherein m is 0, 1 or 2.

16. or R and R together with the carbon atom to which they are attached form a saturated monocyclic C3-6 cycloalkyl or 3- to 6-membered heterocyclyl having 3 to 6 ring atoms, one or two of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon; and wherein said saturated monocyclic C3-6 cycloalkyl or 3- to 6-membered heterocyclyl may be optionally substituted with one or more substituents selected from halo. The compound of formula (I) according to any one of claims 1 to 15, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

17. 17. A compound of formula (I) according to any one of claims 1 to 16, wherein L is absent or L is NH, O or S, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

18. The compound of formula (I) is selected from the group consisting of compounds 1 to 322 below: 【Table 1-1】 【Table 1-2】 【Table 1-3】 【Table 1-4】 【Table 1-5】 【Table 1-6】 【Table 1-7】 【Table 1-8】 【Table 1-9】 【Table 1-10】 【Table 1-11】 【Table 1-12】 【Table 1-13】 【Table 1-14】 【Table 1-15】 【Table 1-16】 【Table 1-17】 【Table 1-18】 【Table 1-19】 【Table 1-20】 【Table 1-21】 【Table 1-22】 【Table 1-23】 【Table 1-24】 【Table 1-25】 【Table 1-26】 【Table 1-27】 【Table 1-28】 【Table 1-29】 【Table 1-30】 【Table 1-31】 【Table 1-32】 【Table 1-33】 2. The compound of formula (I) according to claim 1, selected from:

19. The compound of formula (I) is a compound of the following formula (I-1): 【Chemistry 12】 where R1 is heteroaryl, which is optionally substituted with one or more substituents independently selected from C1-6 alkyl optionally substituted with one or more deuterium; C1-6 haloalkyl; C1-6 alkoxyl; halo; -(C1-6 alkyl)-OH; -(C1-6 alkyl)-O-(C1-6 alkyl), and 3- to 6-membered heterocyclyl; Ar is heteroaryl, which is optionally substituted with one or more substituents independently selected from halo; -CN; C1-6 alkyl optionally substituted with one or more deuterium; C1-6 alkoxyl; and C1-6 haloalkyl; R2 is selected from halo, -CN, C1-6 alkyl, C1-6 haloalkyl, saturated monocyclic C3-8 cycloalkyl, phenyl, and heteroaryl, wherein each of said saturated monocyclic C3-8 cycloalkyl, phenyl, or heteroaryl may be optionally substituted by one or more substituents independently selected from halo, -CN, C1-6 alkyl, C1-6 alkoxyl, C1-6 haloalkyl, and oxo; R and R are independently selected from hydrogen and C alkyl; R10 and R11 are independently selected from hydrogen, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, and -(C1-6 alkyl)-OH; m is 0, 1 or 2; R and R are independently selected from hydrogen, halo, hydroxy or C1-6 alkyl; or R and R together with the carbon atom to which they are attached form a saturated monocyclic C3-6 cycloalkyl or 3- to 6-membered heterocyclyl having 3 to 6 ring atoms, one or two of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon; and wherein said saturated monocyclic C3-6 cycloalkyl or 3- to 6-membered heterocyclyl may be optionally substituted with one or more substituents selected from halo; L is absent or L is NH, O or S; 2. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of the pharmaceutically acceptable salt thereof, wherein the heteroaryl is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, of which 1, 2 or 3 are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, or a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, of which 1, 2, 3 or 4 are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, wherein at least one of the rings is aromatic, and when the total number of S and O atoms in the heteroaryl group exceeds 1, the S and O heteroatoms are not adjacent to one another.

20. R1 is pyrazolyl optionally substituted with one or more substituents independently selected from C1-6 alkyl; Ar is pyrimidinyl, which is optionally substituted with one or more substituents independently selected from C alkyl, which may be optionally substituted with one or more deuterium atoms, and halo; R2 is selected from C1-6 haloalkyl or phenyl, wherein said phenyl is optionally substituted with one or more substituents independently selected from halo; R and R are hydrogen; m is 0 or 1; R and R are independently selected from hydrogen or C alkyl; or R and R, together with the carbon to which they are attached, form a saturated monocyclic C cycloalkyl; and L is absent or L is NH or O; 2. A compound of formula (I) according to claim 1, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

21. The compound of formula (I) is a compound of formula (I-2), 【Chemistry 13】 In the above formula, R1 is selected from C1-6 alkyl, -(C1-6 alkyl)-OH, saturated monocyclic C3-8 cycloalkyl, saturated 3- to 8-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from N, O and S, and heteroaryl, wherein each of said C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, and heteroaryl may be optionally substituted by one or more substituents independently selected from halo, -(C1-6 alkyl)-OH, -(C1-6 alkyl)-O-(C1-6 alkyl), saturated 3- to 6-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from N, O and S, C1-6 alkyl optionally substituted with 1 or 2 deuterium, C1-6 alkoxyl, and C1-6 haloalkyl; Ar is heteroaryl, optionally substituted with one or more substituents independently selected from halo; -CN; C1-6 alkyl optionally substituted with one or more deuterium; C1-6 alkoxyl; and C1-6 haloalkyl; R2 is selected from halo, -CN, C1-6 alkyl, C1-6 haloalkyl, saturated monocyclic C3-8 cycloalkyl, phenyl, or heteroaryl, wherein each of said C3-8 cycloalkyl, phenyl, or heteroaryl is optionally substituted with one or more substituents independently selected from halo, -CN, C1-6 alkyl, C1-6 alkoxyl, C1-6 haloalkyl, and oxo; Z3 is CR10 or N; R3, R4, R5 and R6 are independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -(C1-6 alkyl)-O-(C1-6 alkyl), and -(C1-6 alkyl)-phenyl; or any pair of R3 and R4, or R5 and R6, together with the carbon atom to which they are attached, form a saturated monocyclic C3-6 cycloalkyl, or form a saturated monocyclic 3-6 membered heterocyclyl having 1 or 2 ring heteroatoms selected from N, O and S, thereby forming a spiro ring together with ring B; R10 and R11 are independently selected from hydrogen, halo, C1-6 alkyl, C1-6 alkoxyl, C1-6 haloalkyl, and -(C1-6 alkyl)-OH; m is 0, 1 or 2; R and R are independently selected from hydrogen, halo, hydroxy, or C1-6 alkyl; or R and R together with the carbon to which they are attached form a saturated monocyclic C3-6 cycloalkyl or 3- to 6-membered heterocyclyl having 3 to 6 ring atoms, one or two of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon; and wherein said saturated monocyclic C3-6 cycloalkyl or 3- to 6-membered heterocyclyl may be optionally substituted with one or more substituents selected from halo; L is absent or L is NH, O or S; said heteroaryl is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, one, two or three of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, or a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, one, two, three or four of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, wherein at least one of said rings is aromatic, and when the total number of S and O atoms in the heteroaryl group exceeds 1, said S and O atoms are not adjacent to one another; 2. A compound of formula (I) according to claim 1, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

22. R1 is selected from saturated monocyclic 3- to 8-membered heterocyclyl containing one or two heteroatoms independently selected from N, O and S, and heteroaryl; wherein said heteroaryl is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, one, two or three of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, or a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, one, two, three or four of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon. wherein at least one of said rings is aromatic and when the total number of S and O atoms in the heteroaryl group exceeds 1, said S and O atoms are not adjacent to one another; and wherein each of said 3-8 membered heterocyclyl and heteroaryl may be optionally substituted with one or more substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, -(C1-6 alkyl)-OH, C1-6 alkoxyl, -(C1-6 alkyl)-O-(C1-6 alkyl), and saturated monocyclic 3-6 membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from N, O and S; Ar is a heteroaryl having 5 or 6 ring atoms, one, two or three of which are ring heteroatoms independently selected from N, O and S, the remaining ring atoms are carbon, and if the total number of S and O atoms in the heteroaryl group exceeds one, said S and O atoms are not adjacent to one another, and said heteroaryl is optionally substituted with one or more substituents independently selected from C alkyl, optionally substituted with one or more deuterium, and halo; R2 is selected from halo, C1-6 alkyl, C1-6 haloalkyl, phenyl, and heteroaryl, wherein said heteroaryl is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, one, two or three of which are 1 or 2 ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, or a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, one, two, three or four of which are 1, 2, three or four ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, wherein at least one of said rings is aromatic, and when the total number of S and O atoms in the heteroaryl group exceeds 1, said S and O atoms are not adjacent to one another, and wherein each of said phenyl and heteroaryl may be optionally substituted with 1 or 2 substituents independently selected from halo, C1-6 alkyl, C1-6 alkoxyl, and oxo; Z3 is CR10 or N; R3, R4, R5 and R6 are independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, -(C1-6 alkyl)-O-(C1-6 alkyl), and -(C1-6 alkyl)-phenyl; or any pair of R3 and R4, or R5 and R6, taken together with the carbon atom to which they are attached, form a saturated monocyclic C3-6 cycloalkyl, or a monocyclic 3-6 membered heterocyclyl having 1 or 2 ring heteroatoms selected from N, O and S, thereby forming a spiro ring together with ring B; m is 1 or 2; R and R are independently selected from hydrogen and halo; or R and R, together with the carbon to which they are attached, form a saturated monocyclic C3-6 cycloalkyl; R and R are hydrogen; L is absent or L is O; 22. A compound of formula (I) according to claim 21, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

23. R1 is selected from morpholinyl, thiomorpholinyl, and heteroaryl, wherein said heteroaryl is selected from pyrazolyl, 2,4,5,6-tetrahydrocyclopentadieno[c]pyrazolyl, 1,2,4-triazolyl, 5,6,7,8-tetrahydro[1,2,4]triazolo[1,5-a]pyridyl, 1,3,4-thiadiazolyl, and pyridyl, and said heteroaryl is C1-6 alkyl, C1-6 haloalkyl, ... The compound of formula (I) according to claim 22, optionally substituted with one or more substituents independently selected from: -(C1-6 alkyl)-OH, C1-6 alkoxyl, -(C1-6 alkyl)-O-(C1-6 alkyl), and oxetanyl, or a pharma- ceutically acceptable salt thereof; or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

24. 22. The compound of formula (I) according to claim 21, wherein Ar is heteroaryl selected from pyridyl, pyrimidinyl, and 1,3,5-triazinyl; wherein said heteroaryl is optionally substituted with one or more substituents selected from C1-6 alkyl, optionally substituted with one or more deuterium, and halo, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or a pharma- ceutically acceptable salt thereof.

25. Ar 【Chemistry 14】 wherein R, R, R, R, R, and R are independently selected from hydrogen, halo, and C alkyl optionally substituted with one or more deuterium atoms.

25. A compound of formula (I) according to claim 24, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or a pharma- ceutically acceptable salt thereof.

26. R2 is selected from halo, C1-6 alkyl, C1-6 haloalkyl, phenyl and heteroaryl, where said heteroaryl is selected from isoxazolyl, 1,2,5-oxadiazolyl, pyrazolyl, oxazolyl, pyridyl, thiazolyl, isothiazolyl, thienyl, and benzo[d]isoxazolyl; and where each of said phenyl and heteroaryl is optionally substituted with one or more substituents independently selected from halo, C1-6 alkyl, C1-6 alkoxyl, and oxo; 22. A compound of formula (I) according to claim 21, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

27. The compound of formula (I) is a compound of formula (I-3), 【Chemistry 15】 Where: R1 is selected from C1-6 alkyl, -(C1-6 alkyl)-OH, saturated monocyclic C3-8 cycloalkyl, saturated monocyclic 3- to 8-membered heterocyclyl containing one or two ring heteroatoms independently selected from N, O and S, and heteroaryl; wherein each of said C3-8 cycloalkyl, 3- to 8-membered heterocyclyl, and heteroaryl is optionally substituted with one or more substituents independently selected from halo; C1-6 alkyl optionally substituted with one or more deuterium atoms; C1-6 alkoxyl; and C1-6 haloalkyl; Ar is heteroaryl, optionally substituted with one or more substituents independently selected from halo; -CN; C1-6 alkyl optionally substituted with one or more deuterium; C1-6 alkoxyl; and C1-6 haloalkyl; R2 is selected from halo, -CN, C1-6 alkyl, C1-6 haloalkyl, saturated monocyclic C3-8 cycloalkyl, phenyl, or heteroaryl, wherein each of said saturated monocyclic C3-8 cycloalkyl, phenyl, or heteroaryl may be optionally substituted with one or more substituents independently selected from halo, -CN, C1-6 alkyl, C1-6 alkoxyl, C1-6 haloalkyl, and oxo; R, R, R, R, R and R are independently selected from hydrogen, halo, hydroxy, C alkyl and C alkoxyl; wherein said C alkyl may be optionally substituted with one or more substituents independently selected from hydroxy and C alkoxyl; or any two of R, R, R, R, R and R, together with the carbon atom to which they are attached and the B ring, represent 【Chemistry 16】 wherein R is selected from hydrogen or halo; t is 0, 1, 2, or 3; R10 and R11 are independently selected from hydrogen, halo, C1-6 alkyl, C1-6 alkoxyl, C1-6 haloalkyl, and -(C1-6 alkyl)-OH; m is 0, 1 or 2; R and R are independently selected from hydrogen, halo, hydroxy, or C1-6 alkyl; or R and R together with the carbon to which they are attached form a saturated monocyclic C3-6 cycloalkyl or 3- to 6-membered heterocyclyl having 3 to 6 ring atoms, one or two of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon; and each of said saturated C3-6 cycloalkyl or 3- to 6-membered heterocyclyl may be optionally substituted with one or more substituents selected from halo; L is absent or L is NH, O or S; said heteroaryl is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, one, two or three of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, or a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, one, two, three or four of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, wherein at least one of the rings is aromatic, and when the total number of S and O atoms in said heteroaryl group exceeds 1, said S and O atoms are not adjacent to one another; 2. A compound of formula (I) according to claim 1, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

28. R1 is selected from C1-6 alkyl, -(C1-6 alkyl)-OH, saturated monocyclic C3-8 cycloalkyl, saturated monocyclic 3- to 8-membered heterocyclyl containing 1 or 2 ring heteroatoms independently selected from N, O and S, and heteroaryl; wherein each of said C3-8 cycloalkyl, 3- to 8-membered heterocyclyl and heteroaryl is optionally substituted with one or more substituents independently selected from halo, C1-6 alkoxyl, C1-6 haloalkyl, and C1-6 alkyl optionally substituted with one or more deuterium; Ar is heteroaryl having 5 or 6 ring atoms, one, two or three of which are ring heteroatoms independently selected from N, O and S, the remaining ring atoms are carbon, and if the total number of S and O atoms in the heteroaryl group exceeds one, then the S and O atoms are not adjacent to one another; wherein said heteroaryl is optionally substituted with one or more substituents independently selected from halo; -CN; C alkyl optionally substituted with one or more deuterium; C alkoxyl; and C haloalkyl; R2 is selected from -CN, C1-6 haloalkyl, saturated monocyclic C3-8 cycloalkyl, phenyl, or heteroaryl, where said heteroaryl is a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, one, two or three of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, or a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, one, two, three or four of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon, where at least one of the rings is aromatic, and when the total number of S and O atoms in the heteroaryl group exceeds 1, the S and O atoms are not adjacent to one another; where each of said saturated monocyclic C3-8 cycloalkyl, phenyl, or heteroaryl may be optionally substituted with one or more substituents independently selected from halo, -CN, C1-6 alkyl, and C1-6 haloalkyl; R, R, R, R, R and R are independently selected from hydrogen, halo, hydroxy, C alkyl and C alkoxyl; wherein said C alkyl may be optionally substituted with one or more substituents independently selected from hydroxy and C alkoxyl; or any two of R, R, R, R, R and R, together with the carbon atom to which they are attached and the B ring, represent 【Chemistry 17】 wherein R is selected from hydrogen and halo, and t is 0, 1, 2, or 3; R and R are independently selected from hydrogen, halo, and C alkyl; m is 0, 1 or 2; R and R are independently selected from hydrogen, halo, hydroxy, and C1-6 alkyl; or R and R together with the carbon to which they are attached form a saturated monocyclic C3-6 cycloalkyl or 3- to 6-membered heterocyclyl having 3 to 6 ring atoms, one or two of which are ring heteroatoms independently selected from N, O and S, and the remaining ring atoms are carbon; and each of said saturated monocyclic C3-6 cycloalkyl or 3- to 6-membered heterocyclyl may be optionally substituted with one or more substituents selected from halo; L is absent or L is NH or O.

28. A compound of formula (I) according to claim 27, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of a compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

29. 28. The compound of formula (I) according to claim 27, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof, wherein R1 is (1) C1-6 alkyl, (2) -(C1-6 alkyl)-OH, (3) a saturated monocyclic C3-8 cycloalkyl optionally substituted with one or more substituents independently selected from halo and C1-6 alkoxyl; (4) a saturated monocyclic 6-membered heterocyclyl containing one or two ring heteroatoms independently selected from N, O, and S; and (5) a heteroaryl selected from pyrazolyl, pyridyl, and isoxazolyl, wherein said heteroaryl is optionally substituted with one or more substituents independently selected from C1-6 alkoxyl, C1-6 haloalkyl, and C1-6 alkyl optionally substituted with one or more deuterium.

30. 28. The compound of formula (I) according to claim 27, wherein Ar is heteroaryl selected from pyridyl and pyrimidinyl, wherein said heteroaryl is each optionally substituted with one or more substituents independently selected from halo; -CN; C1-6 alkyl optionally substituted with one or more deuterium atoms; or a pharma- ceutically acceptable salt thereof; or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

31. Ar 【Chemistry 18】 31. The compound of formula (I) according to claim 30, wherein R20, R21, R22, R23 and R24 are independently selected from hydrogen; halo; -CN; C1-6 alkyl optionally substituted with one or more deuterium atoms; C1-6 alkoxyl; and C1-6 haloalkyl; or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof.

32. 28. The compound of formula (I) according to claim 27, or a pharma- ceutically acceptable salt thereof, or a solvate, racemic mixture, enantiomer, diastereomer, or tautomer of the compound of formula (I) or of a pharma- ceutically acceptable salt thereof, wherein R2 is (1) -CN, (2) C1-6 haloalkyl, (3) saturated monocyclic C3-8 cycloalkyl optionally substituted with one or more substituents selected from C1-6 haloalkyl, (4) phenyl optionally substituted with one or more substituents independently selected from halo and -CN; and (5) heteroaryl selected from 1,2,5-oxadiazolyl, indolinyl, 1,2,3,4-tetrahydroquinolinyl, pyrazolyl, indazolyl, and pyrrolyl, each of which is optionally substituted with one or more substituents independently selected from halo, -CN, and C1-6 alkyl.

33. A pharmaceutical composition comprising a compound according to any one of claims 1 to 32, or a pharma- ceutically acceptable salt thereof, and optionally a pharma- ceutically acceptable carrier.

34. 33. A method for inhibiting the activity of ERK in vitro, comprising contacting ERK with an effective amount of a compound according to any one of claims 1 to 32, or a pharma- ceutically acceptable salt thereof.

35. 34. Use of a compound according to any one of claims 1 to 32, or a pharma- ceutically acceptable salt thereof, in the manufacture of a medicament for treating or preventing a disease responsive to inhibition of ERK.

36. 36. The use of claim 35, wherein the medicament is used to treat cancer or an autoimmune disease.

37. 37. The use of claim 36, wherein the cancer is a solid tumor or hematological malignancy selected from leukemia, lymphoma, colorectal cancer, melanoma, glioma, pancreatic cancer, breast cancer, lung cancer, thyroid cancer, or ovarian cancer.

38. The use described in claim 37, wherein the lung cancer is non-small cell lung cancer and the thyroid cancer is papillary thyroid cancer.

39. 33. A compound according to any one of claims 1 to 32, or a pharma- ceutically acceptable salt thereof, for use in the treatment or prevention of a disease responsive to inhibition of ERK.

40. A compound according to any one of claims 1 to 32, or a pharma- ceutically acceptable salt thereof, for use as a medicament.

41. 41. A compound according to claim 40, or a pharma- ceutically acceptable salt thereof, for use as a medicament for treating or preventing a disease responsive to inhibition of ERK.

42. 42. A compound according to claim 41, or a pharma- ceutically acceptable salt thereof, for use as a medicament for treating or preventing cancer or an autoimmune disease.

43. 43. The compound of claim 42, or a pharmaceutically acceptable salt thereof, wherein the cancer is a solid tumor or hematological malignancy selected from leukemia, lymphoma, colorectal cancer, melanoma, glioma, pancreatic cancer, breast cancer, lung cancer, thyroid cancer, or ovarian cancer.

44. The compound of claim 43, or a pharma- ceutically acceptable salt thereof, wherein the lung cancer is non-small cell lung cancer and the thyroid cancer is papillary thyroid cancer.

45. 33. A combination product comprising a compound according to any one of claims 1 to 32, or a pharma- ceutically acceptable salt thereof, and at least one additional therapeutic agent.

46. 46. ​​The combination product of claim 45, wherein the additional therapeutic agent is an anti-tumor agent selected from a radiotherapy agent, a chemotherapy agent, an immunotherapy agent, and a targeted therapy agent.

47. Compound of formula (II): 【Chemistry 19】 or a racemic mixture or enantiomer thereof, wherein R9 is a leaving group; R10 and R11 are independently selected from hydrogen, halo, and C1-6 alkyl; R3, R4, R5, R6, R7 and R8 are independently selected from hydrogen, halo, C1-6 alkyl, C1-6 alkoxyl, or C1-6 haloalkyl; or any two of R3, R4, R5, R6, R7 and R8, together with the carbon atom to which they are attached and the B ring, are 【Chemistry 20】 where R is selected from hydrogen and halo, and t is 0, 1, 2, or 3; with the proviso that when both R and R are hydrogen, then R, R, R, R, R, and R may not all be hydrogen, and when one of R, R, R, R, R, and R is methyl, the others may not all be hydrogen; A compound, or a racemic mixture or enantiomer thereof, wherein the leaving group is selected from halo, C1-6 alkoxyl, and sulfonyloxy, and the sulfonyloxy is selected from C1-6 alkylsulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and p-nitrophenylsulfonyloxy.

48. 【Chemical 21】 A compound selected from:

49. Compound of formula (III): 【Chemical 22】 In the above formula, R is a leaving group; R and R are independently selected from hydrogen, halo, and C alkyl; R3, R4, R5 and R6 are independently selected from hydrogen, halo, C1-6 alkyl, C1-6 alkoxyl, C1-6 haloalkyl, or C1-6 alkyl optionally substituted with phenyl; or any pair of R3 and R4, or R5 and R6, taken together with the carbon atom to which they are attached, form a saturated C3-6 cycloalkyl or a saturated 3-4 membered heterocyclyl having one or two heteroatoms selected from N, O and S, thereby forming a spiro ring together with ring B; with the proviso that R3, R4, R5 and R6 may not all be hydrogen, and when one or two of R3, R4, R5 and R6 are C1-6 alkyl, the others may not all be hydrogen; A compound, or a racemic mixture or enantiomer thereof, wherein said leaving group is selected from halo, C1-6 alkoxyl, and sulfonyloxy, and said sulfonyloxy is selected from C1-6 alkylsulfonyloxy, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, and p-nitrophenylsulfonyloxy.

50. 【Chemical 23】 50. The compound of formula (III) according to claim 49, selected from:

Images